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1.1. Hematopoiesis
Blood cells are generated in the bone marrow in a process known as hematopoiesis, and 
subsequently released in the circulation. Blood is comprised of various mature blood cells; 
red blood cells/erythrocytes which are important for oxygen transport, platelets which are 
best known for their role in blood clotting, and white blood cells/leukocytes which are the 
bodies defense mechanism against pathogens. There are several types of leukocytes; T-cells 
and B-cells which play an important role in adaptive immunity by creating an immunological 
memory after an initial response to a pathogen, and neutrophils, eosinophils, basophils, 
monocytes/macrophages, dendritic cells, and natural-killer cells which are the bodies 
first line of defense known as innate immunity. Neutrophils, eosinophils, and basophils 
are subclassified as granulocytes since these blood cells comprise various granules, which 
contain proteins important for the killing of pathogens, like bacteria and parasites. Mature 
blood cells have a limited lifespan making a constant production of new cells necessary to 
maintain adequate cell numbers.
All blood cells are generated from a rare, self-renewing, population of pluripotent 
hematopoietic stem cells (HSCs) which are located in the bone marrow and of which the self-
renewal (symmetric cell division), and proliferation/differentiation (asymmetric cell division) 
is tightly regulated by, e.g., the bone marrow microenvironment/niche comprised of various 
non-hematopoietic cells.1,2 Downstream of the so-called long-term hematopoietic stem cell 
(LT-HSC) are various hematopoietic stem- and progenitor cells (HSPCs), e.g., multipotent 
progenitor (MPP) cells.3 The MPPs give rise to either lymphoid progenitors, which eventually 
produce T-,   B-, dendritic-, and NK-cells, or myeloid progenitors which can give rise to the 
other mature blood cells, e.g., neutrophils and red blood cells. Growth factors play an 
important role in stimulating differentiation into a specific lineage. A schematic overview of 
the classical, linear, hematopoietic hierarchy, including the most important growth factors 
to stimulate differentiation, is shown in Figure 1.4,5 The production of (mature) blood cells 
is a tightly regulated process, as well as preventing the uncontrolled growth of progenitors. 
However, discrepancies in these processes can occur resulting in (severely) increased or 
decreased levels of certain blood cells. For example, uncontrolled growth resulting in an 
increased number of myeloid progenitors, which have lost their ability to differentiate, can 
result in acute myeloid leukemia (AML), whereas a decreased number of neutrophils results 
in neutropenia.












































Figure 1: Schematic overview of the classical, linear, hematopoietic hierarchy.
Pluripotent hematopoietic stem cells can self-renew and differentiate into more mature multipotent 
progenitors, which can either become myeloid- or lymphoid progenitors, and further differentiate into 
mature progeny. Growth factors play an important role in stimulating differentiation and the most 
important ones are depicted here. For visualization purposes, not all differentiation stages and growth 
factors are depicted.  
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1.2. Severe congenital neutropenia
Severe congenital neutropenia (SCN) patients have a hereditary bone marrow failure 
syndrome characterized by a block in neutrophil differentiation at the promyelocyte stage 
(Figure 2), resulting in severely reduced absolute neutrophil counts (<0.5x109/L). Because 
neutrophils are essential effector cells of the innate immune system for killing bacteria, SCN 
patients show severe, recurrent, and sometimes life-threatening, bacterial infections such 
as gingivitis (infection of the gums), otitis (ear infection), pneumonia and skin infections 
starting within the first 4 weeks after birth.6,7 SCN is a rare condition with a prevalence 
estimated between 3-8.5 cases per million individuals.8 Before treatment with recombinant 
granulocyte colony-stimulation factor (G-CSF) became available for clinical use, the majority 
of SCN patients (>80%) used to die from severe bacterial infections.9 Intriguingly, most 
patients respond to G-CSF therapy despite the fact that endogenous G-CSF serum levels 
are normal or even slightly elevated, raising the question why administration of exogenous 
G-CSF is effective. A plausible explanation for this apparent paradox is that SCN patients are 
hampered in their basal state of granulopoiesis, driven by the transcriptional regulator C/
EBPα.10 However, at high dosages of G-CSF a state termed “emergency” granulopoiesis is 
induced, which is controlled by C/EBPβ. In healthy individuals, emergency granulopoiesis is 
activated during phases of bacterial infections. In SCN patients, sustained G-CSF treatment 
activates C/EBPβ-dependent emergency granulopoiesis, alleviating the severe neutropenia 
in the absence of infections.10 Nowadays, the majority of SCN patients (>90%) are effectively 
treated with G-CSF (officially called colony stimulating factor 3 or CSF3), alleviating the 
differentiation block and resulting in increased numbers of mature neutrophils, reduced 
numbers and severity of bacterial infections, and a dramatic improvement in quality of life.11 
However, follow-up studies revealed that SCN patients have an increased risk of developing 
leukemia. 
NeutrophilGMPLT-HSC promyelocyte myelocyte metamyelocyte band cell
Figure 2: SCN patients show a neutrophil differentiation arrest at the promyelocyte stage.
Schematic overview of the myeloid differentiation pathway resulting in mature neutrophils, which 
is blocked at the promyelocyte stage in SCN patients. For visualization purposes, several HSC and 
progenitor stages have not been depicted.
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1.2.1 Genetic alterations underlying SCN
An intriguing, yet puzzling characteristic of SCN is its wide genetic diversity. Currently, 
mutations in more than 20 genes have been implicated as the cause of SCN.12 The majority 
of SCN patients (~50%) present with autosomal dominant or sporadic mutations in the gene 
ELANE, encoding for the primary granule protein neutrophil elastase (NE), which is highly 
expressed in promyelocytes.13,14 A prevailing hypothesis is that ELANE mutations cause 
misfolding of the mutant NE protein, evoking an unfolded protein response (UPR) and cellular 
stress, eventually resulting in accelerated cell death beyond the promyelocyte stage.15 To 
date more than 200 different ELANE mutations are identified, distributed throughout the 
whole exome. Because not all ELANE mutations predictably result in protein misfolding, 
alternative hypotheses as to how they may cause neutropenia have been proposed, e.g., 
involving altered substrate specificities and/or mis-trafficking of mutant NE from their 
normal residence in granules.16
Although the majority of SCN patients present with a mutation in ELANE, the first case 
of SCN, described in 1956 by Rolf Kostmann, was the result of an autosomal recessive 
mutation in the mitochondrial protein HAX1.6,17 The prevalence of HAX1 mutations varies a 
lot. Whereas ~11% of European SCN patients show homozygous mutations in HAX1, HAX1-
mutant SCN patients are not yet detected in the United States.12 This could be explained 
by the large number of consanguineous families in Europe (mainly from Arabic and Turkish 
origin), significantly increasing the possibility to obtain a mutation in both alleles of the 
HAX1 gene. Mutations in HAX1 are described to activate the nonsense-mediated mRNA 
decay pathway, resulting in loss of the HAX1 protein and mitochondrial leakage.17
In addition to mutations in genes encoding a granule protein (ELANE) or a mitochondrial 
protein (HAX1), mutations in genes encoding, e.g., a cytoskeletal protein (WAS)18, a 
metabolic enzyme (G6PC3)19, an endosomal membrane trafficking protein (VPS45)20, a 
myeloid transcription factor (GFI1)21, a transmembrane protein (JAGN1)22, and a cytokine 
receptor (CSF3R)23 can cause SCN. All these genes affect different proteins with completely 
different functions, and how these mutations result in a promyelocyte differentiation arrest 
and give rise to severe neutropenia is still largely unknown.12 It has been suggested that a 
common mechanism of disease pathogenesis could be increased oxidative stress caused 
by the mutation. For example, mutations in HAX1 result in mitochondrial leakage, while 
mutations in ELANE can cause NE protein misfolding, both possibly resulting in increased 
oxidative stress levels. 
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1.3. Oxidative stress
The term oxidative stress describes an imbalance between the production of the natural 
occurring reactive oxygen species (ROS) and the cell’s ability to detoxify the reactive 
intermediates. ROS are natural by-products of cell metabolism but can also be generated 
by (dis)regulation of other processes in, for example, the mitochondria or endoplasmic 
reticulum (ER) or via extracellular stimuli. DNA oxidation is a major contributor to genomic 
instability and decay by, e.g., acquisition of mutations.24 However, it has become clear 
that ROS are also important for several physiological responses, like cell proliferation and 
differentiation, by oxidation of various phosphatases and protein kinases.25-27 The degree of 
stress ranges from physiological oxidative stress (eustress) to excessive and toxic oxidative 
stress burden (distress, resulting in DNA, protein and lipid damage). Of note, cells produce 
antioxidants to neutralize the excessive ROS to maintain the reduction-oxidation (redox) 
homeostasis.24
1.3.1 NRF2
The master regulator of this redox balance is NRF2. NRF2 is under homeostatic conditions 
located in the cytoplasm in a complex with KEAP1, where KEAP1 ubiquitinates NRF2 resulting 
in its rapid degradation.28 Under oxidative stress conditions cysteinyl residues of KEAP1 are 
modified and KEAP1 loses its ability to ubiquitinate NRF2. NRF2 can then translocate to the 
nucleus, inducing the transcription of various antioxidant proteins which can neutralize the 
excessive ROS.28
1.3.2 PML
In addition to NRF2, the promyelocytic leukemia (PML) protein has also been described to 
act as ROS sensor. PML is a cysteine-rich protein and, similar to KEAP1, these cystine residues 
are oxidized upon oxidative stress. Oxidized PML forms multimers that self-organize into 
PML nuclear bodies (PML-NBs) which serve as SUMOylation factories (Small Ubiquitin-like 
Modifier).29 Dozens of unrelated proteins are described to be able to be present in these 
PML-NBs, varying with cell type or stress conditions.30 By SUMOylating these proteins PML 
is able to regulate their function and degradation. In line with this, PML-NBs have been 
linked to a plethora of cellular processes, e.g., clearing of misfolded proteins31, cell cycle 
arrest32, the DNA damage response33, and metabolism.34 PML downregulates ROS by 
inducing the expression of a subset of p53 targets, which induce antioxidants in response to 
basal oxidative stress.35 Importantly, with active PML mediated antioxidant signaling, NRF2 
responses are blunted, while loss of PML results in increased NRF2 levels.35 In acute stress 
situations, PML NBs activate p53 targets resulting in cell death or senescence.35
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1.4. Leukemic progression of SCN
As mentioned previously, G-CSF/CSF3 treatment significantly reduced occurances and 
severity of bacterial infections while increasing the quality of life in patients with SCN. In 
line with this, a large SCN patient cohort, comprised of 374 SCN patients on long-term CSF3 
treatment enrolled in the SCN International Registry, showed that the mortality rate due to 
infections was severely reduced upon CSF3 treatment.36 However, after 12 years on CSF3 
treatment the cumulative incidence of progression to myelodysplastic syndrome (MDS) or 
AML was 21%, indicating that SCN patients on CSF3 treatment have a highly increased risk 
of leukemic progression.36
1.4.1 Mutations in the CSF3 receptor
Progression to MDS/AML is associated with the appearance of hematopoietic clones with 
somatic mutations in the gene encoding the G-CSF/CSF3 receptor (CSF3R). C-to-T transitions 
converting glutamine codons into stop codons in the cytoplasmic domain of the CSF3R, 
resulting in a truncated CSF3R, were detected in SCN patients in the early 1990s.37,38 It 
was shown that these mutations were acquired, and not inherited, and present in ~80% 
of SCN patients that progressed to AML.39,40 CSF3R-truncating mutations result in loss of 
a large portion of the cytoplasmic domain of the receptor. This domain contains, among 
others, a lysine residue critical for degradation of the CSF3R, resulting in increased numbers 
of receptors on the plasma membrane and sustained CSF3-induced signaling.41,42 CSF3 
treatment induced proliferation, phosphorylation of Stat5, and transcription of Stat5 target 
genes in Csf3r-truncation mutant mice, indicating that inappropriate Stat5 activation plays 
a key role in establishing clonal dominance by Csf3r-mutant HSCs.43 In addition, increased 
levels of ROS were observed in Csf3r-mutant mice upon CSF3 treatment, possibly resulting 
in a more “mutation-prone” environment involved in leukemic progression.44
Several clones with different mutations leading to the expression of truncated CSF3R 
proteins could be detected in patients that did not (yet) show signs of leukemic progression, 
suggesting that CSF3R mutations are acquired early during leukemic transformation.39,40 In 
addition, the existence of multiple CSF3R mutant clones suggest a strong selective pressure 
for acquisition of this type of mutations.40 However, CSF3R mutant clones can persist for 
years as a minor clone before leukemia becomes clinically overt, indicating that additional 
mutations are needed for full malignant transformation.45  
1.4.2 Mutations in RUNX1
Mutations in RUNX1, in addition to CSF3R mutations, were shown to be the most often 
acquired in 31 SCN patients who progressed to MDS or AML (20/31=64.5%).46 RUNX1 is 
a member of the runt transcription factor family and is essential for foetal and adult 
haematopoiesis.47,48 The majority of the RUNX1-mutant SCN-MDS/AML patients already 
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harbored mutations in the CSF3R (17/20=85%), suggesting an important (cooperative) role 
of these mutations in leukemic progression.46 Where CSF3R mutations are all located in 
the C-terminal part of the gene, resulting in a truncated protein, mutations in RUNX1 are 
found throughout the gene. However, the majority of the mutations were located in the 
runt homology domain (RHD) of the protein, important for DNA binding and interaction 
with the regulatory protein core-binding factor β (CBF-β).45,46,49 RUNX1 mutations were only 
observed shortly before leukemia became clinically overt, indicating that this is a late event 
during transformation.45,46
1.4.3 Mutations in epigenetic modifiers
Mutations in epigenetic modifiers, e.g., SUZ12/EZH2/ASXL1/EP300, are also observed, 
albeit less frequently than CSF3R and RUNX1 mutations.45,46 Epigenetics involves changes 
that affect gene expression, but do not involve alterations in the DNA sequence, and are 
therefore reversible. Simplified; gene expression is regulated by the packaging of DNA by 
histones, forming a DNA-protein complex called chromatin. Open chromatin allows for the 
transcription of genes in this region, while closed chromatin prevents this.50 Epigenetic 
modifiers are important for this regulation and mutations in these genes could, for example, 
result in transcriptional silencing of tumor suppressor genes or activation of oncogenes 
without affecting the DNA sequence of these specific genes.50 In addition to histone 
modification, also epigenetic changes on DNA level are important for cellular processes, e.g., 
DNA methylation. Various proteins involved in this process, TET2/IDH2/DNMT3A, are found 
frequently mutated in AML. In this thesis we describe a newly acquired driver mutation in 
Cxxc4 found in a mouse model of leukemic progression of SCN (Chapter 7). CXXC4 has been 
described to be able to bind TET2 and induce its protein degradation, thereby modulating 
TET2 protein abundance.51 
1.4.4 Chromosomal aberrations
In addition to epigenetic deregulation, also chromosomal aberrations resulting in monosomy 
7 or trisomy 21 are observed in SCN-MDS/AML patients.45,46 These aberrations are only 
observed in leukemic samples and are therefore considered late alterations.45,46 Why these 
2 chromosomal aberrations are frequently observed and how they contribute to leukemic 
transformation is not yet known. However, several tumor suppressor genes, e.g., EZH2, are 
present on chromosome 7, while chromosome 21 contains various oncogenes, e.g., RUNX1, 
and one could imagine that loss or gain of these genes might affect the cells characteristics, 
especially when an additional mutation in one of these genes is acquired.  
1.5. Overlap with chronic neutrophilic leukemia (CNL)
Alterations in RUNX1, SUZ12, EZH2, ASXL1, EP300 and chromosomal aberrations can 
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also be present in other leukemias like de novo AML (AML without prior hematological 
disease) or MDS. However, CSF3R mutations are exclusively found in SCN-MDS/AML, 
chronic neutrophilic leukemia (CNL)42,52, and rare cases of de novo AML with mutations in 
CEBPA.53-55 The majority of CNL patients acquire a CSF3R-T618I mutation, but also truncating 
mutations are observed.52 In addition, the CSF3R-T618I mutation can be detected in SCN-
MDS/AML patients.45 The CSF3R-T618I mutation provides autonomous signaling, supporting 
hyperproliferation of mature neutrophil progenitors.52 The truncating and auto-activating 
mutation can be found in the same patient and even on the same allele in both SCN and CNL, 
indicating a strong selective pressure for acquisition of CSF3R mutations in both SCN and 
CNL.45,52 These findings suggest that SCN and CNL might share a similar CSF3 hyporesponsive 
pre-leukemic state, from which cells can escape by acquiring CSF3R-mutations. 
1.6. Outline and scope of this thesis
SCN is a complex disease caused by mutations in several different genes, associated 
with different cellular localization and function. How these genes cause a promyelocytic 
differentiation arrest is largely unknown, but it has been suggested that increased oxidative 
stress levels might play an important role. Additionally, why SCN patients have an increased 
risk of leukemic transformation remains an important point of study. The presence of multiple 
CSF3R-truncating mutations/clones suggests a strong selective pressure for acquisition of 
these mutations, possibly induced by the sustained life-long CSF3 treatment that the majority 
of patients with SCN receive. How truncated-CSF3Rs function in a SCN-mutant background 
is unknown, since mouse models do not mimic the neutropenic phenotype observed in 
patients with SCN. In addition, the observation that patients with SCN-MDS/AML often 
acquire RUNX1 merits for interesting further studies, e.g., the effect of these mutations 
on hematopoietic cells, and why they frequently co-occur with CSF3R-mutations. Whether 
the combination of CSF3R- and RUNX1-mutations is sufficient for leukemic transformation, 
possibly in combination with CSF3-therapy, remains to be determined. The work presented 
in these thesis focuses on unraveling these questions, using in vitro SCN patient- and control-
derived induced pluripotent stem cells (iPSCs), and in vivo mouse models to mimic several 
steps of leukemic transformation.
In Chapter 2 we describe the pros and cons of different models to study SCN and its leukemic 
progression, mainly focusing on the newest disease model; induced pluripotent stem cells 
(iPSCs). iPSCs can be generated from SCN-patient material making it possible to study the 
effect of, e.g., ELANE/HAX1-mutations, as well as the acquisition of CSF3R-mutations, in a 
disease-relevant background.
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In Chapter 3 the generation of 3 SCN-patient-derived iPSCs are described, in addition to 
iPSCs derived from a healthy control. We employed these SCN- and control-derived iPSC 
to investigate if different SCN mutations show overlapping cellular responses, possibly 
explaining why mutations in different genes have the same disease phenotype. Albeit having 
different SCN-causing mutations, the HPCs generated from these iPSCs showed increased 
oxidative stress levels in all 3 SCN-patients compared to the healthy control. Additionally, 
the ELANE-mutant patient of which the mutation predicted NE protein misfolding showed 
increased numbers of PML-NBs, a marker of more excessive oxidative stress. We showed that 
PML not only played a role in lowering oxidative stress levels but is also involved in several 
biological processes important for SCN pathogenesis, like CSF3-therapy responsiveness. 
In Chapter 4 we mimic the first acquired step of leukemic progression of SCN in iPSC by 
introducing a patient-specific CSF3R-truncating mutation using CRISPR-Cas9-mediated 
genome editing. This data provides evidence for the involvement of the SCN mutation in 
disease progression by tipping the balance between proliferative signaling and inflammatory 
signaling towards the latter, making it possible for CSF3R-mutations to be present as minor 
clones for years while creating a mutation-prone environment ideal for the acquisition of 
mutations that are more resistant to inflammatory stimuli like TET2 and RUNX1.
In Chapter 5 a perspective (p)review discusses the role of RUNX1 mutations in the leukemic 
progression of SCN.
In Chapter 6 we addressed the question how truncated CSF3R and RUNX1 mutations, in 
conjunction with CSF3 treatment, contribute to AML development. To study this, we used a 
combination of mouse- and iPSC-models and showed that the combination of mutant Csf3r, 
mutant RUNX1 and CSF3 treatment resulted in a pre-leukemic state in mice. An additional 
acquired mutation in Cxxc4 resulted in full-blown AML by inhibiting TET2 protein levels. 
Mutations in CXXC4 can also be found in human AML and MDS patients, of whom the 
clinical, molecular, and cytogenetic characteristics are described in Chapter 7.
In Chapter 8 we describe a patient with severe aplastic anemia (SAA) who progressed to 
CNL and AML with mutations that are frequently found in the leukemic progression of SCN. 
Non-leukemic HPCs from the SAA and SCN patient showed activation of interferon signaling 
pathways, indicating an important role for inflammation in leukemic progression from bone 
marrow failure syndromes. 
Finally, in Chapter 9 we summarize the findings described in this thesis and discuss how to 
further investigate the leukemic progression of SCN.
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Abstract
Patients with severe congenital neutropenia (SCN) suffer from a severe shortage of 
neutrophilic granulocytes, leading to life-threatening bacterial infections. The severe 
neutropenia and infectious episodes can be alleviated by life-long treatment with granulocyte 
colony-stimulating factor (G-CSF or CSF3). G-CSF therapy has unveiled an increased risk of 
developing myelodysplastic syndromes or acute myeloid leukemia, which is often preceded 
by the expansion of myeloid cell clones with somatic mutations in the CSF3 receptor gene 
(CSF3R). Genetically, SCN is a heterogeneous condition, with over 15 genes identified as 
causative to the disease. Most commonly, mutations are found in ELANE, the gene encoding 
neutrophil elastase, leading to autosomal dominant or sporadic forms of SCN. SCN caused 
by mutations in HAX1 is best known, as this represents the recessive condition originally 
described as Kostmann disease. Despite our knowledge of the genetic causes of SCN, it 
remains ill-understood how the mutations cause neutropenia and why they predispose to 
myeloid malignancies. In this chapter, we will discuss the clinical characteristics of SCN and 
summarize the properties and limitations of the current in vitro and in vivo models used 
to study the pathobiology of the disease. Subsequently, we will review the current status 
of induced pluripotent stem cell models of SCN and discuss their potential and current 
limitations for elucidating disease mechanisms of neutropenia and leukemic progression, as 
well as for developing curative therapies. 
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Severe congenital neutropenia
Severe congenital neutropenia (SCN) is a bone marrow failure syndrome characterized by 
low absolute neutrophil counts (<0.5x109/L) caused by a granulocytic differentiation block at 
the promyelocyte stage, resulting in increased bacterial infections in patients (Figure 1). SCN 











Figure 1: Sequential steps in normal neutrophil differentiation; the maturation arrest in SCN patients 
is marked by the red bar
 
Congenital forms of neutropenia were first reported by Rolf Kostmann in 1956, who 
described a family with inherited severe neutropenia, which he termed infantile genetic 
agranulocytosis2. More than 50 years later, mutations in the gene encoding HCLS1-
associated protein X-1 (HAX1) were found to be the cause of this autosomal recessive form 
of SCN3. HAX1-mutant SCN is confined to consanguineous populations covering less than 
5% of patients worldwide. Mutations in HAX1 introduce a premature stop codon resulting 
in nonsense-mediated messenger RNA decay leading to the loss of HAX1 protein. Although 
multiple functions have been assigned to HAX1, its loss resulting in destabilization of the 
mitochondrial membrane potential and mitochondrial leakage are currently thought to 
explain the SCN phenotype3. 
Mutations in ELANE, encoding the primary granule protein neutrophil elastase (NE), are 
the most frequent cause of SCN, responsible for approximately 30%-40% of cases4,5. ELANE 
mutations result in an autosomal dominant form of SCN and, in contrast to HAX1 mutations, 
the mutational spectrum observed in patients encompasses the entire ELANE gene6. How 
mutations in ELANE cause neutropenia is still unclear. Mislocalization of the mutant NE 
protein7, altered enzymatic activity8 and protein misfolding resulting in activation of the 
unfolded protein response (UPR)7,9 have all been suggested as potential initiators causing 
neutropenia, through the activation of cell death mechanisms at the promyelocyte stage. 
However, definitive proof for the involvement of these mechanisms is still lacking. 
In addition to mutations in ELANE and HAX1, mutations in, e.g., GFI110, WAS11 JAGN112 
and G6PC313 have been shown to cause SCN. A recent review provides a comprehensive 
overview of the genetic causes of SCN, their hereditary patterns, proposed mechanisms of 
action, and clinical features14. 
A unique aspect of SCN is that the majority of patients are treated with the 
hematopoietic growth factor granulocyte colony-stimulating factor (G-CSF), now renamed 
colony-stimulating factor 3 (CSF3), to alleviate the life-threatening neutropenia15. As will 
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be discussed later in this chapter, patients with SCN may develop myeloid malignancies, 
preceded by a preleukemic phase characterized by hematopoietic clones with somatic 
mutations in the CSF3 receptor (CSF3R)16. 
Severe congenital neutropenia mouse models
Mouse models with representative SCN-derived HAX1 and ELANE mutations have been 
generated to gain insight into how these mutations cause neutropenia17. Quite surprisingly, 
neither HAX1-deficient mice nor mice with human-equivalent Elane mutations (V72M, 
G193X) showed signs of neutropenia or a granulocytic differentiation block, neither 
under basal conditions nor after induction of emergency granulopoiesis18-20. Theoretically, 
this could be due to differences between mice and humans in the NE and HAX1 protein 
composition, because only 72% and 80%, respectively, of the amino acids are identical 
(Figures 2 and 3). However, over-expression of human NE mutants in murine HoxB8-driven 
cell lines derived from NE-/- mice also did not result in a granulocytic differentiation defect, 
neither in vitro nor in vivo21, indicating that there are more differences between mice and 
human granulopoiesis besides the structure of NE and possibly HAX1. 
MTLG RRLACL FLACVLPALL LGGTALASEI VGGRRARPHA WPFMVSLQLR 50
APNFVMSAAHGGHFCGATLI CVANVNVRAV RVVLGAHNLS RREPTRQVFA 100
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Figure 2: Human and mouse NE protein sequences show 72% overlapping amino acids (191/267)
Black bars indicate overlapping amino acids, where red bars show mismatched amino acids. Exons are 
shown alternating in black and blue, indicating the 5 different coding exons of the ELANE gene. The red 
characters indicate amino acids generated through splicing.
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MSLFDLFRGF FGFPGPRSHR DPFFGGMTRD EDDDEEE - - -  - EEEGGSWGR 46
P P E E F G F G F SGNPRFHSPQH FSPGGGIRFH DNFGFDDLVR DFNSIFSDMG 96
DSMLKYPDSHAWTLPSHPPE L P G P E S E T P G ERLREGQTLR QPRIFGGVLE 146
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RPPALDDAFSS S P R GD PESP 279
ES YAF DGSQ -
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Figure 3: Human and mouse HAX1 protein sequences show 80% overlapping amino acids (224/280)
Black bars indicate overlapping amino acids, where red bars show mismatched amino acids. Exons are 
shown alternating in black and blue, indicating the 7 different coding exons of the HAX1 gene. The red 
characters indicate amino acids generated through splicing.
Human cell line models
Before the introduction of induced pluripotent stem cell (iPSC) technology, attempts to model 
SCN in human cells have been mainly restricted to retroviral introduction of ELANE mutations 
in the promyelocytic leukemia cell line HL-60. Although HL-60 cells have retained some 
ability to differentiate to neutrophils when stimulated with all-trans retinoic acid (ATRA), an 
obvious caveat of this model is its leukemic nature. Furthermore, retroviral introduction of 
ELANE mutants has the drawback that it will cause expression at nonphysiological levels and 
can create potential off-target effects due to the site of integration. The outcome of these 
experiments was mixed. In one study, overexpression of the ELANE-V174_C181del mutant 
under the control of the tet-regulated promoter resulted in less mature neutrophils induced 
by ATRA relative to controls22, whereas in a comparable study, introduction of ELANE-G185R 
failed to show reduced neutrophil differentiation23. Taken together, the myeloid leukemia 
cell line-based models of SCN are now generally considered as less suitable for studying the 
biology of SCN. 
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Induced pluripotent stem cell models for severe congenital neutropenia
SCN-iPSCs have been generated using different protocols for reprogramming. The first 
published studies made use of retroviral vectors to reprogram skin or bone marrow 
fibroblast derived from patients with ELANE-C194X or HAX1-R86X mutations24,25. Later, 
lentiviral vectors or integration-free episomal vectors were used to avoid off-target effects 
of integration26. A now-well-recognized problem is that iPSC lines may display a significant 
level of variation, owing to phenotypic changes caused  by the reprogramming process27. 
To avoid misinterpretations based on such non-disease-relevant shifts in phenotypes, it is 
important to generate multiple clones derived from the same starting material. Also, the 
introduction of CRISPR-Cas9 mediated genome editing made it feasible to precisely target 
modifications in iPSCs, e.g., to repair the disease-causing gene defects in patient-derived lines 
or to introduce patient-derived mutations in normal controls28. In this way the phenotypic 
consequences of mutations can be definitively assessed. Because the majority of studies on 
SCN-iPSCs published to date did not yet make use of multiple clones or isogenic lines, the 
results discussed in the following sections should be interpreted with some caution.
Hematopoietic induction of induced pluripotent stem cells
To study how the underlying genetic defects affect neutrophil development, hematopoietic 
progenitor cells (HPCs) first need to be generated from SCN-iPSCs. Different methods have 
been developed to generate HPCs and their more mature myeloid progeny from iPSCs. These 
protocols are somewhat variable but have in common that in the first 3-4 days mesodermal 
differentiation is induced by the addition of BMP4, after which hematopoietic cytokines 
(e.g., vascular endothelial growth factor (VEGF), interleukin 3 (IL-3), stem cell factor (SCF), 
and CSF3) are added to the cultures to generate the HPCs, as visualized in Figure 4 22,24,25,29-
32. Nowadays, complete hematopoietic induction kits, e.g., STEMdiff Hematopoietic Kit 
(STEMCELL Technologies) can be purchased, minimizing batch effects due to extensive 
testing. 
Day 0-1 3-4 12-16









Figure 4: Standard protocol for the induction of HPCs
Mesoderm differentiation is induced by addition of BMP4, after which the medium is replaced with 
hematopoietic cytokines e.g. VEGF/IL-3/SCF/CSF3 to induce hematopoietic differentiation. Cells are 
generally harvested between days 12 and 16 to yield the highest number of HPCs.
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The potential of HPCs to produce differentiated progeny can be further tested in colony-
forming unit (CFU) assays, in which cells are plated into semisolid medium with the addition 
of lineage-specific cytokines. Typically, a CFU-G assay can be done to test SCN-iPSC-derived 
HPCs for their ability to respond to G-CSF/CSF3. In addition to the generation of HPCs, cells 
need to be differentiated further into the granulocytic lineage if one wishes to study the 
mechanisms underlying the differentiation block observed in patients with SCN. CSF3 is a 
key hematopoietic cytokine driving the maturation of granulocytes in culture. Importantly, 
it must be kept in mind that CSF3 dosage has a major impact on the outcome of such 
experiments, as the differentiation block can be alleviated in the majority of patients with 
SCN by pharmacological dosages of this cytokine (discussed later in more detail). Different 
stages of neutrophil development based on surface antigen expression can be conveniently 
assayed by flow cytometry33. The EuroFlow consortium defined the combination of 
antibodies to discriminate the different stages of human neutrophil differentiation based on 
expression of HLA-DR, CD45, CD16, CD13, CD34, CD117, and CD11b, as shown in Figure 5, 







































 Figure 5: EuroFlow defined flow cytometry markers to differentiate the various neutrophil differentiation 
stages
HAX1-mutant induced pluripotent stem cells
To date, two studies on HAX1-mutant iPSC derived from patients with SCN have been 
published. Morishima et al. focused on trying to correct the HAX1 mutation by lentiviral 
overexpression of wild-type HAX125. They showed that the HAX1-R86X mutant cells generate 
a smaller proportion of mature neutrophils upon differentiation and produce less myeloid 
colonies in semisolid medium compared with normal controls. Introduction of HAX1 
restored the production of mature neutrophils and myeloid colony-forming cells (CFU-G) 
25. Similarly, CRISPR-Cas9-mediated correction of an HAX1-W44X mutation in iPSCs resulted 
in an increased proportion of mature neutrophils31. Both studies confirmed that mutations 
in HAX1 resulted in disruption of the mitochondrial membrane potential, as shown before 
in primary bone marrow cells from patients with HAX1-SCN3. These findings validate the 
use of patient-derived iPSC for studying the cellular consequences of HAX1 mutations for 
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neutrophil development, but at this point, they provide only limited additional mechanistic 
insights. 
ELANE-mutant induced pluripotent stem cells
Because mutations in ELANE occur throughout the gene, it is likely that different mutations 
may affect the NE protein differently, which might explain observed variations in clinical 
symptoms of SCN. To date, 11 distinct ELANE-mutant iPSC lines have been published (Figure 
6)22,24,29,30,32,35,36. The majority of these studies showed reduced neutrophilic differentiation 
potential of ELANE-mutant lines, but discrepancies between distinct mutants have also 
been observed. While possibly relevant to the type of mutation, it cannot be excluded 
that differences in culture conditions, especially concentrations of G-CSF/CSF3 used in 
myeloid differentiation cultures, contributed to these variations. This asks for some caution 
in the interpretation of these findings, also because most of these studies did not include 
validations in multiple independent clones and/or use of gene-corrected isogenic lines to 
confirm phenotypic reversion. 












Figure 6: Overview of the ELANE gene indicating the different positions of the iPSC generated from 
ELANE-mutant patients
Unfolded protein response activation in ELANE-mutant cells
Studies published thus far mainly aimed at activation of the UPR and increased apoptosis 
in ELANE-mutant myeloid progenitor cells as the cause of neutropenia in SCN. However, 
as explained earlier, not all ELANE mutations predictably result in protein misfolding, 
leaving room for alternative explanations as to how ELANE mutations affect neutrophil 
development. Most ELANE mutations in currently published SCN-iPSCs are predicted to 
result in protein misfolding (Figure 7, C223X cannot be assessed because of the premature 
stop codon)37. However, these lines did not uniformly show induction of the classical UPR 
because often only a few UPR-related transcripts were found to be upregulated, whereas 
others were unchanged or even downregulated24,29,35. Besides the classical UPR pathway, 
the promyelocytic leukemia protein has been reported to recognize and degrade misfolded 
proteins38. We have shown that this alternative “noncanonical” UPR pathway is activated in 
some ELANE-mutant patients associated with NE protein misfolding36 (and Olofsen PA et al., 
manuscript submitted).
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Alanine Valine57
The residue is buried in the core of the protein. The mutant residue is bigger and probably will not fit.
Glutamine 97 Proline
The mutation will cause loss of hydrogen bonds in the core of the protein and disturb correct folding.
Isoleucine 118 Asparagine
The residue is buried in the core of the protein. The mutant residue is bigger and probably will not fit.
The mutation will cause loss of hydrophobic interactions in the core of the protein.
The residue is buried in the core of the protein. The mutant residue is bigger and probably will not fit.
139Proline Leucine
Cystine 151
The residue is buried in the core of the protein. The mutant residue is bigger and probably will not fit.
The mutation will cause loss of hydrophobic interactions in the core of the protein.
Tyrosine
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Glycine 203 Arginine
The residue is buried in the core of the protein. The mutant residue is bigger and probably will not fit.
The mutant residue introduces a charge in a buried residue which can lead to protein folding problems.
Only Glycine is flexible enough to make these torsion angles, mutations will disturb local structure.
The residue is buried in the core of the protein. The mutant residue is bigger and probably will not fit.
The mutant residue introduces a charge in a buried residue which can lead to protein folding problems.
Only Glycine is flexible enough to make these torsion angles, mutations will disturb local structure.
Glycine 214 Arginine
Figure 7: Predicted effect of the amino acid alterations induced by mutations in ELANE
The location of the altered amino acid is shown in purple. The wild type residue is shown in green, 
whereas the mutant residue is shown in red 37.
Use of SCN-iPSCs to develop new therapeutic strategies 
Although patients with SCN are effectively treated by administration of recombinant CSF3, 
better known as G-CSF, neupogen or filgrastim39, they face an increased risk of progression 
toward myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) while on this 
treatment40,41. There are concerns that CSF3 therapy might contribute to the leukemic 
progression, especially because the majority of patients with SCN acquire truncating 
mutations in the G-CSF receptor (CSF3R) early during disease progression16,42. 
SCN-iPSC models have been used to find new treatment strategies as alternatives 
for CSF3 therapy, as options for patients who fail to respond to CSF3 or to avoid development 
of malignancies in patients who need excessive CSF3 dosages to alleviate neutropenia 
40,41. For example, Hiramoto et al. showed that Wnt3a combined with CSF3, but not alone, 
stimulated the maturation of neutrophils in ELANE-C223X iPSC-derived hematopoietic cells. 
They propose that, by using the combination therapy including compounds activating the 
Wnt3a/β-catenin axis, CSF3 doses can be lowered in patients, potentially reducing the risk 
of leukemic transformation24. 
Another new treatment option that has been proposed is the use of the NE-specific 
cell-permeant serine protease inhibitor sivelestat. Sivelestat, in combination with 50 ng/
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ml CSF3, mimicked high dose CSF3 treatment and ameliorated endoplasmic reticulum (ER) 
stress and enhanced cellular survival in ELANE-Q97P and ELANE-I118N mutant cells35. These 
data differ from those reported by Makaryan et al. who showed that the β-lactam-based 
inhibitor MK0339, but not sivelestat, significantly increased the proportion of mature 
neutrophils (CD11b+ cells) in both ELANE-P139L, ELANE-G214R and control iPSCs22. 
Finally, genetic therapeutic options that are currently being explored involve the 
deletion of ELANE by CRISPR-Cas9-mediated genome editing, disrupting both the mutant 
and wild-type alleles30,43. The underlying rationale for this strategy is that the lack of NE 
may not have a major impact on neutrophil function, based on studies in mice and on the 
premise that individuals suffering from Papillon-Lefèvre syndrome, a condition characterized 
by a combined serine protease deficiency, show relatively mild symptoms43,44. Introducing 
indels at exon 2 of ELANE efficiently triggered nonsense-mediated decay and loss of NE in 
hematopoietic stem and progenitor cells (HSPCs) derived from healthy controls or ELANE-
mutant patients with SCN43. The same strategy was explored by Nasri et al., who introduced 
indels in exon 2 of ELANE-mutant iPSCs (A57V and C151Y)30. Both studies show that loss of 
NE resulted in alleviation of the differentiation block, both in HSPCs and iPSC-derived cells. 
Although the first results look promising, the long-term clinical impact of NE loss remains 
uncertain. Therefore efforts to correct rather than delete mutant (and wild type) ELANE 
should continue, even though the repair protocols are currently far from fit to successfully 
implement this clinically. Given the large diversity of ELANE mutations found in patients 
with SCN, a major hurdle to be taken will be to avoid off-target effects of the individual gene 
correction strategies, an essential step before they can be advanced towards clinical grade. 
Clearly, the iPSC lines from patients harboring different ELANE mutations serve as valuable 
tools for fine-tuning these approaches. 
Induced pluripotent stem cells to study leukemic progression
Hematopoietic cell clones with somatic mutations in CSF3R truncating the membrane-distal 
cytoplasmic region of CSF3R are frequently observed in patients who progress to MDS or 
AML. These CSF3R-mutant cells can be present as minor clones years before the leukemia 
becomes clinically overt16. At the final stage of transformation, a majority of patients with 
SCN-MDS/AML acquire mutations in the myeloid transcription factor RUNX1 (64.5%), 
of which the majority were found in clones already harboring CSF3R mutations (85%)45. 
Mouse models have been used to study the combination of CSF3R and RUNX1 mutations, 
in conjunction with CSF3 treatment, in the leukemic progression of SCN46,47. Although these 
mice lack a SCN disease-causing mutation, these studies do give insights in the mechanisms 
of leukemic transformation. We showed that the combination of CSF3R and RUNX1 
mutations, in conjunction with CSF3 treatment, resulted in a preleukemic stage indicated 
by increased blasts in the peripheral blood but not over AML. An additional novel mutation 
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in a gene affecting TET2 levels was acquired, resulting in the possibility to perform serial 
transplantation while mice developed full-blown AML47. 
To study the combinatorial effects of CSF3R, RUNX1 in an SCN background, the 
ELANE/HAX1-mutant iPSCs serve as valuable models. We used CRISPR-Cas9-mediated 
genome editing and lentiviral transduction to introduce CSF3R and RUNX1 mutations, 
respectively. iPSCs derived from healthy donors with CSF3R and RUNX1 mutations mimicked 
the findings in the mouse model, where an increase in immature myeloid progenitors was 
observed due to increased proliferative signaling in response to CSF348. Importantly, similar 
studies in ELANE-iPSC-derived myeloid progenitors showed that this proliferative signature 
was absent. Instead, transcriptome analysis revealed that CSF3R and RUNX1 mutant 
HPCs showed induced expression of inflammatory-related signatures (Olofsen PA et al., 
manuscript submitted). 
Outlook
iPSCs have qualified as potentially useful models for studying the underlying biology 
of SCN and its leukemic progression, but major challenges remain. First of all, it is still 
uncertain to what extent the promyelocyte maturation arrest seen in patients with SCN 
can be faithfully reproduced in iPSC models. Thus far, the reported results are mixed and 
one may even wonder whether this endpoint has a major significance for understanding 
disease mechanisms, given that most patients with SCN can produce mature neutrophils if 
CSF3 is administered. Because little is known about how dosages applied in vivo translate 
to the in vitro context of iPSC cultures, the observed differences in the ability to produce 
neutrophils may depend at least partly on variations in culture conditions, rather than cell-
intrinsic defects of the myeloid progenitors produced by SCN-iPSCs. Hence, it remains largely 
unexplained how the variety of mutations found to cause SCN, affecting such functionally 
distinct proteins, all lead to a severe shortage of neutrophils. Similarly, it remains unclear 
why neutropenia can be alleviated by CSF3 treatment in the majority of patients with 
SCN, despite their underlying genetic heterogeneity. Although still only limited in number, 
studies from several laboratories including ours begin to reveal that elevated oxidative 
stress caused by, e.g., mitochondrial damage (HAX1 mutations) or increased ER stress 
(ELANE mutations), rewiring of cytokine signal transduction and transcriptional programs in 
myeloid progenitors are common denominators in different genetic SCN subtypes, features 
that can faithfully be reproduced in iPSC models 29,31,35,36. Future studies should focus on how 
these alterations affect myeloid progenitors and prevent them from producing adequate 
numbers of neutrophils under both homeostatic and infectious conditions, keeping in mind 
that these defects are reversible by CSF3 treatment, hence subtle rather than absolute. 
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Also, one needs to take into consideration that factors that may aggravate neutropenia in 
patients, such as febrile and infectious episodes, are not easily captured in vitro and this 
limitation obviously also applies to the iPSC-SCN models. To cope with this, it will remain 
essential to cross-validate observations in the iPSC models with primary patient samples, 
which has become feasible now that epigenetic/transcriptome profiling by next-generation 
sequencing can be performed on small cell numbers. If these criteria are met, valid 
endpoints for, e.g., compound testing and functional CRISPR-based screens can be defined. 
A comparable approach can be followed to unravel the functional consequences of ELANE/
HAX1 mutations, in combination with CSF3R and RUNX1 mutations and the role of CSF3 
treatment herein, for leukemic progression 36 (Olofsen PA et al., manuscript submitted). 
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Abstract
Mutations in ELANE cause severe congenital neutropenia (SCN), but how they affect 
neutrophil production and contribute to leukemia predisposition is unknown. Neutropenia 
is alleviated by CSF3 (G-CSF) therapy in most cases, but dose requirements vary between 
patients. Here, we show that CD34+CD45+  hematopoietic progenitor cells (HPCs) derived 
from induced pluripotent stem cell lines (iPSCs) from patients with SCN that have mutations 
in ELANE (n=2) or HAX1 (n=1) display elevated levels of reactive oxygen species (ROS) 
relative to normal iPSC-derived HPCs. In patients with ELANE mutations causing misfolding 
of the neutrophil elastase (NE) protein, HPCs contained elevated numbers of promyelocyte 
leukemia protein nuclear bodies (PML-NBs), a hallmark of acute oxidative stress. This  was 
confirmed in primary bone marrow cells from 3 additional ELANE-mutant SCN patients. 
Apart from responding to elevated ROS levels, PML controlled the metabolic state of these 
ELANE-mutant HPCs as well as the expression of ELANE, suggestive of a feed-forward 
mechanism of disease development. Both PML deletion and correction of the ELANE 
mutation restored CSF3 responses of these ELANE-mutant HPCs. These findings suggest that 
PML plays a crucial role in the disease course of ELANE-SCN characterized by NE-misfolding, 


























PML in severe congenital neutropenia  | 45
3
Introduction
Severe congenital neutropenia (SCN) is a genetically heterogeneous disease that, when 
left untreated, leads to life-threatening bacterial infections from the lack of neutrophils.1 
Autosomal dominant or sporadic mutations in ELANE, the gene encoding neutrophil 
elastase (NE), are the most frequent cause of SCN, whereas mutations in HAX1, encoding 
a multifunctional protein associated with mitochondrial integrity and cytoskeleton 
organization, are responsible for the autosomal recessive form of SCN originally described 
as Kostmann syndrome.2,3 Most patients with SCN receive life-long therapy with colony 
stimulating factor 3 (CSF3/ granulocyte colony-stimulating factor [G-CSF]) to alleviate 
the neutrophilic differentiation block. While the majority of patients repond favorably to 
relatively modest dosages of CSF3 (5-10 mg/kg/day), others need more excessive dosages 
(>50-100 mg/kg/day) to reach clinically beneficial neutrophil levels, whereas some patients 
fail to respond to CSF3 therapy altogether.4 Patients with SCN have an increased risk of 
developing myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) while under 
CSF3 treatment. This particularly applies to patients needing high CSF3 dosages to alleviate 
neutropenia.5,6
How ELANE, HAX1, and other mutations causing SCN affect neutrophil production is still 
largely unknown. A prevailing hypothesis is that cellular stresses, in ELANE-SCN caused 
by NE protein misfolding and in HAX1-SCN by mitochondrial leakage, are drivers of the 
neutropenia.3,7,8 However, the wide spectrum of ELANE mutations found in SCN are not 
all predicted to cause NE misfolding; therefore, alternative mechanisms of how ELANE 
mutations cause neutropenia have been proposed.9-11 This heterogeneity of mutations 
may explain the variability in CSF3 responses seen in patients and possibly also determine 
leukemia risk.4,5,9
The promyelocytic leukemia protein (PML), originally identified as a fusion partner in 
a chromosomal translocation causing acute promyelocytic leukemia, has been studied 
extensively for its role in controlling cell cycle, DNA damage, and inflammation.12-17 
Particularly, these studies dealt with the role of PML nuclear bodies (PML-NBs), hollow 
spherical structures that contain a plethora of regulatory molecules controlling the 
previously mentioned processes. Moreover, PML-NBs have been implicated in degrading 
misfolded proteins by a mechanism not involving the canonical unfolded protein response 
(UPR) signaling pathways.18 Finally, PML plays an important role in how cells deal with 
oxidative stress caused by reactive oxygen species (ROS).19 Whereas nuclear factor erythroid 
2-related factor 2 (NRF2) transcriptionally activates antioxidant pathways at relatively low 
levels of ROS, this role can be taken over by PML upon the acute generation of excess ROS, 
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e.g., induced by exposure of cells to arsenic trioxide (As2O3) or irradiation.
19
To investigate the involvement of PML in SCN, we created patient- and control-derived 
induced pluripotent stem cells (iPSCs) and generated CD34+CD45+ hematopoietic progenitor 
cells (HPCs) from these lines. We show that PML-NBs are elevated in SCN-HPCs with 
predicted NE misfolding mutations and that PML deletion reduces the metabolic activity 
and partly restores CSF3 responses of these cells. In addition, we show that loss of PML 
reduces the levels of mutant ELANE transcript and NE protein, indicating that PML may 
aggravate the SCN phenotype through a feed-forward mechanism. 




Ficoll-gradient separated bone marrow (BM) and blood cells were obtained and frozen 
according to established procedures for viable cell cryopreservation. The study was 
performed under the permission of the institutional review boards of the Erasmus Medical 
Center.
Generation of iPSC 
BM fibroblasts cultured from patients with SCN harboring ELANE mutation p.I60F 
(NC_000019.10:g.852986A>T), ELANE mutation p.R103L (NC_000019.10:g.853345G>T), 
or HAX1 mutation p.W44X (NC_000001.11:g.154273412_154273413insA), and from a 
healthy control BM were reprogrammed, as described previously.20 Cells were cultured in 
mTeSR1 (STEMCELL Technologies) on Geltrex LDEV-Free Reduced Growth Factor Basement 
Membrane Matrix (Thermo Fisher Scientific) and were regularly checked for pluripotency, 
correct karyotype and their ability to generate hematopoietic progenitor cells and mature 
neutrophils. 
CRISPR/Cas9-mediated genome editing 
CRISPR/Cas9-mediated genome editing was used to create PML-/- iPSCs, where a stop 
codon was introduced in exon 3, or correct the ELANE-I60F mutation. In short, 2x106 iPSCs 
were transfected by electroporation with 500 ng px330 (Cas9 plasmid, #42230 Addgene), 
containing a gene-specific guide RNA, and 1500 ng recombination template containing PML 
with a stop codon or ELANE wild-type sequence and a neomycin selection cassette, using 
the 4D-Nucleofector System (Lonza), program CA-137. G418 selection (50 µg/ml) started 
48 hours after electroporation. Single clones were picked and screened for homozygous 
integration of the stop codon and absence of PML protein, or correct integration of the 
wild-type ELANE sequence in the ELANE-I60F mutant allele. All clones were checked for 
retainment of pluripotency.
Hematopoietic induction
HPCs (CD34+CD45+) were produced with the STEMdiff Hematopoietic Kit (STEMCELL 
Technologies) according to the manufacturer’s protocol. Suspension cells were harvested at 
day 12 of the protocol and used for further downstream analysis.
Neutrophil differentiation
To expand myeloid progenitors and subsequently differentiate them into mature neutrophils, 
suspension cells, harvested at day 12 of the hematopoietic induction protocol, were treated 
48 | Chapter 3
as described previously.21 In short, 105 cells/ml were plated in a nontissue culture-treated 
plate in IMDM (Life Technologies) complemented with 10% defined FBS (Hyclone), 10ng/ml 
IL3 (R&D systems), 10ng/ml GM-CSF (Peprotech), 50ng/ml SCF (CellGenix GmbH) and 50ng/
ml CSF3 (Filgastrim, Zarzio). After 4 days medium was switched to IMDM complemented 
with 10% defined FBS and 50ng/ml CSF3. Cells were harvested 5 days later and used for 
subsequent FACS analysis with the EuroFlow AML tube 1 as described previously.22,23
MACS purification and immunofluorescence stainings
Suspension cells expressing CD45 were enriched using CD45 Microbeads (Miltenyi Biotec) 
and subsequent MACS separation according to the manufacturer’s protocol. Cells were 
attached to glass slides with Cytospin 4 and fixed in 4% paraformaldehyde (PFA, Polysciences) 
on ice for 20 minutes. Cells were washed with PBS and the primary antibodies (PML 1:1000 
#M041-3 MBL and NRF2 1:200 #ab31163 Abcam) were incubated overnight at 4°C in 0.05% 
Saponin (Merck, diluted in PBS). After washing 3x 5 minutes in 0.05% Saponin, cells were 
incubated with the secondary antibodies (goat anti mouse Alexa Fluor 488 1:200 Life or 
donkey anti rabbit Cy3 1:800 Bio-Connect) for 1 hour at 37°C. Cells were then washed 3x 
5 minutes in 0.05% Saponin and 2x 5 minutes in PBS after which Hoechst 34580 (1:3000, 
Merck) was added for 10 minutes. Slides were mounted with ProLong Diamond Antifade 
Mountant (Merck) and imaged on a SP5 or SP8 confocal microscope (Leica). Quantifications 
were performed using Fiji software.24
Seahorse assay
The Agilent Seahorse XFe24 Cell Culture microplate (Agilent) was coated with 22.4 µg/ml 
Cell-Tak Cell and Tissue Adhesive (Corning) for 20 minutes at room temperature. Suspension 
cells, obtained after 12 days of hematopoietic induction, were harvested and subsequently 
live cells were sorted using 7AAD. Sorted live cells (1.25x105 per well) were added to the 
coated microplate and centrifuged for 5 minutes at 200g to form a monolayer of cells at 
the bottom of the well. Cell numbers and oligomycin, FCCP and antimycin concentrations 
(all 1.0 µM) were determined after optimalization. Per condition, 5 wells were used for the 
Seahorse Mitochondrial Stress Test, which was performed according to the manufacterer’s 
instructions and measured on a XFe24 analyzer. Data were analyzed with the Seahorse Wave 
Desktop Software (Agilent).
CFU assays
ELANE-I60F patient bone marrow cells (4x104/ml) or bone marrow cells derived from a 
healthy control were seeded in triplo for colony formation in methylcellulose (H4230, 
STEMCELL Technologies) with increasing concentrations of CSF3 (0, 1, 3.33, 10, 33.3, 100 
ng/ml). Colonies were counted after 14 days of culture. A similar protocol was used for the 
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iPSC-derived HPCs, where suspension cells were harvested after 12 days of hematopoietic 
differentiation and seeded (1x104/ml) in colony cultures with CSF3 concentrations as 
described above.
RNA isolation and RNA sequencing
RNA was isolated from CD34+CD45+ HPCs using TRIzol (Thermo Fisher Scientific) and 
GenElute-LPA (Sigma) according to the manufacturer’s protocol. cDNA was generated with 
version 4 of the SMARTer Ultra Low Input RNA kit for sequencing (Clontech). Sequencing 
libraries were generated using the TruSeq Nano DNA Sample Preparation kit (Illumina), 
according to the low sample protocol and run on HiSeq 2500 or Novaseq 6000 instruments 
(Illumina).
Bioinformatics and statistics
Demultiplexing was performed using the CASAVA software (Illumina) allowing for one 
mismatch in the bar-codes. Subsequently, SMARTer adapters and poly-A tails were removed 
(fqtrim; https://ccb.jhu.edu/software/fqtrim/) and quality metrics were estimated (FastQC, 
Babraham bioinformatics & MultiQC, http://multiqc.info) for all of the resulting fastq files. 
Reads were then aligned against the Human Transcriptome (Gencode v19)/Genome (hg19) 
using the STAR aligner.25 Abundance estimation was performed using Cufflinks (refSeq26), 
and raw counts were measured with the HTSeq-count software  set in union mode.27 Next, 
the measured raw counts were used to create clustering and principal component plots and 
to perform differential expression analysis using a combination of DESeq228 and R (https://
www.r-project.org/). Finally, gene set enrichment analysis on the curated gene sets C2 and 
the hallmark pathways H was done using the GSEA software based on the pre-ranked ASHR 
log2 fold change, where a false discovery rate (FDR) <0.05 was considered significant.29,30 
Transcripts per million (TPM) were calculated using StringTie.31
Quantification and statistical analysis 
Data are presented as mean ± SEM. Comparison of two groups was performed using 
unpaired t-test. Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad 
Software Inc.) or DESeq2. A p-value <0.05 was considered significant.
Data sharing statement
For original data, please contact i.touw@erasmusmc.nl.
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Results
Elevated ROS levels and activation of the NRF2 antioxidant pathway in SCN-iPSC-derived 
HPCs 
Both mutations in ELANE and HAX1 have been reported to cause increased ROS levels in 
promyelocytes,3,7,10,11,32 but whether more immature myeloid precursors of patients with 
SCN already experience oxidative stress  because of elevated ROS has not previously been 
addressed. CellROX Deep Red analysis of HPCs derived from SCN-iPSCs with different mutations 
(ELANE-R103L (NC_000019.10:g.853345G>T), ELANE-I60F (NC_000019.10:g.852986A>T), 
and HAX1-W44X (NC_000001.11:g.154273412_154273413insA) showed higher levels of 
ROS in SCN-HPCs compared to normal control HPCs (Figure 1a). Indicative of elevated ROS 
levels, NRF2, the master redox regulator,33 was translocated to the nucleus and subsequently 
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Figure 1: SCN-iPSC-derived CD34+CD45+ cells show elevated ROS levels and increased nuclear trans-
location of NRF2 
(a) Representative FACS histograms and quantifications of mean fluorescent intensities (MFI)  showing 
increased levels of CellROX Deep Red in SCN HPCs. Data are from 3 independent experiments on 2 
clones per genotype. (b) Quantification of the nuclear translocation of NRF2 by immunofluorescence 
stainings of HPCs showing increased nuclear NRF2 levels in SCN HPCs. The red line indicates the 
median NRF2 nuclear intensity for the control HPCs. Data are pooled from 2 independent clones and 
5 independent experiments. Total cells analyzed: control n=765, ELANE-R103L n=721, ELANE-I60F 
n=677, HAX1-W44X n=574. (c) Expression of the antioxidant glutathione reductase (GSR) in transcript 
per million (TPM) obtained from 2 different iPSC clones and 2 independent experiments. *=p<0.05, 
**=p<0.01, ***=p<0.001.
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Accumulation of PML-NBs in ELANE-SCN HPCs with predicted NE-misfolding mutations
PML-NBs are formed upon acute generation of excessive oxidative stress to neutralize the 
effects of ROS that are not being coped with by the NRF2 antioxidant pathway.19 Accordingly, 
the number of PML-NBs significantly increased after incubation of control HPCs with arsenic 
trioxide (As2O3), which induces excessive oxidative stress (Figures S1a,b). In ELANE-I60F 
HPCs, higher numbers of PML-NBs were found relative to controls in the absence of As2O3, 
which was not seen in ELANE-R103L or HAX1-W44X HPCs (Figure 2a). Incubation with the 
antioxidant N-acetylcysteine (NAC) significantly reduced ROS levels and the number of PML-
NBs in ELANE-I60F cells, corroborating that in ELANE-I60F HPCs, PML-NBs were elevated 
by endogenous oxidative stress (Figures S1c,d). Comparison of the predicted structural 
alterations (https://www3.cmbi.umcn.nl/hope/)34 caused by the ELANE mutations showed 
that the ELANE-R103L mutation alters a positively charged amino acid (R) into a smaller 
neutral amino acid (L) at the surface of the protein, thereby possibly affecting interactions 
with other molecules (Figure 2b). In contrast, the ELANE-I60F alteration causes a structural 
change in the core of the protein, by introducing a bulky amino acid, that predicts protein 
misfolding (Figure 2b). To exclude that the increased numbers of PML-NBs was a feature 
of iPSC-derived, rather than bona fide BM-derived HPCs, we quantified PML-NBs in CD34+ 
cells from primary SCN bone marrow samples. These analyses confirmed that PML-NBs 
are increased in ELANE-I60F HPCs relative to controls (Figure 2c). Importantly, this was 
also seen in HPCs from a second patient with SCN with a misfolding mutation (p.P139L 
NC_000019.10:g. 855614C>T), but not in HPCs from 2 patients with ELANE-SCN patients 
that have mutations (p.I120T NC_000019.10:g. 853396T>C, p.S204TfsX11 NC_000019.10:g. 
855962_855969dup) not predicting NE misfolding (Figure 2d). 
PML knockout induces NRF2 nuclear translocation in ELANE-I60F HPCs
Because NRF2 and PML-NBs both neutralize ROS levels, we wondered to what extent deletion 
of PML in the ELANE-I60F and control HPCs affected NRF2 activation. Disruption of PML 
expression by introducing a stop codon in exon 3 (Figures S2a,b) resulted in the complete 
absence of PML-NBs (Figure 3a), while not affecting the generation of HPCs (Figure S2c,d). 
ELANE-I60F PML-/- HPCs showed significantly increased nuclear translocation of NRF2, 
confirming that PML-NBs reduced ROS levels, leading to lower NRF2 activation (Figure 3b). 
No major differences in total ROS levels were seen between PML proficient and deficient 
ELANE-I60F HPCs, indicating that NRF2, possibly in combination with other antioxidant 
pathways, compensated for the loss of PML (Figure 3c). In addition, As2O3 treatment of 
ELANE-R103L cells, which previously did not show increased numbers of PML-NBs but did 
show increased ROS levels and NRF2 translocation (Figures 1 and 2a), resulted in increased 
numbers of PML-NBs but not in increased ROS levels (Figures S1e,f), further strengthening 
the observation that both PML-NBs and NRF2 control ROS levels. No significant differences 
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in nuclear NRF2 were seen between PML proficient and deficient control HPCs, consistent 
with earlier work showing that, under physiological ROS conditions, PML-NBs do not play a 




























































































Isoleucine        Threonine
ELANE I120T
Proline         Leucine
ELANE P139L
Isoleucine                     Phenylalanine
ELANE R103L
Arginine                 Leucine
Figure 2: Increased numbers of PML-NBs in ELANE¬-SCN HPCs with predicted NE-misfolding muta-
tions
(a) Quantifications of the number of PML nuclear bodies (PML-NBs) per cell, by immunofluorescence 
stainings, shows increased numbers of PML-NBs in ELANE-I60F derived HPCs (data are pooled from 2 
independent clones, 5 independent experiments and 2 different stainings resulting in; control n=1119, 
ELANE-R103L n=720, ELANE-I60F n=732, HAX1-W44X n=914, where n=the number of cells). The red 
line indicates the median number of PML-NBs/cell for the control HPCs. (b) Amino acid alterations of 
the ELANE-R103L and -I60F mutations, with a close-up of the mutation in ribbon-presentation. The 
wild type amino acid is depicted in green and the mutant in red. (c) Quantifications of the number 
of PML-NBs in CD34+ bone marrow cells, showing increased numbers of PML-NBs in ELANE-mutant 
HPCs with predicted NE misfolding (I60F and P139L). The red line indicates the median number of 
PML-NBs/cell for the control HPCs. Cells analysed: control 1 n=89, control 2 n=127, ELANE-I60F n=79, 
ELANE-P139L n=63, ELANE-I120T n=103 and ELANE-S204TfsX11 n=74. (d) Amino acid alterations of the 
ELANE-P139L and -I120T mutations, depicted as outlined under (b). ***=p<0.001.








































































































































































Figure 3: PML acts as a ROS sensor in ELANE-I60F HPCs
(a) Representative immunofluorescent image showing complete loss of PML-NBs after introduction of 
a STOP-codon in exon 3 of the PML gene and subsequent PML-NB quantification. The red line indicates 
the median number of PML-NBs/cell for the control HPCs. Number of cells analysed (n): control 
n=441, control PML-/- n=175, ELANE-I60F n=353, ELANE-I60F PML-/-n=172. (b+d) Quantifications of 
immunofluorescent images showing (b) increased nuclear NRF2 levels in ELANE-I60F PML deficient 
HPCs, but not in control (d). Data are pooled from 3 independent experiments (ELANE-I60F: n=365; 
ELANE(-I60F) PML-/-: n=370; control: n=631; control PML-/-: n=644, where n= the number of cells). 
The red line indicates the median number of NRF2 nuclear intensity for the PML proficient HPCs. 
Microscope settings (laser power) differed between figures. (c) Relative quantification of the mean 
fluorescent intensity (MFI) showing no increased CellROX Deep Red levels after PML knockout, where 
PML proficient cells (ELANE-I60F or control) were used as baseline. Data are from 3 independent 
experiments. ***=p<0.001.
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SCN mutations result in distinct transcriptional profiles in HPCs 
To further study how ELANE and HAX1 mutations affect cellular responses of HPCs, we 
performed RNA sequencing on FACS purified CD34+CD45+ cells derived from 2 different 
iPSC clones, stemming from 2 independent hematopoietic induction experiments for 
each genotype. Principal component analysis of these transcriptome data showed distinct 
clustering for each SCN subtype and controls (Figure S3a). The homozygous HAX1-W44X 
mutation is predicted to activate nonsense-mediated mRNA decay (NMD).35 This was 
confirmed by gene set enrichment analysis (GSEA), which showed strongly elevated NMD-
related transcripts in these HAX1 mutant HPCs, but not in the ELANE mutant subtypes (Figure 
S3b and data not shown). In line with the fact that loss of HAX1 results in mitochondrial 
leakage,3 MitoTracker Red CM-H2XRos and TMRM stainings showed reduced mitochondrial 
membrane potential in HAX1 mutant HPCs (Figure S3c). Surprisingly, no upregulation of 
transcripts linked to the canonical unfolded protein response (UPR) pathway in ELANE-
I60F HPCs was seen, as would be predicted from a mutation leading to protein misfolding 
(Figures S3d,e). Transcriptome analysis on more mature myeloid cells derived from these 
HPCs, by culturing the cells in the presence of CSF3, did not show upregulation of classical 
UPR-related genes and pathways (Figures S3f-h). Because PML-NBs have also been shown to 
control degradation of misfolded proteins, independent of the canonical UPR18, these data 
suggest that a PML-dependent mechanism, rather than the classical UPR, controlled levels 
of misfolded NE in the ELANE-I60F HPCs. 
PML activates metabolic pathways in ELANE-I60F HPCs
To assess which additional intracellular processes are controlled by PML, we compared the 
transcriptomes from HPCs generated from PML proficient and deficient ELANE-I60F and 
control iPSC lines. Deletion of PML reduced MYC and mTORC1-induced transcription in HPCs 
from ELANE-I60F, but not control HPCs, suggesting that PML drives metabolic pathways 
in these ELANE mutant HPCs (Figure 4a). Oxygen consumption assays showed that PML 
enhanced basal- and maximal respiration as well as ATP production in ELANE-I60F, which 
was not seen in control HPCs (Figure 4b). In addition, transcriptional signatures indicated 
that PML activated cell cycling of ELANE-I60F HPCs, which translated into a moderately 
elevated fraction of cells in S-phase, while this was not seen in control HPCs (Figures S4a,b). 
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Figure 4: PML activates metabolic pathways in ELANE-I60F HPCs 
(a) GSEA comparing PML proficient and deficient cells showing that PML induces MYC and mTORC1 
signalling in ELANE-I60F, but not in control HPCs. Data are derived from 3 independent experiments. 
(b) Oxygen consumption rate (OCR) measured with the Seahorse mitochondrial stress test (Agilent) 
showing PML dependent increases in basal respiration, ATP production and maximum respiration in 
ELANE-I60F cells (n=5). NES: normalized enrichment score, FDR: false discovery rate. ***=p<0.001, 
****=p<0.0001.
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PML induces expression of ELANE-I60F
Transcriptome analysis further showed that ELANE was highly expressed in ELANE-I60F 
HPCs, relative to controls, whereas this increase in transcript levels was not observed in 
ELANE-R103L and HAX1-W44X HPCs (Figure 5a). Both wild-type and mutant transcripts 
could be detected in an approximately equal ratio in ELANE-I60F HPCs (Figure S5a). PML 
knockout significantly reduced transcription of both the normal and mutant alleles in the 
ELANE-I60F HPCs (Figures 5b and S5b), implying that PML drives the expression of ELANE-
I60F and thereby exacerbates the disease phenotype. Extending this observation to protein 
levels, neutrophil elastase (NE) was detected at significantly higher levels in ELANE-I60F 
HPCs cells compared to control (Figure 5c). In both ELANE-I60F and control PML-/- HPCs, NE 
levels were strongly reduced, thus confirming the critical role of PML in ELANE expression 
in HPCs (Figure 5c). To exclude that this was a unique feature of the ELANE-I60F mutation 
in iPSC-derived HPCs, we analysed NE expression in the CD34+ HPCs from the primary BM 
samples shown in Figure 2c. In addition to the elevated formation of PML-NBs, NE protein 
levels were higher in the HPCs from patients with SCN with the NE- misfolding mutations 
(I60F and P139L) than in those from patients with other ELANE mutations or control HPCs 
(Figure 5d). 
Correction of the ELANE-I60F mutation reverses the PML-mediated phenotype
To exclude that the increased formation of PML-NBs and higher expression of NE resulted 
from variations between the iPSC lines related to, e.g., reprogramming or differences in (epi-)
genetic states of the lines, we corrected the ELANE-I60F mutation by CRISPR-Cas9 mediated 
genome editing in a fully isogenic setting (Figures S6). Immunofluorescent stainings showed 
that the numbers of PML-NBs in the corrected HPCs returned to basal levels (Figure 5e). 
Similarly, immunoblot analysis of 2 independent corrected clones showed that the increased 
NE levels in ELANE-I60F HPCs were reduced to control levels in corrected HPCs (Figure 5f). 
In line with PML-induced expression of metabolic and cell cycle-related pathways, GSEA 
showed significantly reduced expression of MYC targets, mTORC1 signalling, E2F targets 
and G2M checkpoint in ELANE-I60F corrected lines (Figure 5g). These data establish that 
both the increase in PML-NB formation, NE expression, and metabolic/cell cycle-related 
transcripts in ELANE-I60F HPCs were solely caused by the I60F amino acid alteration. 
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Figure 5: PML induces expression of ELANE-I60F
(a+b) Expression of ELANE in transcripts per million (TPM) showing (a) upregulated expression in 
ELANE-I60F, but not ELANE-R103L and HAX1-W44X (data are derived from 2 independent clones and 
2 independent experiments), and (b) increased levels of ELANE mRNA in ELANE-I60F HPCs, which is 
reduced to control levels when PML is absent (n=3 independent experiments). (c) Immunoblot showing 
PML dependent neutrophil elastase (NE) protein abundance, with increased levels in ELANE-I60F cells. 
d) Immunblot of patient BM cells showing increased NE protein abundance in ELANE-mutant cells with 
predicted NE misfolding (I60F and P139L) but not others (I120T and S204TfsX11). (e) Quantification of 
immunofluorescence images showing increased, ELANE-I60F driven, numbers of PML-NBs. Data are 
pooled from 3 independent experiments and 3 independent ELANE-I60F corrected clones resulting in; 
control: n=126; ELANE-I60F: n=144; ELANE-I60F corrected n=442, where n= the number of cells. The 
red line indicates the median number of PML-NBs/cell for the control HPCs. (f) Immunoblot showing 
increased NE protein abundance in ELANE-I60F cells, which is reduced to control levels upon correction 
of the mutation, as shown in 2 independent clones. (g) GSEA comparing ELANE-I60F HPCs with corrected 
ELANE-I60F HPCs (2 independent experiments and 3 independent corrected clones) showing increased 
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MYC, mTORC1 and cell cycle-related signatures in ELANE-I60F HPCs. ELANE PML-/- = ELANE-I60F PML-
/-, NES: normalized enrichment score, FDR: false discovery rate, *=p<0.05, **=p<0.01, ***=p<0.001.
PML inhibits the CSF3 response of ELANE-I60F myeloid progenitors 
The patient with SCN from whom the ELANE-I60F iPSC line was derived showed a poor 
clinical response to CSF3, where treatment with an excessive dosage of 60-70μg/kg CSF3 
resulted in only a modest increase in mature granulocytes. This was confirmed in CFU-G 
colony assays with titrated dosages of CSF3, showing that, while bone marrow cells from 
the patient with HAX1-W44X SCN and 2 healthy controls show a dosage dependent increase 
in colony formation, the ELANE-I60F CFUs did not respond to CSF3 dosages exceeding 100 
ng/ml (Figure 6a). Notably, colony formation in the presence of a myeloid cytokine cocktail 
consisting of IL-3, GM-CSF and CSF3 was within the normal range, (i.e., 127 colonies per 
105 Ficoll-purified BM cells plated, where the normal reference of control BM cells in our 
laboratory is between 90-800 colonies per 105 cells). Thus, the lack of CSF3 response was 
not caused by a loss of myeloid progenitors per se. Similar CSF3 titration experiments 
showed that ELANE-I60F iPSC-derived HPCs were hyporesponsive to increasing dosages of 
CSF3 in CFU-G assays, which was restored after correction of the mutation (Figure 6b). A 
comparable restoration of the CSF3 response was seen in PML-deficient ELANE-I60F HPCs. 
Flow cytometric analysis of CD11b expression, a marker for myeloid differentiation, showed 
that ELANE-I60F HPCs produced significantly less CD11b+ cells relative to control, upon 
switching to CSF3-containing suspension cultures, consistent with a reduced response to 
CSF3. In agreement with the inhibitory effects of PML seen in colony assays, PML deletion 
almost completely restored the percentage of cells expressing CD11b (Figure 6c left panel). 
Additionally, although significantly increased numbers of CD117+ immature myeloid cells 
(myeloblasts/promyelocytes) remained present in the ELANE-I60F cultures compared 
with control cells, this fraction decreased upon deletion of PML (Figure 6c right panel). 
Corroborating these findings, cytologic analysis showed that ELANE PML-/- and ELANE-I60F 
gene-corrected cells differentiated towards mature neutrophils in these cultures, whereas 
ELANE-I60F cells mainly accumulated in more immature stages of myeloid differentiation 
(Figure 6d). Taken together, these data imply that PML contributes to the poor CSF3 response 
and decreased neutrophil differentiation seen in this patient with SCN.
































































































































































ELANE-I60F HAX1-W44X normal BM 1
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ELANE-I60F
ELANE-I60F PML-/- ELANE-I60F corrected
Figure 6: PML inhibits the CSF3 response of ELANE-I60F HPCs
(a) CFU-G assays on ELANE-I60F bone marrow cells showing a very limited CSF3 response with increasing 
dosages of CSF3, where HAX1-W44X and normal bone marrow cells show a CSF3-induced increase 
in colony formation. (b) CFU-G assays on iPSC-derived HPCs showing a similar hyporesponsiveness 
in ELANE-I60F cells, which is restored upon correction of the mutation and partly restored by the 
removal of PML (data are pooled from 3 independent experiments performed in triplicate). Dashed line 
indicates a non-linear fitted curve. (c) Representative FACS histogram depicting CD11b expression (left 
panel) and subsequent quantifications of the myeloid cells present in CSF3-containing liquid culture 
(right panel, n=3) showing an elevated ratio of  immature versus mature myeloid cells in ELANE-I60F 
cells relative to controls, which was partly reverted to normal after PML knockout (ELANE PML-/- = 
ELANE-I60F PML-/-). *=p<0.05, **=p<0.01. (d) Representative May Grünwald-Giemsa stained images 
of parental, PML deficient and corrected ELANE-I60F cells.
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Discussion
By generating iPSC models, we addressed how CD34+CD45+ HPCs from patients with SCN are 
affected by mutations in ELANE or HAX1, with emphasis on the levels of oxidative stress. We 
showed that, although elevated ROS levels and activation of the NRF2 antioxidant pathway 
were detectable in all cases tested, increased PML-NB formation was seen in a subgroup 
of ELANE-SCN patients with mutations leading to NE protein misfolding. Elevated PML-NB 
formation is a characteristic of cells undergoing acute and more excessive oxidative stress 
than cells under more physiological conditions.19 The focus of this study was to unravel the 
function of PML in these cases. 
Previous studies have shown that ELANE mutations evoke “classical” UPR responses in both 
mouse and human SCN models, likely caused by NE misfolding.11,36 However, in a more 
recent study, mutant ELANE failed to induce an UPR, even though the mutation predicted NE 
misfolding.37 A possible explanation for this discrepancy is that the wide spectrum of ELANE-
mutations in patients with SCN differentially affect NE protein structure and folding.9,10 It 
is therefore not inconceivable that different structural changes might result in variable 

























Figure 7: Graphical representation of the PML-mediated responses in ELANE-I60F HPCs 
ELANE-mutations with predicted NE misfolding result in excessive doses of ROS, inducing the formation 
of PML-NBs. PML-NBs are important for reducing ROS levels, while also inducing metabolism, 
proliferation and cell cycling. In addition, PML reduces the response to CSF3 and induces the 
transcription of (mutant) ELANE, providing a feed-forward mechanism.
Our findings fit into a model (Figure 7) in which ELANE mutations that result in NE protein 
misfolding, e.g., by insertion of a bulky amino acid in the core of the protein, induce an 
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increased level of oxidative stress in CD34+CD45+ HPCs. As a consequence, PML-NBs 
are being formed, which not only act to reduce excessive ROS levels, but also stimulate 
metabolism and, to a lesser extent, proliferation of the HPCs. In addition, PML dampened 
the CSF3 responsiveness of ELANE-I60F HPCs in vitro, providing a possible explanation for 
the ineffective clinical CSF3 response in this patient. Finally, transcription of (mutant) ELANE 
and NE protein expression strongly depended on PML, suggestive of a PML-driven feed-
forward loop aggravating the consequences of the NE misfolding mutation.
Even though a confirmation of the ELANE-I60F iPSC-derived data was obtained in primary 
CD34+ cells from this patient with SCN, as well as in a SCN patient with an other predicted 
misfolding mutation (ELANE-P139L), it still needs to be addressed to what extent cases of SCN 
with NE misfolding mutations other than ELANE-I60F and ELANE-P139L fit into the model 
shown in Figure 7. Keeping in mind that a large number of different ELANE mutations have 
been reported in both SCN and cyclic neutropenia (CyN), some of which overlap between 
the two conditions9, additional unknown host factors must have an impact on disease 
characteristics, i.e., determining (i) cyclic versus severe neutropenia, (ii) risk of leukemic 
transformation and (iii) response to CSF3 treatment and variations in dosaging. 
Despite these limitations, we propose that SCN cases in which CD34+ cells accumulate 
increased numbers of PML-NBs due to specific ELANE mutations predicting NE-misfolding 
represent a distinct subgroup of patients with specific clinical features. First of all, as 
increased ROS levels lead to more severe oxidative damage, these patients may face a 
higher risk to develop MDS or AML than patients with lower levels of oxidative stress in their 
HPCs. This is in line with the fact that patients with SCN who do not respond well to CSF3 
treatment have a much higher chance to progress to MDS or AML than good responders.5,6,38 
The finding that PML enhanced MYC and mTORC1 signaling in ELANE-I60F HPCs, leading to 
increased metabolic and proliferative activity, supports the notion of increased potential 
for progression to leukemia.39,40 This appears in contrast with earlier studies showing that 
PML represses the AKT/mTOR pathway under hypoxic conditions in, for example, models 
of neoangiogenesis.41,42 Potential explanations for this discrepancy might relate to the 
fact that PML functions can be divergent depending on the oxidative state of cells (i.e., 
hypoxic versus hyperoxic) or depend on the cell type or developmental stage of cells. In 
line with this, although PML has well-documented tumor suppressive functions, more 
recent evidence suggests that, depending on the cellular context, PML also has oncogenic 
properties.43,44 Further studies are needed to resolve this issue and also to elucidate how 
PML and upregulation of mTORC1 signaling are transcriptionally connected.  
62 | Chapter 3
Finally, the observation that expression of NE levels in the ELANE-I60F HPCs strongly 
depended on PML is intriguing. RNA-sequencing data indicated that transcription of both 
wild-type and mutant ELANE alleles fully depended on the presence of PML. PML ChIP 
sequencing data from the PML-RARα zinc-inducible U937 cell line (UPR9) showed that PML 
binds to the promoter/enhancer region of ELANE,45 which could suggest that PML directly 
controls its transcription. Although suggestive of a PML-mediated feed-forward loop 
as illustrated by the dashed arrow in Figure 7, the possibility that mutant NE is, at least 
partly, degraded by a PML-driven mechanism should be taken into account, similar to the 
mechanism shown in a model of neurodegeneration.18
In summary, this study sheds further light on the complex and heterogeneous natural history 
of SCN and identified a subset of patients with ELANE-SCN characterized by the activation 
of PML-mediated responses of hematopoietic progenitors, which may ultimately help to 
design new strategies for disease management for these cases.
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FACS analysis and cell sorting
SSEA4-PE (#330406, BioLegend, Amsterdam, the Netherlands) and Tra-1-60 Alexa Fluor 647 
(AF647, #560122, BD Biosciences, San Jose, CA, USA) were used for regular pluripotency 
screenings of the iPSCs. Hematopoietic induction of iPSC was assessed using CD34-
PE (#345802, BD Biosciences), CD34-Alexa Fluor 700 (#343525, BioLegend), CD45-APC 
(#555485, BD Biosciences) and/or CD45-FITC (#A07782, Beckman Coulter, Woerden, the 
Netherlands) antibodies. Cytoplasmic oxidative stress levels were measured with CellROX 
Deep Red, while mitochondrial membrane potential was measured using MitoTracker 
Red CM-H2XRos and TMRM (all Thermo Scientific). Dead cells were excluded using 
7-aminoactinomycin-D (7AAD, Life Technologies) or 4’,6-Diamidino-2-Phenylindole (DAPI, 
Thermo Fisher Scientific). Cell cycle analysis were performed with the BrdU flow kit (BD 
Pharmingen) according to the manufacturer’s instructions. Flow cytometry was performed 
using a BD LSRII flow cytometer (BD Biosciences). Cell sorting was done using a FACSAria 
instrument (BD Biosciences). Analysis of FACS data was performed using FlowJo (TreeStar). 
SDS-PAGE/Immunoblotting
Lysates were prepared, and immunoblot analyses performed as previously described1. The 
primary antibody (#ab131260, Abcam) was used to detect NE protein levels. Goat anti-
rabbit HRP (#A16116, Life Technologies) was used as secondary antibody, after which the 
SuperSignal West Pico Plus Chemiluminescent Substrate (Thermo Fisher Scientific) was used 
to detect the signal on an Amersham Imager 600 instrument. A β-actin antibody (Sigma) 
was used as loading control, followed by incubation with the secondary IRdyes donkey 
anti-mouse 680LT antibody (Licor, Homburg, Germany) to detect the signal on an Odyssey 
instrument (Licor). 
Arsenic trioxide and N-acetylcysteine treatment
Cells in suspension were harvested at day 12 of the hematopoietic induction and treated 
for 1 hour at 37°C with 1μM Arsenic trioxide (As2O3) or 2mM N-acetylcysteine (NAC, Sigma). 
Subsequently, cells were used for immunofluorescence stainings or CellROX Deep Red flow 
cytometry.
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Figure S1: PML-NB formation can be induced with As2O3 and reduced with NAC treatment
(a,c,e) Quantifications of the number of PML nuclear bodies (PML-NBs) per cell, by immunofluorescence 
stainings, showing (a) increased numbers of PML-NBs in control cells treated with arsenic trioxide 
(As2O3, 1μM for 1 hour), (c) reduced numbers of PML-NBs upon treatment with the antioxidant 
N-acetylcysteine (NAC, 2mM for 1 hour) in ELANE-I60F cells and (e) increased numbers of PML-NBs in 
ELANE-R103L cells treated with As2O3 (1μM for 1 hour). Total cells analyzed:  control n=151, control+ 
As2O3 n=169, ELANE-I60F n=134, ELANE-I60F+NAC n=190, ELANE-R103L n=156, ELANE-R103L+ As2O3 
n=126. (b,d,f) A representative FACS histogram showing CellROX Deep Red levels which are (b) increased 
upon treatment with As2O3 in control HPCs, (d) reduced upon treatment with NAC in ELANE-I60F HPCs, 
and (f) not significantly altered in ELANE-R103L HPCs upon treatment with As2O3. ***=p<0.001.
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Figure S2: CRISPR-Cas9 mediated genome editing of PML
(a) A guide RNA targeting exon 3 of PML, which is shared by all isoforms, was used to introduce 3 
STOP codons, and a neomycin selection cassette, into the PML coding sequence. (b) Sanger sequencing 
data showing homozygous integration of the recombination template in ELANE-I60F PML-/-, while 
the control PML-/- cells have a heterozygous integration and a frameshift mutation, resulting in a 
premature stop codon, in the allele that shows no integration of the recombination template. The 
blue line indicates part of the guide RNA. (c) FACS plots showing the floating cells at day 12 of the 
hematopoietic induction protocol. The percentages of CD34+CD45+ HPCs differ between experiments 
(ranging from 10-50%), but no significant alterations are observed after CRISPR-Cas9 genome editing. 
(d) FACS histogram showing the CD11b expression of CD34+CD45+ of the floating cells at day 12 of the 
hematopoietic induction protocol (light colors) and at the end of the neutrophil differentiation protocol 
(dark color). A small percentage of CD34+CD45+ HPCs express CD11b, but no significant differences are 
observed between lines. At the end of the neutrophil differentiation protocol a clear induction of CD11b 
expression can be observed.
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Figure S3: Transcriptome analysis suggests different mechanisms of disease initiation in different SCN 
patients
(a) Principal component analysis (PCA) showing separate clustering of HPCs derived from different 
SCN-patients (n=2 different clones and 2 independent experiments). (b) Gene set enrichment analysis 
(GSEA) showing upregulation of transcripts associated with the reactome ‘nonsense mediated 
decay enhanced by the exon junction complex’ in HAX1-W44X derived HPCs compared to control. 
(c) Representative FACS histogram showing reduced MitoTracker Red and TMRM levels, indicative of 
reduced mitochondrial membrane potential, in HAX1-W44X derived HPCs. (d) GSEA indicating lack of 
transcript expression associated with the canonical unfolded protein response pathway in ELANE-I60F 
derived HPCs. (e) Expression of various UPR-related genes (in TPM) showing no differences between 
control and ELANE-I60F HPCs (n=2 different clones and 2 independent experiments). (f) GSEA indicating 
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no induction of the canonical unfolded protein response pathway in more mature granulocytic cells 
from ELANE-I60F. (g) Expression of various UPR-related genes (in TPM) showing no differences between 
control and ELANE-I60F derived granulocytic cells (n=2 independent experiments). (h) Representative 
May Grünwald-Giemsa-stained images of more mature myeloid cells used for RNA sequencing 7 days 
after the start of the neutrophil differentiation protocol.
NES: normalized enrichment score, FDR: false discovery rate, TPM: transcripts per million.
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Figure S4: PML activates cell cycling in ELANE-I60F HPCs
(a) GSEA comparing PML proficient and deficient cells, which shows that PML does not influence E2F 
targets and G2M checkpoint related transcripts in control HPCs, while inducing expression of these 
transcripts in ELANE-I60F (data derived from 3 independent experiments). (b) BrdU analysis showing 
a moderately increased fraction of S-phase cells in PML proficient ELANE-I60F HPCs, compared to 
PML deficient ELANE-I60F HPCs (data combined from 3 independent experiments). NES: normalized 
enrichment score, FDR: false discovery rate. ELANE PML-/- = ELANE-I60F PML-/-.












Figure S5: ELANE expression
(a+b) IGV snapshot showing approximately equal expression of the ELANE-I60F wildtype (A, in green) 
and mutant (T, in red) allele in RNA sequencing data of (a) control and ELANE-I60F HPCs as shown in 
Figure 5a and (b) ELANE-I60F and ELANE PML-/- HPCs as shown in Figure 5b.
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Figure S6: CRISPR-Cas9 mediated correction of ELANE-I60F mutation
(a) CRISPR-Cas9 strategy to correct the ELANE-I60F mutation, where the guide RNA overlaps the 
mutation, thereby increasing the probability of targeting the mutant allele. The correct sequence 
was introduced with a recombination template containing a neomycin selection cassette, located in 
the next intron, to be able to select for the recombined clones. (b) Sanger sequencing data showing 
correction of the ELANE-I60F mutation, and heterozygous introduction of the PAM mutation present 
in the recombination template, in the corrected ELANE-I60F lines. (c) FACS plots showing the floating 
cells at day 12 of the hematopoietic induction protocol. The percentages of CD34+CD45+ HPCs differ 
between experiments (ranging from 10-50%), but no significant alterations are observed after CRISPR-
Cas9 genome editing.
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Abstract
Somatic RUNX1 mutations are found in approximately 10% of patients with de novo acute 
myeloid leukemia (AML), but are more common in secondary forms of myelodysplastic 
syndrome (MDS) or AML. Particularly, this applies to MDS/AML developing from certain types 
of leukemia-prone inherited bone marrow failure syndromes. How these RUNX1 mutations 
contribute to the pathobiology of secondary MDS/AML is still unknown. This mini-review 
focusses on the role of RUNX1 mutations as the most common secondary leukemogenic hit 
in MDS/AML evolving from severe congenital neutropenia (SCN).  
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Introduction 
The occurrence and frequency of RUNX1 mutations in a variety of hematological malignancies 
has been well-documented1. Originally identified as a chromosomal translocation partner 
in the so-called core-binding factor (CBF) leukemias, somatic RUNX1 mutations were 
also found in myeloid malignancies, particularly in myelodysplastic syndrome (MDS) and 
acute myeloid leukemia (AML)2-10. Somatic mutations in RUNX1 cluster mostly within the 
N-terminal Runt homology domain (RHD) whereas mutations disrupting the C-terminal 
transactivation domain (TAD) occur less frequently4,8,10,11. Importantly, mutations in 
RUNX1 were identified as the cause of familial platelet disorder, in which patients show a 
predisposition to develop MDS or AML (FPDMM or FPD/AML)12. These germline mutations 
are similar to those acquired in MDS/AML12. Finally, it has become clear that somatic RUNX1 
mutations are particularly prevalent in MDS/AML secondary to inherited bone marrow 
failure syndromes (iBMFs) such as Fanconi anemia and severe congenital neutropenia (SCN), 
and in radiation-associated MDS/AML13-15. These forms of secondary MDS/AML (sMDS/
AML) are characterized by an adverse prognosis due to refractoriness to treatment. Why 
secondary RUNX1 mutations are associated with sMDS/AML and how they contribute to the 
pathogenesis of these conditions remains largely unclear. Here, we will discuss the current 
insights and ideas regarding mutant RUNX1 in the context of malignant transformation of 
iBMFs, taking SCN as the leading example. Specifically, we will briefly summarize and discuss 
our most recent insights into these issues based on observations in patients, mouse- and 
induced pluripotent stem cell (iPSC)-models. 
Severe congenital neutropenia
SCN is an iBMF characterized by severely reduced neutrophil counts, leading to life-
threatening bacterial infections16. Autosomal dominant mutations in ELANE, the gene 
encoding neutrophil elastase, are the most frequently observed genetic defects in SCN 
patients. How these mutations give rise to severe neutropenia is still largely unknown16. 
Life-long administration of colony stimulating factor 3 (CSF3), also known as granulocyte 
colony-stimulating factor (G-CSF), successfully alleviates the neutropenia in the majority of 
SCN patients17. Importantly, SCN patients have a high risk of developing MDS or AML, with 
a median incidence of 21%, 15 years after initiation of CSF3 treatment18,19. The majority 
of SCN patients with leukemic progression show the appearance of hematopoietic clones 
with somatic mutations in CSF3R, resulting in a truncated form of CSF3R with defective 
internalization and aberrant signaling properties20. These clones may persist for months 
or even years before MDS or AML becomes overt21, raising the question how these CSF3R 
mutants contribute to the malignant transformation of SCN. Activation of oxidative stress 
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through enhanced production of reactive oxygen species (ROS) and sustained activation of 
signal transducer and activator of transcription STAT5 have been put forward as candidate 
mechanisms by which activation of truncated CSF3R drive clonal expansion of myeloid 
progenitors 22,23.
RUNX1 mutations in SCN-MDS/AML patients 
Like for numerous other disease conditions, the introduction of massive parallel (“next 
generation”) sequencing has greatly advanced our insights into the genomic defects 
associated with the leukemic progression of SCN. A retrospective analysis in an ELANE-SCN 
patient, who continuously received CSF3 therapy for 15 years and during which period serial 
BM sampling was done, showed that after the occurrence of multiple CSF3R mutant clones 
2 years after the start of CSF3 treatment, no additional mutations were detected until MDS/
AML became clinically overt24. At that fully transformed stage, a limited number of clonal 
mutations in regulatory genes, including RUNX1, SUZ12, ASXL1 and EP300, were present24. 
This pattern of leukemic evolution was confirmed in a follow-up study involving 31 SCN-
MDS/AML cases15. Importantly, this study revealed that mutations in RUNX1 are by far the 
most frequent somatic secondary mutations in SCN-MDS/AML and preferentially occurred 
in CSF3R mutation clones. In SCN-MDS/AML, mainly RUNX1 mutations disrupting the runt 
homology domain (RHD), essential for DNA binding and for interaction with the regulatory 
protein core-binding factor β, were found15,24. In view of these characteristics, the molecular 
pathogenesis of SCN/AML serves as an attractive model to investigate the role of secondary 
RUNX1 mutations in a molecularly well-defined process of leukemic progression. 
Mouse model to study the impact of Csf3r and RUNX1 mutations in 
conjunction with CSF3-treatment 
The impact of Runx1 and mutants on hematopoietic cell development has been investigated 
in a variety of mouse models and has been the subject of several recent reviews1,25-27. 
Notwithstanding some contradictory results, possibly related to discrepancies in the 
immune-phenotyping based classification of stem cell subpopulations, it is generally 
accepted that wild type Runx1 has no major impact on the production and function of long-
term hematopoietic stem cells (LT-HSCs) in mice, both under homeostatic conditions and 
under conditions of proliferative stress28. More relevant in the context of RUNX1 mutations 
in SCN-MDS/AML are the mouse models with RUNX1-RHD mutations equivalent to those 
recurrently found in patients5. Watanabe-Okochi and colleagues studied the effects of such 
a mutant in transplantation experiments, in which donor bone marrow (BM) cells were 
transduced with a murine leukemia virus (MLV)-derived vector to express the most common 
RUNX1 mutant D171N and reported that this resulted in MDS and MDS/AML 29. However, 
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integration of the MLV-based vector in the Mecom (Evi1) locus caused overexpression of 
Evi1 in these mice29. Because the combination of RUNX1 mutations and high EVI1 expression 
is rarely seen in MDS/AML, and because high Evi1 expression can be leukemogenic by itself, 
the contribution of RUNX1-RHD in MDS/AML development in more general could not be 
accurately deduced from this model29,30. In fact, expression of mutant D171N in human cord 
blood cells had marginal effects on the rate of proliferation and differentiation capacity of 
CD34+ cells in in vitro suspension culture relative to empty vector control cells, suggesting 
that isolated RUNX-RHD mutations are only weakly leukemogenic31. 
To study the role of RUNX1-D171N in a context relevant to SCN-MDS/AML, we 
used a mouse model expressing a truncated Csf3r (Csf3r-d715) identical to the mutant 
CSF3R form in SCN patients32,33. To avoid the tropism of MLV-based vectors for oncogenic 
enhancers, we generated a lentiviral expression vector to express RUNX1 mutant D171N31 in 
conjunction with enhanced green fluorescent protein (eGFP) in Csf3r-d715 BM cells, which 
were subsequently serially transplanted in wild type recipients. Recipients were treated 
either 3x a week with CSF3 or with PBS (solvent control). Transcriptome analysis and whole 
exome sequencing on FACS purified eGFP+Lin-c-Kit+ (LK) populations were done to identify 
molecular pathways associated with leukemic progression. Sequential CD34+ cell samples 
from a SCN/AML patient with identical CSF3R and RUNX1 mutations24 and whole genome 
sequencing data from diagnostic AML samples were used for clinical comparisons34.
CSF3 treatment of primary recipients transplanted with Csf3r-RUNX1 mutant BM 
cells resulted in sustained (30+ weeks) presence of eGFP+LK cells in the peripheral blood 
(PB), which had the morphological appearance of myeloblasts. The PB also contained eGFP+ 
neutrophils, indicating that myeloid differentiation was not completely blocked. Importantly, 
none of these primary recipient mice succumbed to symptoms of AML, suggesting that the 
elevated myeloblasts in the PB reflected a pre-leukemic rather than a fully transformed state. 
However, upon transplantation in secondary and tertiary recipients, mice developed Csf3r-
RUNX1 mutant AML that was no longer dependent on CSF3 administration. Transcriptome 
profiles of purified eGFP+LK cells sorted before transplantation, showed that expression of 
RUNX1 mutant protein in Csf3r mutant cells resulted in elevated proliferative/metabolic 
signatures characterized by elevated MYC and mTORC1 signaling relative to empty vector 
controls. Strikingly, at the sequential steps of leukemic transformation in the mouse model, 
these signatures declined while TNFα-, interferon- and interleukin-6-driven inflammatory 
responses were increasingly upregulated. Whole exome sequencing performed on the LK-
cells from these stages revealed that an internal tandem duplication (ITD) in Cxxc4 was 
acquired. In the secondary and tertiary recipients all AML cells harbored the Csf3r, RUNX1 
and heterozygous Cxxc4 mutations, while the primary recipient showed a subclonal Cxxc4 
mutation (VAF: 0.27). The mutation resulted in a 7-fold higher expression of CXXC4 protein. 
CXXC4 was previously shown to inhibit TET2 protein levels35,36 and in agreement with this, 
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TET2 levels were strongly reduced in the CXXC4 mutant/overexpressing leukemic samples. 
Intriguingly, CXXC4 mutations have also been detected in human AML cases, including the 
ITD mutations identified in our mouse model34. These observations in mice fit into a model 
in which the activation of a truncated Csf3r by the sustained administration of CSF3 and 
the presence of RUNX1-RHD mutant D171N give rise to a premalignant state, characterized 
by the accumulation of LK cells in the PB and elevated activation of proliferative signalling 
(Figure 1). An additional clonal mutation that reduces the levels of TET2 drives the full 
transformation to AML, at which stage the leukemia-initiating cells have lost their need for 
CSF3 for propagation in vivo and the AML blasts have adopted an inflammatory signature 
identical to that of SCN/AML cells with identical mutations in CSF3R and RUNX1 (Figure 
1)24,37. Although CXXC4 mutations have thus far not been reported in clinical SCN/AML 
samples, mutations potentially affecting TET2 levels and/or function, such as mutations in 
polycomb repressor complex-2 genes (EZH2, SUZ12) are recurrently present15,24.    
Figure 1: Model of leukemic progression in mice based on serial transplantation of Csf3r-d715/RUNX1-
RHD mutant BM cells. 
In primary recipients, the combination of Csf3r-d715 and RUNX1-D171N gives rise to accumulation of 
immature LK cells. This occurs only when mice are treated with G-CSF (CSF3) and mice do not succumb 
to symptoms of leukemia. Upon secondary and subsequent transplantations of these LK cells, a G-CSF 
independent AML develops, which is characterized by elevated inflammatory responses and reduced 
TET2 protein levels.       
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Studies in induced pluripotent stem cell (iPSC) models
The use of patient-derived iPSC lines has created new possibilities to model diseases, 
including myeloid malignancies38. In the context of RUNX1, these studies have mainly dealt 
with FPD/AML, characterized by germline RUNX1 mutations39-41. Key features of these 
iPSC lines are (i) their reduced ability to generate CD34+CD45+ hematopoietic stem and 
progenitor cells (HSPCs) and (ii) their affected ability of megakaryocyte (Mk) production 
and pro-platelet formation, thus explaining the platelet defects observed in patients. The 
reduced production of HSPCs from FPD-derived iPSCs is consistent with a role of RUNX1 
in hematopoietic development from pluripotent stem cells42. As mentioned above, in SCN 
patients who develop MDS or AML, RUNX1 mutations are most often acquired in CSF3R 
mutant HSPC clones. Hence, it is important in this context to assess the consequences of 
somatic RUNX1 mutations in HSPCs cells that already harbor a CSF3R nonsense mutation. 
To achieve this, a CRISPR/Cas9-based strategy was used to introduce a patient-derived 
CSF3R nonsense mutation into iPSCs. After switching the cells to hematopoietic culture 
conditions (STEMdiff Hematopoietic Kit from STEMCELL Technologies), CD34+CD45+ cells 
were lentivirally transduced to express the RUNX1-RHD D171N mutant. These experiments 
showed that the combined presence of CSF3R and RUNX1 mutations had a moderate effect 
on myeloid differentiation, characterized by a relative abundance of immature neutrophilic 
differentiation stages, but not by an absolute differentiation block (Figure 2). As such, these 
findings corroborate the findings in the mouse model described above and further suggest 
that secondary RUNX1 mutations in clones with CSF3R mutations do not confer a fully 
transformed, i.e., MDS/AML like phenotype. In agreement with this, transcriptome analysis 
showed that the CSF3R-RUNX1 mutant cells had elevated proliferative signatures but did not 
show the inflammatory profiles seen in the SCN/AML patient and the mouse AML cells. A 
key question that remains to be addressed is how mutations in ELANE, HAX1 and other SCN-
causing mutations contribute to leukemic progression in conjunction with CSF3R and RUNX1 
mutations. Preliminary data from these models suggest that ELANE and HAX1 mutations 
cause elevated levels of reactive oxygen species (ROS) in CD34+CD45+ HSPCs generated from 
SCN-iPSCs, resulting in the upregulation of anti-oxidant pathways43 (and Olofsen PA et al., 
manuscript submitted). Future work should clarify whether and to what extent the oxidative 
damage caused by ROS and the adaptive anti-oxidant protection mechanisms contribute to 
malignant transformation. 












































Figure 2: Myeloid differentiation of iPSC-derived CD34+CD45+ cells, genome-edited to express a 
truncated form (d715) of CSF3R and transduced with RUNX1-D171N lentiviral expression vector or 
empty vector (ev) control. 
Cells were cultured in suspension for a total of 9 days in medium supplemented with myeloid growth 
factors, i.e., a cocktail of IL3, SCF, GM-CSF and G-CSF for the first 4 days, followed by G-CSF as the single 
growth factor for the next 5 days.  
Conclusions and outlook
The role of RUNX1 mutations in the development of MDS and AML remains incompletely 
understood. Studies in mouse-, patient- and iPSC-models, addressing the role of a recurrent 
RUNX1 mutation (D171N) in combination with the most frequent CSF3R mutation in the 
leukemic progression of SCN (CSF3R-d715), showed that RUNX1-D171N enhanced the 
activation of proliferative signaling pathways but only mildly affected myeloid differentiation, 
leading to a relative accumulation of immature cells but not to an absolute differentiation 
block. Furthermore, the studies in mice showed that the combination of these two mutations 
is not enough for leukemic progression, even when the mice were subjected to sustained 
G-CSF (CSF3) treatment. These findings established that additional events, one of which 
affecting TET2 levels, are necessary for full leukemic transformation. Leukemic progression 
in all models was also associated with enhanced interferon-g, interleukin-6 and TNFα/NFκB 
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signaling, suggesting that inflammation is a major additional component in the development 
of myeloid malignancy involving RUNX1 mutations. How this interplay between mutant 
CSF3R signaling, aberrant transcriptional control by mutant RUNX1, loss of TET2 function and 
inflammatory responses contributes to leukemic transformation and what the exact causal 
relationships between these mechanisms are remains to be addressed. Detailed insights 
into this complex network of events may help to discover biomarkers for early detection 
of leukemic progression of SCN and possibly other forms of iBMFs and may provide leads 
for novel forms of therapeutic intervention to avoid full malignant transformation of these 
conditions. 
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Abstract
Severe congenital neutropenia (SCN) patients treated with CSF3/G-CSF to alleviate 
neutropenia frequently develop acute myeloid leukemia (AML). A common pattern of 
leukemic transformation involves the appearance of hematopoietic clones with CSF3 
receptor (CSF3R) mutations in the neutropenic phase, followed by mutations in RUNX1 
before AML becomes overt. To investigate how the combination of CSF3 therapy and CSF3R 
and RUNX1 mutations contributes to AML development, we make use of mouse models, 
SCN-derived induced pluripotent stem cells (iPSCs), and SCN and SCN-AML patient samples. 
CSF3 provokes a hyper-proliferative state in CSF3R/RUNX1 mutant hematopoietic progenitors 
but does not cause overt AML. Intriguingly, an additional acquired driver mutation in Cxxc4 
causes elevated CXXC4 and reduced TET2 protein levels in murine AML samples. Expression 
of multiple pro-inflammatory pathways is elevated in mouse AML and human SCN-AML, 
suggesting that inflammation driven by downregulation of TET2 activity is a critical step in 
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Introduction
Severe congenital neutropenia (SCN) is an inherited bone marrow failure syndrome 
characterized by an almost complete lack of neutrophils, leading to life-threatening bacterial 
infections.1 SCN is most often caused by autosomal dominant mutations in ELANE, the gene 
encoding neutrophil elastase, but how these mutations give rise to severe neutropenia is 
still largely unknown.1 In the majority of SCN patients, neutropenia is successfully alleviated 
by life-long administration of colony-stimulating factor 3 (CSF3), also known as granulocyte 
CSF (G-CSF).2 SCN patients are at risk of developing high-risk myelodysplastic syndrome 
(MDS) or acute myeloid leukemia (AML), with a reported median incidence of 21%, 15 years 
after initiation of CSF3 treatment.3,4 Leukemic progression correlates with the appearance 
of hematopoietic clones with somatic mutations in CSF3R, resulting in a truncated form 
of CSF3R with defective internalization and aberrant signaling properties.5 These mutant 
clones arise before MDS or AML becomes clinically overt, indicating that additional defects 
are needed for malignant transformation. 
Mutations in RUNX1 are the most prevalent mutations (64.5%) acquired during leukemic 
transformation of SCN and typically occur in clones already harboring somatic CSF3R 
mutations (85%).6 RUNX1 is a member of the runt transcription factor family and is essential 
for fetal hematopoiesis.7,8 RUNX proteins share the highly conserved runt homology domain 
(RHD) involved in DNA binding and in the interaction with the regulatory protein core-
binding factor β.9 In SCN-MDS/AML, mainly RUNX1 missense mutations in the RHD were 
found in combination with the CSF3R-truncating mutations.6,10 Although recurrent mutations 
in other genes (e.g., encoding the epigenetic modifiers ASXL1 and SUZ12) were also found, 
these were far less frequent. How truncated CSF3R mutants and RUNX1 mutations in 
conjunction with disease-causing ELANE mutations contribute to AML development in SCN 
is unknown. To address this question, we used a combination of in vivo mouse models and 
in vitro patient-derived induced pluripotent stem cell (iPSC) models, engineered to express 
patient-specific CSF3R and RUNX1 mutations. 
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Results
CSF3R and RUNX1 mutations elevate CSF3 induced proliferation of LK progenitor cells
We first investigated how a RUNX1 mutation affects CSF3 responses of mouse hematopoietic 
stem and progenitor cells (HSPCs) in vitro. The patient-specific truncated CSF3R, Csf3r-d715, 
or wild type (WT) lineage-depleted bone marrow (BM) cells expressing the patient-specific 
RUNX1-D171N (RHD) mutation (Figures S1A,B) or an empty vector (ev) control were cultured 
in stem cell expansion medium with or without CSF3 (Figures 1A and 1B). In the absence of 
CSF3, no differences in absolute cell numbers between any of the conditions were seen (Figure 
1A), whereas addition of CSF3 induced a strong and sustained hyperproliferative response in 
Csf3r-d715 cells that was slightly, but not significantly, extended by mutant RUNX1 (Figure 
1B). Csf3r-d715 cells expressing RUNX1-RHD (d715-RHD cells) cultured in CSF3 medium 
showed selective expansion of lineage-negative, Sca1-negative, c-Kit-expressing (LK) cells 
relative to d715-ev control cells, which showed a more equal distribution between LK and 
more primitive LSK (Lineage-, Sca1+, c-Kit+) cells (Figure 1C). Notably, d715-RHD cell cultures 
consistently showed a higher number of LK cells and reduced numbers of differentiated 
cells relative to the ev controls from day 5 onward (Figure 1D). d715-RHD cells also 
displayed a moderate ability of secondary and tertiary replating in CSF3-containing colony 
cultures, whereas d715-ev or WT-RHD cells lacked this capability (Figure 1E). Comparative 
transcriptome analysis and subsequent single-sample gene set enrichment analysis (ssGSEA) 
of LK cells from CSF3-supplemented cultures purified by fluorescence-activated cell sorting 
(FACS) on days 2, 5 and 9 showed higher activation of hallmark pathways of cell proliferation 
(E2F, G2M checkpoint, and MYC) and metabolism (mTORC1) in d715-RHD cells relative to 
d715-ev cells (Figure 1F). In summary, these results show that mutations in Csf3r and RUNX1 
have additive effects on proliferation of myeloid cells, leading to expansion of LK cells and 
reduced production of more mature myeloid cells.
In vivo expansion of Csf3r-d715/RUNX1-RHD mutant HSPCs induced by sustained CSF3 
administration 
To address how the Csf3r and RUNX1 mutations in combination with CSF3 administration 
affected hematopoiesis in vivo, we performed transplantation experiments using lentivirally 
transduced lineage-negative Csfr-d715 BM cells (Figure S1C). Western blot analysis 
confirmed the presence of human RUNX1-D171N protein (Figure S1D). Transduction 
efficiency, analyzed by flow cytometry based on the presence of the IRES-GFP cassette 
in the lentiviral vector (Figure S1C), was approximately 40%-50% in lineage-negative BM 
cells (Figure S1E) and 65% in d715-RHD or d715-ev LSK cells (Figure S1F). These cells were 
transplanted into lethally irradiated WT recipients. Starting 4 weeks after transplantation, 
mice were treated three times per week with CSF3 or PBS (n=9 per group; Figure 1G). 
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GFP+ cells in the peripheral blood (PB) within each group varied between mice (Figure 1H). 
Overall, mice transplanted with d715-RHD BM cells and treated with CSF3 showed the 
highest level of long-term chimerism; i.e., exceeding 16 weeks following transplantation 
and 12 weeks after initiation of CSF3 administration (Figure 1H). Fluctuations in GFP+ PB 
cell percentages in individual mice over time suggest that CSF3 propagated the persistence 
rather than a dominant outgrowth of d715-RHD clones. Strikingly, CSF3-treated d715-RHD 
mice had significant percentages (16.5% average, SEM 7%) of GFP+ LK cells in PB, which was 
not seen in the other experimental groups (Figure 1I; <1%). These cells were characterized as 
myeloblasts by morphology (Figure 1J) and comprised 1%-2% myeloid colony-forming cells 
(Figure 1K; 50-100 colonies/5000 cells), equivalent to the observations of in vitro cultures 
(Figures 1C-1E). Although more than 5% myeloblasts in the PB are a characteristic of AML, 
none of the CSF3-treated d715-RHD mice showed acute symptoms of AML, such as bleeding 
or anemia. In addition, no defect in myeloid differentiation was observed as percentages of 
GFP+CD11b+GR1+ neutrophils in PB were comparable between groups (Figure S1G). At the 
time of sacrifice, no excessive GFP+ blasts in the BM were seen, with the exception of mouse 
29 (Figure 2A). On the other hand, increased numbers of GFP+ cells were detected in the 
spleens of d715-RHD CSF3-treated mice (Figure 2B). These findings suggest that the CSF3-
treated d715-RHD mice display a pre-malignant phenotype characterized by cellular but no 
symptomatic features of overt AML. 
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Figure 1: Csf3r-d715 and RUNX1-RHD in conjunction with CSF3 treatment causes the expansion of LK 
cells
(A-B) Proliferation of empty vector (ev)- or RUNX1-RHD virus-transduced cells in stem cell expansion 
medium (A) without CSF3 and (B) with 50 ng/ml CSF3. Error bars show one-sided standard error of the 
mean (SEM) of 3 independent experiments (biological replicates). (C) Representative FACS contour plots 
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showing LK/LSK distribution of d715-ev (left panel) and d715-RHD (right panel) in CSF3-supplemented 
cultures (day 9), with ± indicating the SEM. (D) Distribution of immature and differentiated cell types 
in CSF3-containing cultures spanning 23 days. Error bars show one-sided standard error of the mean 
(SEM) of 3 independent experiments (biological replicates). (E) CSF3-induced colony formation in 
primary colony assays and in secondary and tertiary replating cultures (n=3 independent experiments 
[biological replicates] in triplicate [technical replicates]). (F) Comparative transcriptome profiles 
of CSF3-stimulated d715-ev and d715-RHD LK cells on days 2, 5, and 9 of culture (n=1 sample per 
timepoint). (G) Experimental setup. CSF3/PBS administration started 4 weeks after transplantation. 
(H) Longitudinal analysis of GFP expressing cells in the PB (n=9 mice per experimental group, biological 
replicates). (I) Accumulation of GFP-expressing LK cells in PB of CSF3-treated d715-RHD-transplanted 
mice but not in other groups. Data are from PB samples taken 14 and 16 weeks after transplantation 
(n=11 or 12 per group) with ± indicating the SEM. (J) Myeloblast morphology of FACS-purified PB LK 
cells. The scale bar indicates 20 μm. (K) CSF3 induced colony formation of PB LK cells (mice 29, 30, and 
31) and representative example of the colony (n=1 experiment in triplicate [technical replicates]). See 
also Figure S1.
Premalignant Csf3r/RUNX1 mutant BM cells progress to AML in secondary recipients
The ability to engraft in secondary recipients is a hallmark of murine leukemia models. To 
determine to what extent this applied to the pre-malignant nature of d715-RHD BM cells 
from CSF3-treated mice, we transplanted BM cells from mouse 29, which presented with 
the highest level of engraftment 25 weeks after primary transplantation, in sub-lethally 
irradiated secondary recipients that were subsequently treated with CSF3 (n=6; Figures 
2C and 2D). GFP+c-Kit+ cells were detectable in the blood 4 weeks after transplantation 
and could be detected untill the end of the experiment (Figures 2E and 2F). Contrary to 
the LK cells expanding in primary recipients, these cells weakly co-expressed the myeloid 
marker CD11b, suggestive of a myeloid bias within the LK compartment (Figure 2G). High 
percentages of GFP+c-Kit+ cells were present in the BM, spleen, and liver (Figure 2H). Prior 
to sacrifice, mice were severely anemic because of an erythroid differentiation block at the 
CD71+Ter119+ basophilic and early chromatophilic erythroblasts (RII) stage in the BM and 
spleen (Figures S2A and S2B). Histological analysis showed a normo- to hypercellular BM 
with more than 90% myeloid blast infiltration with significant nuclear atypia and atypical 
mitoses and apoptosis (Figure 2I), consistent with the diagnosis of AML. 
Outgrowth of d715-RHD AML without CSF3 administration
To interrogate whether the d715-RHD-derived AML was still dependent on CSF3 
administration, we transplanted leukemic cells into tertiary recipients that were subsequently 
treated with PBS or CSF3 (n=4 per group; Figure 2J). GFP+ cells in the PB were detectable 
from 10 weeks untill the end of the experiment and increased over time in PBS- and CSF3-
treated groups with similar kinetics (Figures 2K and 2L). 























































































































































































































































































Figure 2: Spleen infiltration and CSF3-independent leukemogenic properties of d715-RHD cells 
(A and B) Distribution of GFP-expressing cells in (A) BM and (B) spleen in primary recipients, showing 
enhanced spleen infiltration in CSF3-treated d175-RHD mice. (C) Relative distributions of total GFP+ 
and GFP+c-Kit+ cells in various organs of mouse 29. (D) Secondary transplant setup; cells from mouse 
29 were transplanted into 6 recipients. (E-G) Expansion of GFP+ cells in PB of 6 secondary recipients (E, 
biological replicates), with (F) the c-Kit+ immuno-phenotype and (G) Intermediate CD11b expression on 
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c-Kit+ cells. (H) Organ distribution of GFP+ and GFP+c-Kit+ cells. (I) H&E staining of the spine, showing a 
hypercellular BM with more than 90% myeloblast infiltration. The scale bars indicates 200 and 20 μm, 
respectively. (J) Tertiary transplantation setup. (K) Equal expansion of GFP+ cells in PB of CSF3-treated 
(n=4) or PBS-treated (n=4) mice (biological replicate). (L) The c-Kit+ phenotype of PB GFP+ cells in CSF3- 
and PBS-treated mice. (M) Blast morphology of FACS-purified c-Kit+ PB cells. (N) Organ distribution 
of GFP+ and GFP+c-Kit+ cells in PBS- or CSF3-treated mice (n=4 per group). (O) FACS analysis showing 
an immature (c-Kit+) mixed myeloid (CD11b+) and T-cell (CD3+) immuno-phenotype of AML blasts; the 
boxes indicate c-Kit+CD11b-CD3-. Error bars represent SEM. See also Figure S2.
c-Kit+ AML cells weakly expressed lineage markers (Figure 2L) but retained their myeloblast 
morphology (Figure 2M). The BM, spleen, and liver contained equivalent numbers of GFP+ 
cells independent of CSF3 treatment (Figure 2N), confirming that the outgrowth of AML no 
longer depended on CSF3 administration. Immuno-phenotyping revealed that, in addition 
to CD11b, the leukemic blasts co-expressed CD3, suggestive of a mixed myeloid/T-lymphoid 
phenotype (Figure 2O). As expected, all mice developed symptoms of AML, including 
severe anemia and a block of erythropoiesis in the BM and spleen (Figures S2C-S2E; data 
not shown). Although significant numbers of GFP- CD71intermediate/loWTer119+ poly/ortho-
chromatophilic erythroblasts and enucleated erythrocytes (RIII/RIV) were found in the liver, 
these cells did not compensate for the anemia (Figures S2C, S2F, and S2G). 
Leukemic progression in d715-RHD mice is accompanied by elevated pro-inflammatory 
cytokine responses  
To determine which signaling pathways changed during the sequential steps of 
transformation, we performed transcriptome profiling on FACS-purified BM- or PB-derived 
LK cells (1) prior to transplantation, (2) from d715-RHD CSF3 treated primary recipients (pre-
leukemic) and (3) c-Kit+ cells from leukemic (secondary and tertiary recipient) mice (because 
these cells co-express lineage markers). Unsupervised clustering based on gene sets derived 
from GSEA-defined hallmark pathways revealed that LK cells from non-leukemic (t=0, red), 
pre-leukemic (primary recipients, blue) and the c-Kit+ cells from the leukemic (secondary 
and tertiary recipients, green) mice clustered based on interferon γ (IFN-γ)- (Figure 3A), 
inflammatory- (Figure 3B), and tumor necrosis factor alpha (TNFα)/nuclear factor κB (NFκB)-
responses (data not shown), which increased with progressive stages of transformation. 


















































































































































































































































































































































































Figure 3: Elevated inflammatory transcriptomes associated with leukemic progression in d715-RHD 
mouse models 
(A and B) Heatmap showing unsupervised clustering and expression of the top 100 differentially 
expressed transcripts in BM and PB samples of control, pre-leukemic, and leukemic LK/c-Kit+ cells (A) 
associated with IFN-γ signaling and (B) inflammatory response. 
Comparison of the mouse model to clinical SCN-AML 
To determine whether the gene expression changes in the mouse model mimic the clinical 
progression of SCN to AML, we took advantage of bio-banked samples of a previously 
reported ELANE mutant-SCN patient who received life-long CSF3 therapy and acquired CSF3R 
(d715) and RUNX1 (D171N) mutations identical to our mouse model.10 GSEA comparisons 
in the mouse showed that activation of inflammation-associated pathways TNFα via NFκB 
signaling, IFN-γ, inflammatory response, and interleukin-6 (IL-6)/JAK/STAT3 signalling were 
significantly elevated in leukemia samples relative to non-leukemic LK populations (the 
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expression data of WT and Csf3r-d715 were combined and compared with the combined 
data of the eight tertiary transplant recipients; Figure 4A). On the other hand, canonical 
proliferative hallmark signatures (E2F, G2M checkpoint, and MYC) initially upregulated in 
the premalignant state conferred by the activated CSF3R-d715 and RUNX1-RHD (Figure 1F), 
were significantly blunted in the leukemic samples (Figure 4B).
Transcriptome analysis of FACS-purified CD34+ cells from the neutropenic phase (SCN 
1992) and the AML phase (SCN-AML 2007) showed markedly similar hallmark signature 
patterns compared with the mouse model: upregulation of TNFα via NFκB signaling, IFN-γ 
and inflammatory responses, and IL6/JAK/STAT3 signaling pathways (Figure 4C) and down 
regulation of the proliferation signatures E2F, G2M checkpoint, and MYC (Figure 4D). GSEA 
comparing the CD34+ cells of the SCN-AML phase with 3 healthy controls showed the same 
transcriptional alterations (Figures S3A and S3B). 
In addition, we found 55 of 241 significantly (p<0.05) upregulated transcripts in SCN-AML 
samples overlapping with significantly (q<0.05) upregulated transcripts in mouse AML 
samples (Table S1), whereas 53 of the 188 downregulated transcripts were overlapping 
(Table S2). These data furnish a rich substrate for further studies into the critical 
downstream mechanisms contributing to leukemic progression. For instance, ANXA2, 
CDKN1A, CISH, DUSP1, FOS, and IL10RA are prominent inflammatory genes that were 
commonly upregulated in mouse AML and patient SCN-AML samples (Table S1). Similarly, 
genes that are downregulated merit further study in the context of inflammation-driven 
leukemogenesis (Table S2). 
Whole exome sequencing identifies a mutation in Cxxc4 as a somatic clonal driver for 
progression to AML 
Because we discriminated a pre-leukemic stage in our mouse model, we asked whether 
leukemic progression was caused by acquisition of additional driver mutations. To address 
this, we performed whole-exome sequencing on AML cells from one secondary recipient 
(29T1) and eight tertiary recipients (2911-2918). These leukemic mice harbored a relatively 
small number of newly acquired somatic mutations that were mostly subclonal and varied 
between individual mice (data not shown). The single mutation present in all leukemic mice 
was a clonal heterozygous abnormality (VAF: 0.52±0.06) characterized by a 6 nucleotide 
(GGCGGC) internal tandem duplication (ITD) in Cxxc4/Idax, introducing 2 glycine residues 
at amino acid position 158 of the WT protein (Figure 5A). This mutation already appeared 
in a subclone (VAF: 0.27) in primary recipient mouse 29 and expanded in the secondary 
and tertiary recipients, in which all AML cells harbored the Csf3r-d715, RUNX1-RHD, and 
Cxxc4-ITD mutations (Figure 5B). Notably, Csf3r-d715 donor BM samples did not contain any 
detectable reads with Cxxc4-ITD mutations, indicating that the mutation was acquired de 
novo as a somatic driver mutation during leukemic transformation (Figure 5B).
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Figure 4: Leukemic progression of d715-RHD mouse model and SCN (SCN-AML) is associated with 
increased inflammatory and decreased proliferative signaling
(A and B) GSEA analyses comparing control (WT and d715 transcriptional data combined, n=2) versus 
leukemic (tertiary recipients 2911-2918, n=8) LK/c-Kit+ cells showing (A) upregulation of inflammatory 
signaling and (B) downregulation of proliferative pathways in the leukemic mice. GSEA comparing CD34+ 
cells from the SCN-phase (1992) and the SCN-AML phase (2007), showing (C) increased inflammatory 
pathways and (D) down-regulated proliferation signatures. NES = normalized enrichment score, FDR = 
false discovery rate. See also Figure S3 and Tables S1 and S2. 
The Cxxc4-ITD mutation correlates with elevated CXXC4 and reduced TET2 protein levels
To assess the effects of the Cxxc4 mutation, we first determined its effect on protein 
expression. The predicted molecular weight of WT mouse CXXC4 is 36.4 kDa. Immunoblotting 
confirmed the presence of this CXXC4 isoform in Csf3r-d715 BM cells (Figure 5C) and 
showed 7-fold higher expression levels (7.25 ±0.64) in pre-leukemic and leukemic samples 
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harboring the Cxxc4 mutation. CXXC4/IDAX is genetically closely linked to TET2 and was 
originally encoded within the ancestral TET2 gene before it became a separate gene during 
evolution.11 CXXC4 is an inhibitor of Wnt/β-catenin signaling.12 Suggestive of elevated CXXC4 
activity, transcriptome analysis using GSEA showed reduced Wnt/β-catenin signaling in 
Cxxc4-ITD-expressing leukemia samples (2911-2918) relative to WT Cxxc4 BM LK cells (data 
not shown). More striking in the context of leukemic progression, it was shown that CXXC4 
activates proteolytic degradation of TET2 through a mechanism involving caspases 3 and 
8.11 Indeed, we found that TET2 protein levels were severely reduced in leukemic relative 
to normal samples (0.20 ±0.08), whereas reduced expression of Tet2 was not observed 
on transcriptional level (Figure 5C; data not shown). Quantification of TET2/CXXC4 ratios 


















































































































Figure 5: Cxxc4 mutations and expression of CXXC4 and TET2 proteins in AML cells 
(A) Schematic overview of the CXXC4 gene showing acquisition of a Cxxc4-ITD in mouse leukemic cells. 
(B) Fish plot illustrating the clonal pattern of leukemia development. (C) Immunoblot showing elevated 
CXXC4 protein levels (36.44 kDa) and reduced TET2 protein levels (212.13 kDa) in pre-leukemic and 
leukemic samples derived from primary recipient 29 (biological replicates). (D) Quantification of TET2/
CXXC4 ratios. See also Figure S4.
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CXXC4 mutations in human AML
To determine whether CXXC4-ITD mutations similar to those identified in the mouse model 
are relevant for human disease, we analyzed whole-genome sequencing data from 591 AML 
patients generated at the Munich Leukemia Laboratory (MLL), complemented by targeted 
sequencing of 87 consecutive AML patients from the HOVON102 clinical trial. The CXXC4 
protein shows high homology between mouse and human (Figure S4). In total, 6 CXXC4-ITD 
mutations were found (Figure 6A). Interestingly, the insertion of 2 glycine residues caused 
by the ITD in our mouse model was also found in 2 de novo AML patients. Besides the 
tandem glycine insertions, smaller insertions comprising 1 glycine residue or larger ITDs 
comprising 6 glycine residues were found. Cross-referencing with the gnomAD database 
(v.2.1.1), which contains sequences from 141,456 unrelated individuals (https://gnomad.
broadinstitute.org/), showed that the CXXC4-ITD was absent or detected in 10 to 140-fold 
lower frequencies than in our cohort. This suggests that some CXXC4-ITD mutations may be 
somatic, whereas others may be present in the germline and predispose to leukemia. The 
fact that these insertions were all located in or around the glycine repeats suggests that this 
region is important for protein expression and/or stability. 
CXXC4-ITD reduces TET2 levels and has a prolonged half-life relative to wild type CXXC4 
protein
To determine how a patient-specific CXXC4-ITD (Gly160_165dup) exerts its enhanced effect 
on reducing TET2 levels relative to WT CXXC4, we lentivirally introduced both forms in K562 
and HEK293T cells. Ectopic overexpression of WT CXXC4 as well as the CXXC4-ITD resulted 
in a significant reduction in TET2 protein levels (Figure 6B), confirming the observations 
of Ko et al.11 Because we observed increased CXXC4 protein levels in murine Cxxc4-ITD 
leukemic cell samples (Figure 5C), we wondered whether elevated protein levels are the 
result of prolonged protein stability of the CXXC4-ITD protein. Indeed, translation inhibition 
by cycloheximide to block de novo protein synthesis showed that the CXXC4-ITD was 
maintained at higher levels than WT CXXC4 (Figure 6C), providing a plausible explanation 
for its elevated abundance in the mouse leukemia cells.
CSF3R-d715 RUNX1-RHD increases proliferative signaling in CD34+CD45+ cells derived from 
control iPSCs while inducing inflammatory pathways in SCN iPSC
A limitation of the mouse transplantation model is that it lacks the disease-causing mutation 
of ELANE-SCN. However, Elane mutations equivalent to those found in SCN patients do not 
cause neutropenia in murine models,13 precluding the possibility to analyze the additional 
effect of ELANE mutations in murine models. To model leukemic progression in human SCN, 
we introduced the CSF3R-d715 mutation by CRISPR-Cas9-mediated genome editing and the 
RUNX1-D171N mutation by lentiviral transduction (containing IRES-GFP; Figure S1C) in iPSCs
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Figure 6: Human CXXC4-ITD mutation result in a more stable CXXC4 protein and reduced TET2 levels
(A) Schematic overview of the human CXXC4 gene showing CXXC4-ITD mutations in de novo AML. 
(B) Overexpression of wildtype (WT) or CXXC4-ITD (duplication of Glycines 160-165) in K562 cells 
shows a subsequent reduction in TET2 protein levels by immunoblot. (C) Representative image and 
quantification of an immunoblot, showing increased stability of the CXXC4-ITD protein upon prolonged 
treatment with 1 μg/ml cycloheximide. See also Figure S4.
from an ELANE mutant-SCN patient (Figures S5A-S5C) and performed RNA sequencing on 
GFP+CD34+CD45+ hematopoietic progenitor cells (HPCs) derived from two independent 
experiments. First we checked, in control iPSCs, whether the GFP+ CSF3R-d715 mutant 
HPCs recapitulated the findings of in vitro mouse experiments (Figure 1F). When comparing 
RUNX1-RHD cells with ev control cells, the expression pattern corroborated the mouse 
experiments; e.g., increased proliferation-related signaling (compare Figure S6A with Figure 
1F; the leukemic mice shown in Figure 3 acquired an additional mutation in CXXC4, altering 
the transcriptome). In addition, we observed reduced inflammatory signaling, establishing 
that RUNX1 mutations per se do not cause inflammatory signaling but, instead, are involved 
in gaining a proliferative advantage (Figure S6A). 
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In contrast, in RUNX1 mutant-expressing cells derived from an ELANE mutant patient a slight 
increase in inflammatory responses (e.g., IFN-γ signaling) was observed compared with ev 
controls, which was associated with leukemic progression in the mouse model and SCN-
AML patient (compare Figure S6B with Figures 1F and 4). In line with the data from control 
cells and the in vitro mouse data, the proliferation-related signatures G2M checkpoint and 
E2F targets were enriched upon expression of the RUNX1-RHD mutant in an ELANE mutant, 
CSF3R-d715 background (Figure S6B). However, MYC targets were not induced, and even 
inhibited, in ELANE mutant cells (Figure S6B). These data suggest that the SCN background 
already primes for leukemic progression, where the combination of ELANE, CSF3R, and 
RUNX1 mutations already shows signs of tipping the balance between inflammatory and 
proliferative signaling as seen during the leukemic progression in the mouse model and SCN 
patient. 
Analysis of 5mC/5hmC levels in mouse leukemia samples
Several recent studies have linked TET2 to inflammatory responses and connected loss of 
TET2 to inflammation-driven clonal hematopoiesis, pre-leukemia, and MDS.14-19 The effects 
of TET2 on repressing inflammation have been assigned to its methylcytosine dioxygenase 
activity but also to its ability to recruit histone deacetylase (HDAC)-mediated repressor 
activity to pro-inflammatory genes.17,19 To investigate whether the Cxxc4-ITD and subsequent 
reduction in TET2 levels altered the 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine 
(5mC) levels of the DNA, we performed quantitative mass spectrometry experiments 
on the LK cells derived from the leukemic mice.20 Surprisingly, we did not observe major 
alterations in the proportion of 5mC and 5hmC nucleotides compared with LK cells from 
WT or d715 mice (Figure S7A), suggesting that the reduction of TET2 levels did not alter 
the methylcytosine dioxygenase activity. This might either be due to technical limitations, 
a redundancy with other methylcytosine dioxygenases,21 or to the fact that reduced TET2 
levels were not restrictive for its enzymatic activity. On the other hand, this could suggest 
that a noncanonical function of TET2, such as its ability to recruit HDAC activity to chromatin, 
rather than its enzymatic activity was mainly affected by the Cxxc4-ITD. 
CSF3R-d715 RUNX1-RHD cells switch transcriptional signatures from proliferative to 
inflammatory upon HDAC inhibition in human iPSC models
We next aimed to functionally validate the findings from leukemic mice in a human SCN-
derived iPSC model expressing the truncated CSF3R-d715 and the RUNX1-RHD mutant. An 
obvious experiment would be to introduce the CXXC4-ITD in these cells by CRISPR-Cas9-
mediated genome editing, but this was technically infeasible because of the high GC-
repeat content in the target region. Instead, to discriminate between the two functions 
of TET2 proposed above, we wanted to find out how inhibition of its enzymatic activity by 
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administration of octyl-(R)-2hydroxyglutarate (2HG) and its ability to recruit HDAC activity by 
administration of the HDAC inhibitor MS275 (Entinostat) affected the transcriptional profile 
of CSF3R-d715 RUNX1-RHD expressing SCN-iPSC-derived CD34+CD45+ HPCs. In line with the 
unaltered 5hmC levels in mouse AML cells, hallmark analyses showed that 2HG did not 
induce an inflammatory profile as observed in Cxxc4 mutant mouse AML cells (Figure S7B). 
In contrast, HDAC inhibition with MS275 ignited inflammatory signaling while inhibiting 
the proliferative signatures in control and ELANE mutant cells, recapitulating the signaling 
profiles of Cxxc4 mutant mouse AML cells and SCN-AML patient material (Figures 7A ans 7B; 
data not shown). Although HDAC inhibition may also affect pathways independent of TET2, 
these data fit into a model of leukemic progression in which TET2 represses inflammatory 
signaling through its ability to recruit HDACs to pro-inflammatory genes,17,19 whereas DNA 
hydroxyl-methylation had little or no effect. This model may apply specifically to the context 
of leukemic progression of SCN involving acquisition of CSF3R and RUNX1 mutations but 
could also be relevant to other forms of AML (e.g., with RUNX1 mutations and/or secondary 
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Induced pluripotent stem cell model: SCN-d715-RHD
Figure 7: HDAC-inhibitor MS275 induces inflammatory signatures in SCN iPSC-derived CD34+CD45+ 
cells
(A and B) GSEAs comparing CD34+CD45+ CSF3R-d715 RUNX1-RHD cells from ELANE mutant SCN 
cells treated with DMSO or the HDAC inhibitor MS275, derived from two independent experiments 
(biological replicates), showing (A) induced inflammatory signaling and (B) reduced proliferative 
signatures in MS275 treated cells. NES = normalized enrichment score, FDR = false discovery rate. See 
also Figure S5. 
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Discussion
In this study, we investigated how mutations in CSF3R and RUNX1, frequently associated 
with leukemic progression of SCN in conjunction with CSF3 treatment,1 contribute to AML 
development. By developing a mouse model with the most recurrent CSF3R and RUNX1 
mutations, we found that this combination resulted in the accumulation of myeloblasts and 
myeloid colony-forming progenitors in PB, which persisted for 25+ weeks while on sustained 
CSF3 treatment. Although myeloblasts were found in PB, mice did not reveal signs of overt 
AML. These findings agree with clinical observations in an ELANE mutant SCN patient with 
CSF3R and RUNX1 mutations (in the absence of other somatic defects) who showed CSF3-
dependent expansion of a CSF3R/RUNX1 mutant myeloblast clone that spontaneously 
disappeared after CSF3 treatment was stopped.6 These findings heralded that full malignant 
transformation of SCN to AML requires additional defects. This was confirmed in serial 
transplantation experiments in which we identified a clonal mutation in Cxxc4 as a driver of 
AML development. This mutation resulted in increased levels of CXXC4 protein. CXXC4 has 
been recently shown to control caspase-mediated degradation of TET2,11 and, in agreement 
with this, TET2 levels were severely reduced in AML cells. 
CXXC4 mutations were also found in a minority of de novo AML patients. At what frequencies 
CXXC4 mutations are present in SCN-AML or other forms of secondary AML and whether 
they coincide with acquisition of other mutations (e.g., in RUNX1) is currently under study. 
The possibility that mutations in other genes affecting the TET2 pathway will have similar 
consequences for development of SCN-AML must be considered in this context. In agreement 
with this, mutations in SUZ12, a component of EZH2-containing polycomb repressor complex 
2 (PRC2), which inhibits CXXC4 expression,22 have been detected in the SCN-AML patient 
used for this study and others.6,10 Mutations in ASXL1, also recurrent in SCN-AML, may have 
similar effects and have recently been functionally connected to leukemic transformation in 
conjunction with RUNX1 mutations.23,24 These findings are consistent with the concept that 
reduced TET2 levels contribute to leukemic progression of SCN. 
Another key finding that emerged from our study concerns the connection between 
inflammation, clonal expansion, and leukemic progression of SCN. A role for inflammation 
in regulating hematopoietic stem cell fate in normal and several disease-related conditions, 
including MDS, has been suggested previously.15 Some studies showed that pro-
inflammatory cytokines initially activate stem cells to exit from a dormant state but, when 
chronically active, cause a loss of stem cell fitness, which eventually results in age-related 
BM failure.25-27 Importantly, TET2 has been shown to repress pro-inflammatory cytokine 
genes in macrophages and dendritic cells, in part by recruitment of HDAC2,19 whereas, 
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inversely, loss of Tet2 fosters an inflammatory state characterized by upregulation of IL-6 and 
TNF-α.16,28,29 More recent studies in Tet2-deficient mice showed that inflammation drives 
clonal expansion of pre-leukemic myeloid precursors.14,17,30 Taken together, these findings 
fit into a model where reduction of TET2 levels through gene disruption or downregulation 
of expression induces an inflamed state. Acquisition of a RUNX1 mutation would then 
stimulate outgrowth of a malignant clone that evolves into AML.  
Although the transcriptome analysis of mouse AML cells, the SCN-AML patient sample, and 
HDAC inhibitor-treated SCN iPSC-derived CD34+CD45+ cells showed elevated IL-6-, IFN-g- 
and TNF-α-mediated inflammatory responses, increased transcription of these cytokine 
genes themselves was not seen (data not shown). This could suggest that the inflammatory 
responses were activated by a cell-extrinsic, rather than a cell-intrinsic (autocrine) stimulus. 
Because these studies were done on immature CD34+ or c-Kit+ fractions, it is possible that 
affected macrophages and/or dendritic cells derived from these cells and/or environmental 
cells, e.g., endothelial cells, produced elevated levels of pro-inflammatory cytokines, induc-
ing an inflammatory state in immature progenitor populations in a paracrine manner. An 
alternative possibility is that the genomic damage underlying SCN itself activates inflam-
matory signaling, e.g., IFN-g-induced pathways, which is aggravated when TET2 levels are 
reduced. For instance, increased IFN-g signaling has been reported in the context of DNA 
double-strand breaks induced by etoposide treatment or X-ray irradiation of cells.31,32
In conclusion, this study provides insights into sequential steps in leukemic progression of 
SCN and identifies pro-inflammatory mechanisms as important mediators of this process. 
Questions that still need to be addressed are how mutant neutrophil elastase proteins 
shape the “fertile ground” for the acquisition of CSF3R mutations and how CSF3 treatment 
contributes to reshaping this into the cellular state in which elevated inflammatory responses 
are induced and tolerated and RUNX1 mutations can be acquired, resulting in progression 
to AML. Resolving these issues holds promise for clinical management of SCN, and possibly 
other leukemia predisposition syndromes, with the objective to avoid or interfere early in 
the malignant transformation of these conditions. 
Limitations of Study
Although CSF3R/RUNX1/CXXC4 mutant cells could repopulate and form AML in multiple 
secondary (n=6) and teriary (n=8) recipients, the CXXC4-ITD mutation originally arose in 
a single primary recipient (1/9), who acted as a donor for subsequent retransplantation 
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studies. 
Hence, rather than being frequently involved in the leukemic progression of SCN, the 
CXXC4-ITD mutation should be taken as evidence that downregulation of TET2 and the 
associated upregulation of inflammatory signaling contribute to malignant transformation 
in conjuction with the CSF3R and RUNX1 mutations. Supporting a role of CXXC4 mutations 
in human disease, CXXC4-ITD mutations very similar to those detected in the mouse model 
were found in a subset of de novo AML patients, some but not all of which are found in the 
healthy population, but at much lower frequencies. Further studies are needed to address 
wether CXXC4 mutations in human AML are somatic or germline. Studies to unravel co-
occurrence with other mutations in, e.g., RUNX1 or TET2 could provide further insight in 
the pathogenic mechanism of CXXC4 alterations. Inhibition of HDAC-recruiting function 
of TET2 with the HDAC inhibitor MS275 provides a possible mechanism of how reduced 
TET2 levels can induce inflammatory signaling, but this inhibitor may also affect pathways 
independent of TET2. How TET2 regulates inflammation at specific gene targets and how 
RUNX1 mutations affect this process (e.g., by enabling pre-leukemic cells to escape from 
inflammation-mediated exhaustion) merits further study. 
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Further information and requests for resources and reagents should be directed to and will 
be fulfilled by the Lead Contact, Ivo P. Touw (i.touw@erasmusmc.nl).
Materials Availability
Viral constructs and iPSC lines generated in this study will be made available on request, 
but we may require a payment and/or a completed Materials Transfer Agreement if there is 
potential for commercial application.
Data and Code Availability
The RNA sequencing dataset comparing the effect of the introduction of RUNX1-D171N 
(RHD) in Csf3r-d715 mice bone marrow cells generated during this study, as shown in Figure 
1, is available at ArrayExpress: E-MTAB-9373.
The RNA sequencing dataset comparing different stages of leukemic progression in a mouse 
model of SCN generated during this study, as shown in Figures 3 and 4 and Tables S1 and S2, 
is available at ArrayExpress: E-MTAB-9377.
The RNA sequencing dataset comparing the transcriptome of a SCN patient who progressed 
to AML (SCN-AML) with the SCN phase and healthy controls generated during this study, as 
shown in Figures 4 and S3 and Tables S1 and S2, is available at ArrayExpress: E-MTAB-9381.
The DNA sequencing dataset comparing different stages of leukemic progression generated 
during this study, as shown in Figure 5, is available at ArrayExpress: E-MTAB-9376.
The RNA sequencing dataset comparing the effect of the introduction of RUNX1-D171N 
(RHD) in control- or SCN -CSF3R-d715 hematopoietic progenitor cells (HPCs) generated 
during this study, as shown in Figure S6, is available at ArrayExpress: E-MTAB-9375.
The RNA sequencing dataset comparing SCN CSF3R-d715 RUNX1-D171N (RHD) HPCs 
treated with the HDAC inhibitor MS275, octyl-(R)-2hydroxyglutarate (2HG) or solvent 
control (DMSO) generated during this study, as shown in Figures 7 and S7, is available at 
ArrayExpress: E-MTAB-9374.
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mice
All animals were kept according to Erasmus MC guidelines and experiments were performed 
under CCD license EMCAVD101002017869. FVB/n Csf3r-d715 knock-in mice,33 were bred at 
the Erasmus MC animal facility under specific pathogen free conditions and the mice were 
genotyped by PCR. FVB/n wild-type (WT) control mice were purchased from Envigo, Horst, 
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the Netherlands. All animals used were male, single housed, 10-12 weeks old at the start of 
the experiment, and randomly assigned to experimental groups.  
Lentivirally transduced CSF3R-d715 lineage negative bone marrow cells were transplanted 
72 hours after the first transduction. GFP expression was determined by flow cytometry and 
1x105 GFP positive cells were transplanted, together with their GFP negative counterparts 
and 1x105 spleen cells, into 8.5 Gy irradiated (Cesium-137, GammaCell GC40) FVB/n wildtype 
(WT) recipients. Secondary transplant FVB/n WT recipients received 5 Gy irradiation and 
3x106 total bone marrow cells together with 1x105 spleen cells. The tertiary FVB/n WT 
recipients were irradiated with 8.5 Gy (IBL637 Cs-137) and received 2x105 total bone marrow 
cells together with 1x105 spleen cells. 
Mice were injected subcutaneously three times a week with 100 µg/kg CSF3 (Filgrastrim, 
Zarzio) or vehicle control (PBS). Treatment was started five weeks after transplantation in 
the primary recipients. The secondary recipients started CSF3 treatment four weeks after 
transplantation, while the tertiary transplant recipients received CSF3 or PBS treatment two 
weeks after transplantation. The tertiary recipients received a higher dose of CSF3 (200 μg/
kg). From the start of the experiment, all mice received 50 μg/ml of Ciprofloxacin in the 
drinking water.
Patient samples
Ficoll-gradient separated bone marrow and blood cells were obtained and frozen according 
to established procedures for viable cell cryopreservation. The study was performed under 
the permission of the Institutional Review Boards of the Erasmus MC, the Netherlands 
(registration number MEC-2008-387 for biobanking and MEC-2012-030 for the genetic 
analysis of leukemic progression in SCN patients).
Generation of iPSC 
Bone marrow fibroblasts cultured from a healthy control (22 year old female) and a SCN 
patient (3 months old female) harboring ELANE mutation (chr19:852986A>T) I60F were 
reprogrammed at the iPSC core facility of the Erasmus MC using a previously described 
protocol.34 Cells were cultured in mTeSR™1 (STEMCELL Technologies) on Geltrex™ LDEV-Free 
Reduced GroWTh Factor Basement Membrane Matrix (Thermo Fisher Scientific) at 37°C and 
5% CO2, and were regularly checked for pluripotency and correct karyotype (Supplemental 
Figure 5a). 
METHOD DETAILS 
Bone marrow isolation and lineage depletion
Bone marrow (BM) was isolated from femurs, tibias and sternum of the mice. Cells were 
harvested by crushing bones in a mortar, and the harvested marrow depleted from 
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erythrocytes by Stem-Kit lysing solution (Beckman Coulter). The early stem and progenitor 
compartment was enriched using the Biotin Mouse Hematopoietic Progenitor (Stem) 
Enrichment Set (Thermo Fisher Scientific), according to the manufacturer’s protocol. 
Viral expression constructs, virus production and transduction of BM cells
pMY-RUNX1 retroviral vectors35 were obtained from Gang Huang (Cincinnati Children’s 
Hospital, Cincinnati). RUNX1b mutant 4518 (D171N, RHD mutant) insert was subsequently 
cloned into the pBabe vector36 and used in in vitro mouse studies. For the in vivo and iPSC 
studies, the RUNX1 mutant was inserted into the lentiviral CSI vector (kind gift from Brian 
Duncan, University College London). The lentiviral CSI vector was also used to express 
CXXC4-wildtype and CXXC4-ITD (Glycine 160-165 duplication). All constructs were tested 
for correct introduction of inserts by enzymatic digestion and Sanger sequencing. Retroviral 
supernatants were harvested from HEK293T cells 48 hours after transfection with 5 μg of 
pBabe RUNX1 RHD mutant or empty vector (EV), together with 5 μg pCL-eco37 and 30 μl 
TransIt transfection reagent (Mirus). Lentiviral supernatants were obtained from HEK293T 
cells 48 hours after transfection with 4 μg of the CSI vector, 3 μg pSPAX2, 1 μg pMD2.G 
and 25 μl FuGENE HD (Promega). Viral supernatant and 1x106 lineage depleted BM cells 
were incubated in RPMI medium (Gibco) supplemented with 10 ng/ml each of murine 
interleukin-3 (IL-3), interleukin-6 (IL-6, Tebu-bio), stem cell factor (SCF, Preprotech) and 
granulocyte macrophage colony-stimulating factor (GM-CSF, Tebu-bio) on retronectin coated 
dishes (TaKaRa). Fresh virus supernatant was again added after 24 hours and transduced BM 
cells harvested another 48hours later (72 hours after the first transduction).
SDS-PAGE/Immunoblotting
RUNX1 expression was determined using a RUNX1 antibody directed to human AML1 (4334, 
Cell Signaling Technology) or an antibody that recognized both human and mouse AML1 
(8529, Cell Signaling Technology). CXXC4 (NBP1-76491, Novus Bio) and TET2 (ab94580, 
Abcam) antibodies were used to determine both mouse and human protein levels. 
Preparation of lysates, and Western blot analyses were performed as previously described.38
Murine colony assays
Lineage negative bone marrow cells from FVB/n mice harboring either a WT or a truncated 
CSF3R were isolated, and retrovirally transduced with either RUNX1 RHD mutant or an empty 
vector control. Cells were then seeded for colony formation (4x104/ml) in methylcellulose 
(M3234, STEMCELL Technologies) with 50 ng/ml CSF3. Colonies were counted after 7 to 9 
days of culture and replated if applicable. 
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Suspension cultures
1x105 lineage depleted bone marrow cells per ml were plated after transduction into 
LODISH stem cell expansion medium. LODISH medium consisted of CellGro GMP serum-
free stem cell groWTh medium (SCGM, CellGenix, Freiburg, Germany) supplemented with 
10 ng/ml each of SCF, thrombopoietin (TPO, Preprotech), insuline-like groWTh factor (IGF, 
R&D systems), fibroblast groWTh factor (FGF, Preprotech) and with or without 50 ng/ml 
CSF3. Angiopoietin was harvested as conditioned medium of transfected HEK293T cells, and 
added to the culture medium in a 1:5 dilution. 
Flow cytometry and cell sorting
Cellular composition of the liquid cultures and in vivo tissues were analyzed using flow 
cytometry. The following antibodies and recombinant proteins were used: Sca1-Pacific 
blue (PB), CD34-Phycoerythrin (PE), CD48-PE, CD150-PE.Cy7, Ter119 Allophycocyanin (APC)
(all Biolegend), CD117-APC, CD16/32-APC.Cy7, CD11b-PE, Gr1-APC, CD3-PE.Cy7, CD71 PE 
(all BD Biosciences), CD19 Alexa Fluor 700 (AF700, Life) and CD117 PerCpCy5.5 (SONY). 
Lineage positive cells were detected using the murine lineage detection kit (BD Biosciences) 
subsequently stained with streptavidin-pacific orange (PO, Fisher Scientific).
SSEA4-PE (Biolegend) and Tra-1-60 Alexa Fluor 647 (AF647, BD Biosciences) were used for 
regular pluripotency screenings of the iPSCs. Hematopoietic induction of iPSC was assessed 
using CD34-PE and CD45-BV421 antibodies (both BD Biosciences). Dead cells were excluded 
by using 7-aminoactinomycin-D (7AAD, Life) or 4’,6-Diamidino-2-Phenylindole (DAPI, Fisher 
Scientific). Flow cytometry was performed using a BD LSRII flow cytometer (BD Biosciences). 
For subsequent cell sorting a FACSAria (BD Biosciences) was used. Analysis of FACS data was 
performed using FlowJo (TreeStar).
Blood, bone marrow, spleen and liver isolation from mice
Peripheral blood was obtained by cheek puncture. Upon sacrifice, bone marrow was 
isolated from femurs and tibias of the mice. Cells were harvested by flushing the bones and 
subsequently filtered. Cells from spleen and liver were obtained by mashing parts of the 
organs through a filter.  
Histological and morphological analyses
Mouse organs were fixed in 4% formaldehyde overnight, dehydrated and prepared for 
paraffin embedding, after which they were stained with Haemotoxylin and Eosin (H&E). 
Cells were attached to glass slides using a Cytospin 4 (Thermo Scientific) according to the 
manufacturer’s protocol and stained with May-Grünwald Giemsa staining. Stainings were 
performed according to routine protocols.
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Introduction of CXXC4 in K562/HeLa and protein stability assays
Lentiviral supernatant containing either an empty vector control, CXXC4-wildtype or the 
CXXC4-ITD (duplication of Glycines 160-165) was added to K562 and HeLa cells. Transduced 
cells were sorted for GFP+ expression and subsequently used. To test protein stability of 
CXXC4-wildtype or -ITD, we added 1ug/ml of the translation inhibitor cycloheximide (Merck) 
and harvested the cells 0, 8, 16 or 24 hours after the start of the treatment. 
Targeted sequencing of CXXC4
Custom CXXC4 amplicon sequencing was performed on patients of the HOVON102 trial 
using the Illumina PCR-based Custom Amplicon Library Preparation workflow. Forward 
primer AGGGGATAAGGTGGAGAGGA and reverse primer CCCCTGGAACTGCGACAA were 
used to amplify the Glycine repeat region of CXXC4. Libraries were paired-end sequenced 
with the MiSeq V2 Nano kit (Illumina) on the Illumina MiSeq. Bioinformatic analysis was 
performed as previously described.39
CRISPR/Cas9-mediated genome editing 
To introduce the CSF3R-d715 mutation in iPSCs, 2x106 cells were electroporated with 500 
ng px33040 (Cas9 plasmid, Addgene plasmid #42230) and 1500 ng recombination template 
containing the d715 mutation and a puromycin selection cassette (Supplemental Figure 4b), 
using the 4D-Nucleofector System (Lonza), program CA-137. Puromycin selection (300 ng/
ml) started 48 hrs after electroporation. Single clones were picked and screened for correct 
and heterozygous integration of the CSF3R mutation and pluripotency (Supplemental 
Figures 5a,b). 
Hematopoietic induction and colony assays from iPSC
Hematopoietic Stem and Progenitor cells (HSPCs) were produced with the STEMdiff™ 
Hematopoietic Kit (STEMCELL Technologies) according to the manufacturer’s protocol. 
Floating cells were harvested at Day 12 of the protocol.
Lentiviral production and transduction of iPSC
Lentiviral supernatant was harvested at 24 and 48 hours after transfection of HEK293T cells 
with 4 μg of the CSI vector, 3 μg pSPAX2, 1 μg pMD2.G, and 25 μl FuGENE HD (Promega). 
Viral particles were 100x concentrated by ultracentrifugation (Optima XPN-80, Beckman 
Coulter) for 2 hours at 20.000g and 4°C. Virus (25 ul/ml) and hexadimethrine bromide 
(polybrene, 4 ug/ml, Sigma) were added to the hematopoietic induction cultures 60 hours 
before harvesting the floating cells.
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TET inhibitor experiments
DMSO (solvent control), 0.1 mM Octyl-(R)-2HG (Sigma-Aldrich) or 2 µM MS275 (Santa Cruz) 
was added for 16 hours to the hematopoietic induction cultures before harvesting the 
floating cells.
RNA isolation and RNA sequencing
RNA was isolated from FACS purified mouse LK or c-Kit+ cells, human CD34+ cells from the 
bone marrow (SCN phase, 1992) or blood (AML phase, 2007) or CD34+CD45+ hematopoietic 
stem and progenitor cells derived from the iPSCs using TRIzol (Thermo Fisher Scientific) 
according to the manufacturer’s protocol. For the in vitro mouse experiments cDNA was 
generated with the SMARTer Ultra Low Input RNA kit for sequencing (version 3, Clontech), 
while version 4 of the SMARTer Ultra Low Input RNA kit for sequencing (Clontech) was used 
for the other samples. Sequencing libraries were generated using TruSeq Nano DNA Sample 
Preparation kits (Illumina), according to the low sample protocol and run on HiSeq 2500 or 
Novaseq 6000 instruments (Illumina). 
Whole exome sequencing
100 ng genomic DNA was fragmented using enzymatic fragmentation and sample libraries 
were constructed following the SeqCap EZ HyperPlusCap workflow User’s Guide version 1.0 
(Roche). Unique, dual index adapters (Integrated DNA technologies) were used for ligation. 
After ligation of adapters and an amplification step, exome target sequences were captured 
using in-solution oligonucleotide baits (SeqCap EZ Developer Library mm9_exome_L2R_
D02). Amplified captured sample libraries were paired-end sequenced (2x100 cycles) on the 
HiSeq 2500 platform (Illumina).
Bioinformatics and statistics
Demultiplexing was performed using the CASAVA software (Illumina) allowing for one 
mismatch in the barcodes. Subsequently quality metrics were estimated (FastQC, Babraham 
bioinformatics & MultiQC, http://multiqc.info) for all of the resulting fastq files. Afterwards 
reads were aligned against the Mouse Transcriptome (Gencode m12)/Genome (mm10) or 
Human Transcriptome (Gencode v19)/Genome (hg19) using the STAR aligner.41 Abundance 
estimation was performed using Cufflinks42 (refSeq), and raw counts were measured with 
the HTSeq-count software set in union mode.43 Next the measured raw counts were used to 
create clustering and principle component plots and perform differential expression analysis 
both using DESeq2 and R44 (https://www.r-project.org/). Finally gene set enrichment 
analysis, with the hallmark pathways H, was done using the GSEA software45,46 (https://
www.gsea-msigdb.org/gsea/msigdb/genesets.jsp?collection=H). 
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QUANTIFICATION AND STATISTICAL ANALYSIS 
Data are presented as mean ± SEM. Comparison of two groups was performed using 
unpaired t-test. Statistical analyses were performed using GraphPad Prism 5.0c (GraphPad 
Software Inc., San Diego, CA) or DESeq2. A p-value <0.05 was considered significant.
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Figure S1: Lentiviral transduction of mouse bone marrow cells (related to Figure 1)
(A,B): Position of the G-to-A missense mutation shown by Sanger sequencing, resulting in D171N 
amino acid change in RUNX1b (wild type) protein. (C): Lentiviral expression constructs used for 
transplantation experiments. (D): Expression of mutant RUNX1 protein in lentivirus-transduced lineage 
depleted hematopoietic progenitors; immunoblot stained with Ab8529 (left panel), detecting both 
mouse and human RUNX1 after short (s.e.) and long (l.e.) exposure; and with Ab4334 (right panel), 
specific for human RUNX1. (E): FACS dot plots showing GFP expression in lineage negative cells before 
transplantation. (F): FACS dot plots showing GFP expression in ~ 65% of LSK cells. (G): Representative 
FACS dot plots showing GFP+CD11b+GR-1+ neutrophils in the PB. Data are from samples taken 14 and
16 weeks after transplantation (n=11 or 12 per group).
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Figure S2: Analysis of erythroid cell populations (related to Figure 2)
(A-G): CD71 and Ter119 staining is used to discriminate between the 4 stages of erythropoiesis with 
FACS. RI: CD71highTer119-, RII: CD71highTer119+, RIII: CD71intermediateTer119+, RIV: CD71-Ter119+. 
(A): erythroid cells observed in the bone marrow of the secondary recipients and (B): in the spleen. 
(C): Representative FACS dot plot showing the different stages of erythroid development based on CD71 
and Ter119 in the bone marrow or liver of tertiary recipients. (D): histogram showing erythropoiesis of 
the GFP- cells in the bone marrow of the tertiary recipients and (E): the GFP+ erythroid cells in the BM. 
(F): GFP- erythroid cells in the liver and (G): GFP+ erythroid cells in the liver.
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Figure S3: Leukemic progression of SCN (SCN-AML) is associated with increased inflammatory and 
decreased proliferative signaling (related to Figure 4)
GSEA comparing CD34+ cells from 3 healthy controls with the SCN-AML phase (2007) showing (A): 
increased inflammatory pathways and (B): down-regulated proliferation signatures. ES = enrichment 
score, NES = normalized enrichment score, FDR = false discovery rate.





Cxxc4 mouse MNTNVCVEPG  PSPEAPGL PK  ESHLPEGALN   SLVDYNSEME  RYRSFAT SF Y   KTNGGAFPQA  A K I A R I T T P I   70
CXXC4 human MNTNVCVEPG  PSPEAPGL PK  ESHLPEGALN   SLVDYNSEME  RYRSFAT SF Y   KTNGGAFPQA  A K I A R I T T P I   70
Cxxc4 mouse FPSSAAAAAA  AARI GMSPWN   CDNAATAAA-     TAMLWGSGGG  GGGGGGGGGG   GGAG -  -  -  -  -    -  -  -  -  RKSSSA   129
CXXC4 human FPSSAAAAAA  AARI GMSPWN   CDNAATAAAA   TAMLWGSGGG  GGGGGGGGGG   GGGGGGGGGG  GGGGRKSSSA   140
Cxxc4 mouse AASSSASSS -   A I L PA A GGGG  GGGGGGSGGG  GGGGGGGRTS  MHHRNDSQRL  GKAGCPPEPS  LQMANTNFLS  198
CXXC4 human        AASSSASSSS  A I L PA - GGGG  GGGGGGS - - -   - - - - - - - RTS  MHHRNDSQRL  GKAGCPPEPS  LQMANTNFLS  199 
Cxxc4 mouse       TL SPEHCRPL  AGECMNKLKC  GAAEAE I MNL  PERVGTFSA I   PA L GG I SLPP  GV I VMTALHS  PAAASAAVTD  268
CXXC4 human        TL SPEHCRPL  AGECMNKLKC  GAAEAE I MNL  PERVGTFSA I   PA L GG I SLPP  GV I VMTALHS  PAAASAAVTD  269
Cxxc4 mouse SAFQ I ANLAD  CPQNHSSSSS  SSSGGAGGAN  PAKKKRKRCG  VCVPCKRL I N  CGVCSSCRNR  KTGHQ I CKFR  338
CXXC4 human      SAFQ I ANLAD  CPQNHSSSSS  SSSGGAGGAN  PAKKKRKRCG  VCVPCKRL I N  CGVCSSCRNR  KTGHQ I CKFR  339
Cxxc4 mouse KCEELKKKPG  TSLERTPVPS  AEAFRWFF  366
CXXC4 human       KCEELKKKPG  TSLERTPVPS  AEAFRWFF  367
Gly160_Gly165dup
Gly124dup
Figure S4: Alignment of mouse and human CXXC4 protein sequences and positioning of mutations in 
human AML (related to Figures 5 and 6)
Mutations marked in blue indicate alterations found in human AML; the mutation marked in red 
indicates the CXXC4 alteration found in the murine AML cells. Orange and red bars indicate start and 
finish of the 2 amplicons used for targeted sequencing.










































1kb 1kbCAG  TAG = STOP
TATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCCCAATCCCAGTCTGGCACCAGCGATCAGGTCC
ATACACGAGGTCCCCCTGGGTTCTCGTCAAAGGTGGGTCGGGGTTAGGGTCAGACCGTGGTCGCTAGTCCAGG





GT CGGGGCAGA TGA A AGCAGCCGTGCCC T GGGAGT CCCA T A T A CAGC T CAGAGA CC TGTGGCC T CCCCA C T C T GGT
AGA CC T A TGTGC T CCAGGGGGA CCCA AGAGCAGT T T CCA CC T AGCCCCA A T CCCAGT C TGGCA CCA A T A A C T T CGT
AGCA T A CA T T A T A CGA AGT T A TGGCGCGCC T T A A T T A A A CGCGT C T T AGT A CA AG T A AGA A T T CCGA T CA T A T T CA
A A CCC T T A A T A T A A C T T CGT A T A A TGT A T GC T A T A CGA AGT T A T T A CGT C TGA AGAGGAGT T T A CC T CCAGCCA CC
GGAG T CCCA T A A CAGC T CAGAGA CC TG TGGCC T CCCCA C T C TGGT CC
AGT T T CC CC A GCCCCA A CA T C TGG A CCAGCGA T CAGGT CC
CCCAGGGCCAGGGCA C T A T C T CCGC TG TGA C T CCA C T CAGCCCC T C T
TGAGA A CC T C TGGT T CCAGGCCAGCCCC T TGGGGA CCC T GG T A A CCA
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Figure S5: Characterization of pluripotency and the introduction of CSF3R mutation in iPSCs (related 
to Figures 7, S6, S7 and STAR Methods)
(A): FACS histograms (blue) showing TRA-1-60 and SSEA4 expression in SCN-iPSC and SCN-iPSC with the 
CRISPR-Cas9 targeted CSF3R-d715 mutation. Red histograms are from unstained cells. (B): Schematic 
overview of the recombination template used to introduce the CSF3R-d715 mutation with CRISPR-Cas9 
and Sanger sequencing data showing the heterozygous integration of the recombination template. 
(C): FACS dot plot showing CD34 and CD45 expression of floating cells harvest at Day 12 of hematopoietic 
induction with the STEMdiff Hematopoietic kit.
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Induced pluripotent stem cell model: SCN-d715B
Figure S6: Transcriptome analysis in control and SCN iPSC-derived CD34+CD45+ cells with truncated 
CSF3R: the SCN background alters the inflammation/ proliferation balance (related to Figures 1, S5)
GSEA analyses comparing CD34+CD45+ cells from CSF3R-d715 transduced with either empty vector or 
RUNX1-RHD in (A): control cells showing reduced inflammatory signaling and increased proliferative 
signatures, and in (B): ELANE-mutant SCN cells showing slightly increased inflammatory signaling, 
while the proliferation induction is less pronounced. Data shown is derived from 2 independent 
experiments. ES = enrichment score, NES = normalized enrichment score, FDR = false discovery rate.











































































































































Induced pluripotent stem cell model: SCN-d715-RHD
Figure S7: Inhibition of TET2 activity does not mimic the expression signatures observed in AML 
(related to Figures 4, 7)
(A): Dot plot showing no differences between the percentage of 5mC or 5hmC modified nucleotides in 
control, primary-, secondary-, and tertiary-transplant recipient mice. Inflammatory and proliferation 
related GSEA comparing (B): DMSO or 2HG treated, CSF3R-d715, RUNX1-RHD CD34+CD45+ cells 
derived from ELANE-mutant SCN-iPSC (two independent experiments).
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Table S1: Upregulated transcripts in mouse AML and SCN-AML samples (related to Figures 3 and 7)
wt+d715 (TPM) 2911-2918 (TPM) SCN 
(TPM)
SCN-AML 
(TPM)Transcripts Mean SEM Mean SEM p-value q-value p-value
ADAP1 76.610 7.734 112.078 3.714 0.000 0.000 3.123 107.222 0.007
AKAP12 1.174 0.495 8.178 0.717 0.000 0.000 0.125 9.114 0.019
ALDOC 4.566 0.518 20.833 2.173 0.000 0.000 4.085 66.011 0.034
ANXA2 98.767 2.025 170.653 17.325 0.002 0.005 148.538 1166.104 0.030
ARID3B 6.817 0.057 10.026 0.784 0.003 0.008 4.991 48.246 0.040
C2 0.000 0.000 3.416 0.473 0.000 0.000 0.000 1.029 0.000
CASS4 0.989 0.989 3.595 0.339 0.005 0.015 0.045 28.485 0.002
CDKN1A 32.308 4.833 95.238 4.043 0.000 0.000 12.338 150.233 0.022
CISH 20.392 0.286 56.367 6.222 0.000 0.000 10.556 143.478 0.022
CSF3R 81.353 6.397 116.220 6.645 0.000 0.001 86.063 568.637 0.032
CXCL2 0.000 0.000 1.235 0.424 0.001 0.004 92.786 1003.455 0.019
CYTH4 92.696 13.180 142.309 10.530 0.000 0.000 8.796 127.143 0.016
DGAT2 4.360 0.969 15.291 2.522 0.000 0.000 0.060 44.868 0.001
DUSP1 74.312 1.299 337.066 110.876 0.018 0.041 387.031 2744.965 0.035
DUSP2 129.095 30.487 277.417 46.648 0.019 0.043 62.289 808.883 0.013
ECHDC2 0.951 0.110 3.173 0.599 0.014 0.033 2.398 59.611 0.023
EFNA1 2.406 1.089 8.496 1.225 0.000 0.001 2.614 66.791 0.020
ESAM 37.701 1.076 111.813 12.971 0.000 0.000 17.079 129.748 0.048
F13A1 47.495 8.898 510.433 86.608 0.000 0.000 17.280 705.205 0.003
FAM49A 10.927 0.263 14.803 0.993 0.004 0.012 0.093 52.449 0.000
FGD5 2.089 0.546 14.054 1.059 0.000 0.000 0.595 26.595 0.008
FOS 41.011 16.634 457.660 181.649 0.004 0.011 436.335 6789.652 0.010
GDPD5 0.224 0.224 4.420 0.626 0.000 0.000 0.000 61.903 0.000
GNG11 32.207 4.152 43.629 2.385 0.004 0.011 51.361 489.900 0.028
HCK 0.672 0.518 32.154 3.692 0.000 0.000 19.422 341.296 0.012
HIP1 2.020 0.294 14.266 0.459 0.000 0.000 2.172 19.226 0.047
ICAM1 44.452 10.317 84.731 3.274 0.000 0.000 14.345 154.835 0.027
IER2 273.214 19.229 847.096 137.990 0.000 0.002 344.232 3173.270 0.023
IL10RA 9.567 5.397 23.257 3.637 0.012 0.030 22.399 275.262 0.018
KCNK6 2.574 1.785 9.410 0.902 0.000 0.000 0.965 37.293 0.009
KLF2 2.028 0.239 19.443 9.241 0.007 0.017 14.971 128.116 0.036
MAP3K1 1.557 0.415 4.109 0.262 0.000 0.000 0.352 11.187 0.028
MIR22HG 0.000 0.000 3.166 0.754 0.000 0.000 4.310 11.151 0.040
MYRF 0.000 0.000 1.503 0.311 0.000 0.000 0.000 17.450 0.001
PARP8 29.957 11.253 50.302 3.074 0.000 0.002 1.413 25.464 0.022
PDE2A 17.286 1.015 40.984 4.261 0.000 0.000 0.051 63.809 0.000
PEAK1 0.876 0.174 4.056 0.247 0.000 0.000 0.172 11.633 0.011
PELI2 4.112 0.100 5.844 0.292 0.002 0.007 1.817 27.706 0.028
PLK2 1.958 0.831 4.445 0.598 0.011 0.027 0.000 37.952 0.001
PMAIP1 1.514 0.463 181.861 9.115 0.000 0.000 112.887 667.623 0.047
POU2F2 5.479 0.488 10.329 0.980 0.001 0.003 0.894 14.981 0.047
PPAP2A 4.018 2.135 7.460 0.526 0.013 0.030 0.040 109.365 0.001
PTGIR 2.619 0.815 9.546 0.698 0.000 0.000 14.987 193.512 0.020
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wt+d715 (TPM) 2911-2918 (TPM) SCN 
(TPM)
SCN-AML 
(TPM)Transcripts Mean SEM Mean SEM p-value q-value p-value
RBPMS 73.450 12.444 159.384 11.375 0.000 0.000 22.089 243.656 0.018
RHOB 7.714 0.559 24.352 4.253 0.000 0.000 7.875 75.929 0.044
RXFP1 0.000 0.000 2.603 0.242 0.000 0.000 2.255 218.103 0.002
S100A16 0.101 0.101 15.640 3.291 0.000 0.000 0.450 201.869 0.000
SGCE 15.925 0.527 41.888 2.877 0.000 0.000 0.848 81.740 0.012
SORT1 17.619 1.869 31.723 1.231 0.000 0.000 1.734 49.372 0.008
SPARC 1.000 0.918 15.064 1.596 0.000 0.000 137.496 772.904 0.049
SPP1 5.969 2.560 98.210 6.977 0.000 0.000 4.538 98.258 0.022
TNNT1 2.163 0.091 37.240 2.072 0.000 0.000 0.000 63.938 0.001
VNN1 1.068 1.068 5.946 0.614 0.000 0.000 19.620 148.520 0.039
YES1 0.469 0.263 1.798 0.292 0.002 0.006 1.096 70.475 0.003
ZFP36 62.796 9.864 341.485 84.642 0.001 0.003 372.547 2042.670 0.049
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Table S2: Downregulated transcripts in mouse AML and SCN-AML samples (related to Figures 3 and 7)
wt+d715 (TPM) 2911-2918 (TPM) SCN 
(TPM)
SCN-AML 
(TPM)Transcripts Mean SEM Mean SEM p-value q-value p-value
ABLIM1 3.135 2.449 0.443 0.180 0.003 0.008 17.242 0.000 0.000
ALDH1A1 40.810 18.173 2.811 0.750 0.000 0.000 267.785 1.687 0.001
APOE 1457.806 75.156 139.495 26.103 0.000 0.000 151.051 10.498 0.039
BLNK 8.679 2.850 0.087 0.041 0.000 0.000 71.718 5.069 0.042
BLVRB 124.042 8.566 34.675 6.532 0.000 0.000 348.949 30.415 0.035
CEP152 21.006 1.614 10.996 0.601 0.000 0.000 46.303 3.988 0.038
CHST2 0.732 0.250 0.116 0.036 0.010 0.024 45.965 0.026 0.000
CKAP2L 158.325 12.128 69.921 3.530 0.000 0.000 38.703 3.558 0.047
DEPDC1B 90.213 13.161 41.690 2.524 0.000 0.000 127.093 12.717 0.041
DHX32 47.015 10.050 14.669 1.364 0.000 0.000 72.522 4.681 0.034
DTL 150.428 0.056 59.978 2.771 0.000 0.000 109.663 14.026 0.049
DYNLT3 133.093 10.515 63.246 2.294 0.000 0.000 50.740 0.000 0.001
EPOR 103.405 2.778 23.938 5.811 0.001 0.004 100.145 1.177 0.005
FAM178B 1.034 0.402 0.000 0.000 0.000 0.001 183.409 0.364 0.002
FRMD6 14.164 2.754 8.098 0.623 0.009 0.023 25.186 0.000 0.001
FZD3 1.105 0.460 0.190 0.027 0.000 0.000 6.719 0.002 0.002
GATA1 370.954 32.021 48.081 15.706 0.003 0.008 427.197 4.972 0.002
GNG2 32.650 0.353 10.757 1.946 0.000 0.001 65.696 4.499 0.027
GPR183 6.159 1.352 0.850 0.260 0.000 0.000 74.745 4.742 0.042
HMMR 71.704 8.790 42.926 3.632 0.005 0.014 118.365 4.299 0.015
HNRNPLL 178.291 2.327 19.761 4.419 0.000 0.000 48.831 0.697 0.005
IGLL1 18.724 1.757 0.063 0.063 0.000 0.000 937.323 55.152 0.015
IL1B 3.883 0.750 0.142 0.079 0.000 0.002 263.481 27.556 0.040
KCNH2 1.367 0.451 0.268 0.098 0.022 0.048 219.696 0.744 0.001
KIF15 43.094 0.878 26.427 1.275 0.000 0.000 52.337 3.100 0.024
KLF1 454.940 39.636 52.026 20.291 0.006 0.015 700.309 4.974 0.001
LEF1 3.373 1.681 0.032 0.024 0.000 0.000 66.537 0.022 0.001
LTBP1 4.494 1.367 0.084 0.024 0.000 0.000 41.812 2.023 0.018
MMRN1 35.972 0.586 6.478 1.504 0.000 0.001 55.165 2.381 0.015
MS4A2 49.546 3.729 8.008 3.627 0.000 0.000 34.475 1.267 0.023
MYCT1 38.009 6.315 23.830 1.273 0.006 0.015 28.496 0.000 0.001
NDN 12.449 2.148 0.119 0.063 0.000 0.000 52.644 1.734 0.023
NHLRC1 17.069 1.609 9.799 0.890 0.005 0.014 67.709 2.740 0.021
NMNAT3 56.707 0.478 29.187 1.108 0.000 0.000 126.918 3.366 0.007
NUDT12 22.107 1.271 6.863 0.514 0.000 0.000 23.473 1.334 0.046
OAT 314.230 18.419 178.851 6.536 0.000 0.000 290.159 40.190 0.046
PDZD8 26.334 1.826 17.264 1.248 0.004 0.011 62.318 5.040 0.026
PTPN22 46.281 8.276 12.565 1.787 0.000 0.000 43.349 1.812 0.025
REC8 3.687 0.059 1.097 0.234 0.007 0.018 291.910 3.809 0.003
SLAIN1 65.971 2.351 32.809 3.312 0.000 0.001 61.145 0.036 0.000
SLC14A1 298.487 11.272 10.699 3.687 0.000 0.000 22.432 1.285 0.046
SLC18A2 122.849 1.763 28.599 5.559 0.001 0.002 20.948 0.013 0.018
SLC44A1 9.040 1.376 0.812 0.230 0.000 0.000 28.705 2.720 0.039
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wt+d715 (TPM) 2911-2918 (TPM) SCN 
(TPM)
SCN-AML 
(TPM)Transcripts Mean SEM Mean SEM p-value q-value p-value
SNX9 106.569 2.147 37.675 1.870 0.000 0.000 35.243 1.191 0.015
STEAP3 40.553 1.689 13.375 1.970 0.000 0.000 40.457 3.494 0.047
TGM2 19.927 6.583 3.418 0.704 0.000 0.000 59.561 1.928 0.011
TMEM246 14.893 0.026 0.842 0.120 0.000 0.000 64.100 0.051 0.000
TOP2A 187.231 10.462 75.674 4.452 0.000 0.000 117.467 15.956 0.049
TRIB2 236.288 7.422 11.866 4.045 0.000 0.001 84.766 4.264 0.015
TSPYL5 0.766 0.766 0.000 0.000 0.022 0.049 32.012 0.000 0.000
TTK 54.824 12.176 31.376 2.024 0.003 0.010 52.528 3.994 0.038
WEE1 137.495 0.252 59.770 1.893 0.000 0.000 183.638 22.740 0.045
XK 30.586 1.902 14.624 1.372 0.000 0.000 32.481 0.042 0.001
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Abstract 
Acquired aplastic anemia and severe congenital neutropenia (SCN) are bone marrow (BM) 
failure syndromes of different origin, however, they share a common risk for secondary 
leukemic transformation. Here, we present a patient with severe aplastic anemia (SAA) 
evolving to secondary chronic neutrophilic leukemia (CNL; SAA-CNL). We show that SAA-
CNL shares multiple somatic driver mutations in CSF3R, RUNX1, and EZH2/SUZ12 with cases 
of SCN that transformed to myelodysplastic syndrome (MDS) or acute myeloid leukemia 
(AML). This molecular connection between SAA-CNL and SCN progressing to AML (SCN-
AML) prompted us to perform a comparative transcriptome analysis on nonleukemic 
CD34high hematopoietic stem and progenitor cells, which showed resembling transcriptional 
profiles indicative of interferon (IFN)-driven pro-inflammatory responses. These findings 
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Introduction
We recently treated a patient with chronic neutrophilic leukemia (CNL) evolving from severe 
aplastic anemia (SAA). Both CNL and aplastic anemia (AA) are very rare hematological 
diseases. In western contries, the incidence of AA is 2-3 per 106 persons per year; however, 
only ~200 CNL cases have been reported in the first 15 years after its formal recognition 
in 2001 as a distinct entity in the classification system of the World Health Organization 
(WHO).1,2 The genetic hallmark of CNL are mutations in the colony-stimulating factor 3 
(CSF3) receptor-gene (CSF3R), which permit augmented and/or autonomous signaling and 
are detected in >80% of CNL patients.3-5 These CSF3R mutations were recently integrated 
in the WHO classification.5 The most commonly found CSF3R mutation in CNL is the CSF3R-
T618I alteration, which provides autonomous signaling, supporting hyperproliferation 
of mature neutrophil progenitors.5 Severe congenital neutropenia (SCN), a bone marrow 
failure with a high risk of progression to myelodysplastic syndrome (MDS) and acute 
myeloid leukemia (AML),6,7 is another hematological entity in which CSF3R mutations are 
detected in 70%-80% of patients during the course of leukemic transformation. The CSF3R 
mutations found in SCN are mostly truncating the cytoplasmic tail of the receptor, which 
is critical for receptor endocytosis and lysosomal routing.8 Interestingly, an autoactivating 
CSF3R mutation identical to those found in CNL patients was present in a case of SCN that 
progressed to AML (SCN-AML).9 Moreover, combinations of truncating and autoactivating 
CSF3R mutations have also been reported in cases of CNL,5 fueling the concept that CNL 
might be preceded by a premalignant state characterized by CSF3 hyporesponsiveness, 
which in analogy to SCN can be overcome by the acquisition of CSF3R mutations.10 Given 
the molecular link between SCN-AML and CNL, we conducted a comparative analysis of the 
present patient with SAA evolving to secondary CNL (SAA-CNL) and the previously described 
SCN-AML patient,9 aiming to interrogate clonal evolution and uncover possible common 
disease mechanisms underlying the malignant transformation of these cases.
174 | Chapter 8
Methods
Patient samples
Ficoll density gradient separated bone marrow (BM) and peripheral blood (PB) cells were 
obtained from healthy donors, the SCN-AML patient (SCN phase), and the SAA-CNL patient 
(CNL phase) and frozen according to established procedures for viable cell cryopreservation. 
BM aspirate smear samples served as the DNA source of the SAA phase in the SAA-CNL 
patient. The study was performed under the permission of the institutional review boards 
of the University Hospital Basel (Basel, Switzerland; registration number Req-2019-00126) 
and the Erasmus MC (Rotterdam, the Netherlands; registration number MEC-2008-387 
for biobanking and MEC-2012-030 for the genetic analysis of leukemic progression in SCN 
patients).
Microscopy
BM aspirate and PB smears were fixed in formalin solution containing 4% paraformaldehyde 
followed by a subsequent May-Grünwald-Giemsa staining. Images were captured by a Leica 
DM4B widefield microscope (Leica Microsystems GmbH, Wetzlar, Germany) equipped with 
an Olympus UC90 camera (Olympus, Shinjuku, Tokyo, Japan). For acquisition, Olympus 
Cell sense Entry (Olympus, Shinjuku, Tokyo, Japan) software was used and images were 
annotated using ImageJ (ImageJ2, Fiji).11
Flow cytometry and cell sorting
Hematopoietic stem and progenitor cells (HSPCs) were stained using CD34-PE (clone 8G12, 
BD Biosciences), neutrophils using CD11b-BV510 (clone ICRF44, BioLegend), while dead 
cells were excluded by using 4’,6-Diamidino-2-Phenylindole (DAPI, Fisher Scientific). The 
cells were sorted with a FACSAria cell sorter (BD Biosciences). 
DNA isolation and DNA sequencing 
DNA was extracted from BM samples using a QiaSymphony (Qiagen). Next-generation 
sequencing (NGS) libraries were prepared with the IonTorrent library kit using the 
Oncomine myeloid research gene panel (Supplementary Table 3) and sequenced with an 
IonGeneStudio S5 instrument (ThermoFischer). The coverage of the samples was >3000-
fold with all exons being covered. The sequencing data were analyzed using the Oncomine 
workflow on an IonReporter server with a variant detection limit set to 5%. The Illumina 
TruSight Myeloid panel (Illumina, Supplementary Table 4) was used to detect mutations in 
the sorted populations, whereas BM failure-associated genes were analyzed by a custom 
designed Illumina panel focusing on genes indicating a predisposition for progression to 
leukemia when mutated (Supplementary Table 2).  The Illumina NGS libraries were paired-
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end sequenced (2x221bp) on an Illumina HiSeq 2500 System (Illumina, San Diego, CA) in 
rapid run mode and variant calling was performed as described previously.12 Variants with a 
minor allele frequency of <0.1% were automatically selected, and variants causing an amino 
acid change or splice site base change were reported.
RNA isolation and RNA sequencing
RNA was isolated from sorted human CD34high cells from the BM (SCN phase, 1992 and 3 
healthy controls) or PB (SAA-CNL patient pre-transplant). cDNA was generated using the 
SMARTer Ultra Low Input RNA kit for sequencing (version 4, Clontech) and libraries were 
generated using the TruSeq Nano DNA Sample Preparation kit (Illumina), according to the 
low sample protocol, and run on a Novaseq 6000 instrument (Illumina). Demultiplexing was 
performed using the Casava software (Illumina) allowing for one mismatch in the bar-codes. 
Subsequently quality metrics were estimated for all of the resulting fastq files (FastQC, 
Babraham bioinformatics & MultiQC, http://multiqc.info). Afterwards trimmed reads were 
aligned against the Human Transcriptome (Gencode v19)/Genome (hg19) using the STAR 
aligner.13 Abundance estimation was performed using Cufflinks (refSeq14) and raw counts 
were measured with the HTSeq-count software set in union mode.15 Next the measured 
raw counts were used to create clustering and principle component plots and to perform 
differential expression analysis both using DESeq2 (after ASHR shrinkage) and R (https://
www.r-project.org/).16 Finally, gene set enrichment analysis with the hallmark pathways H 
(https://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp?collection=H) was done using 
the GSEA software based on the pre-ranked log2 fold change ASHR shrunken DESeq2 data.17-
19
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Results
Case history
The SAA-CNL patient was referred to the clinic at the age of 42 years for evaluation of bone 
marrow (BM) transplantation. He was diagnosed with SAA at the age of 22 years, for which 
he was treated with intensive immunosuppressive therapy (IST; 2x anti-lymphocyte globulin 
and 1x anti-thymocyte globulin (ATG) together with cyclosporine-A (CsA)) over a period of 
18 years with initial response to IST but subsequent relapse. The IST at the age of 23 years 
and 31 years resulted in partial remission for almost 9 and 3 years, respectively. After the 
third cycle at the age of 34 years, the patient depended on a maintenance therapy with CsA 
(350 mg/d) for 6 years. At the age of 41 years, that is, 19 years after the initial SAA diagnosis, 
increasing neutrophil counts up to 39 G/L were observed in peripheral blood (PB) in the 
absence of infection, inflammation, or solid tumor. BM examination revealed hypercellularity 
with excess mature neutrophils without an increase in myeloblasts (Figure 1A&B). Discrete 
reactive dysplastic changes were observed, which did not classify for diagnosis of MDS. 
Cytogenetic analysis showed a normal karyotype (46, XY) and a normal array comparative 
genomic hybridization (array-CGH) profile. Together with the findings in PB and BM, and the 
presence of a CSF3R-T618I mutation, the criteria of the WHO classification for the diagnosis 
of CNL were fulfilled (Table S1). 
A B
Figure 1. Microscopical analysis of PB and BM at CNL diagnosis. 
(A) Neutrophilia in PB. (B) BM examination shows hypercellularity resulting from proliferation of the 
myeloid lineage without an increase in myeloblasts. The pictures were acquired by a Leica DM4B 
widefield microscope equipped with an Olympus UC90 camera:  original magnification x20 (A) and 
x50 (B), respectively; Mäy-Grünwald-Giemsa stain. The images were taken at room temperature using 
immersion oil. For acquisition, Cell sense Entry software was used; the images were subsequently 
annotated using ImageJ.
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Therapy with ruxolitinib was initiated based on previous data showing spontaneous JAK-
mediated signaling in CSF3R-T618I mutants and the possible therapeutic potential of 
ruxolitinib in CNL.5 Upon normalization of neutrophil counts, ruxolitinib was tapered 
after 4 months and stopped after 5 months due to progressive thrombocytopenia (Figure 
2). Because thrombocytopenia and elevated neutrophil counts persisted (Figure 2), the 
patient underwent allogeneic hematopoietic stem cell transplantation from a 12 of 12 HLA 
identical unrelated donor after myeloablative conditioning with cyclophosphamide and 
pharmacokinetics-guided busulfan. Graft-versus-host disease (GvHD) prophylaxis consisted 
of ATG, methotrexate, and CsA. To date, almost 4 years post-transplant, the patient remains 
in complete hematological, morphological, and molecular remission with 100% donor 
chimerism in BM as well as in the CD3+ and CD66+ leukocyte fraction in PB. Mild chronic 
GvHD developed but immunosuppressive treatment could be stopped 1 year posttransplant.
16
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Figure 2. PB cell counts in relation to CNL diagnosis. 
Hemoglobin levels (HB) and neutrophil granulocyte (NEUT) and platelet  (PLT) cell counts are depicted 
before, during, and after treatment with ruxolitinib at the indicated dosage. DX, diagnosis; HSCT, 
hematopoietic stem cell transplantation.
Genetic analysis
Next generation sequencing (NGS) of BM cells from the SAA-CNL patient with the IonTorrent 
Oncomine Myeloid research gene panel uncovered, in addition to the CSF3R-T618I mutation 
(variant allele frequency (VAF): 29%), mutations in SETBP1 (VAF: 42%), EZH2 (VAF: 40%) 
and RUNX1 (VAF: 5%) (Table S3 & Figure 3). The patient did not carry mutations in genes 
associated with BM failure syndromes, e.g., ELANE, HAX1, SBDS, SRP54, and GATA2 (Table 
S2). Retrospective analysis of a BM sample taken 7 years before CNL diagnosis revealed no 
specific mutation, implying the acquisition of these mutations particularly during the last 
years of the disease course.
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Flow cytometric analysis of a PB sample taken from the SAA-CNL patient just before 
transplantation showed the presence of CD34high cells, raising the possibility that a further 
evolution step toward a more blast-like phenotype might have been in progress. To further 
investigate the clonal cellular hierarchy at this stage, we performed Illumina TruSight 
myeloid panel sequencing (Table S4) on fluorescence-activated cell sorter (FACS)-purified 
CD34highCD11b- hematopoietic stem and progenitor cells (HSPCs), CD34dimCD11b+ myeloid 
precursor cells, and CD34-CD11b- cells from cryopreserved PB. This analysis revealed that 
the SETBP1, EZH2, CSF3R and RUNX1 mutations were only present in the CD34dimCD11b+ 
myeloid progenitors cells with VAFs that were grossly similar to the noncryopreserved 
unsorted CNL sample (Table 1). On the other hand, none of these mutations were detected 
in the CD34highCD11b- HSPC fraction, indicating that these phenotypically immature cells 
were not derived from a SETBP1/EZH2/CSF3R/RUNX1 mutant ancestor, but represent SAA-
derived nonleukemic progenitors. 


















0% 0% 0% 0%0%
Figure 3. VAFs of mutations during evolution from SAA to CNL. 
VAF 8 years before transplantation, at diagnosis of CNL, pretransplant, and 1, 3, 6, and 12 months after 
allogeneic hematopoietic stem cell transplantation. 
Table 1: CSF3R, EZH2, SETBP1 and RUNX1 mutation status per sorted population 
Gene Mutation
Variant allele frequency (VAF)
CD34dimCD11b+ CD34highCD11b- CD34-CD11b-
CSF3R T618I 6.8% - -
EZH2 Y663C 38.8% - -
SETBP1 G870S 28.8% - -
RUNX1 V164fs 7.3% - -
-,0%; VAF, variant allele frequency
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Comparative transcriptome analysis of SCN and SAA HSPCs  
Based on the clonal evolution patterns that SCN-AML and SAA-CNL have in common, we 
asked if, and to what extent, comparable regulatory pathways might be affected in the 
nonleukemic CD34high HSPCs in this SAA-CNL patient compared with SCN. To investigate 
this, we made use of material from a previously described ELANE-mutant SCN patient who 
later on progressed to AML.9 As shown in Figure 4A, besides the CSF3R-T618I mutation, 
both patients show mutations in RUNX1 and in SUZ12 or EZH2, encoding proteins of the 
polycomb-repressive complex (PRC2), upon leukemic progression. We performed whole-
transcriptome analysis on the CD34high HSPCs from the pretransplant sample of the SAA-
CNL patient that lacked SETBP1/EZH2/CSF3R/RUNX1 mutations and compared these with 
CD34high cells from healthy donors (n=3). The same analysis was done on CD34high cells from 
the ELANE mutant SCN patient, which at the time of analysis during the neutropenic phase 
had a minor (<10%) clone with a CSF3R-truncating mutation.9 Gene set enrichment analysis 
(GSEA) indicated upregulation of several overlapping pathways in both the SAA-CNL and the 
SCN patient compared with healthy controls, among which were induction of  apoptosis, 
activation of the p53 pathway, mTORC1 signaling, and responses to reactive oxygen species 
(Figure S1). Most strikingly, the CD34high HSPCs from the SAA-CNL and the SCN patient 
displayed transcriptional profiles characterized by upregulation of inflammatory-related 
signatures, in particular type I (IFN-α) and type II (IFN-γ) interferon responses (Figures 4B 
and C). A selection of IFN-response genes that were most strongly upregulated in both the 
SAA-CNL and SCN HSPCs is shown in Figure 4D and includes PML and PARP9, genes involved 
in oxidative stress and DNA-damage responses, respectively, possibly linking the induction 
of apoptosis- and reactive oxygen species-induced signatures to increased interferon 
signaling.20,21 Taken together, these results suggest that IFN-driven proinflammatory 
responses represent a feature of SAA and SCN CD34high HSPCs that may contribute to the 
preleukemic state of these cells. 





















































































































































































































Figure 4. Comparative analysis between the SAA-CNL and SCN-AML patient regarding mutations and 
transcriptional profile. 
(A) Mutational spectrum observed in the SCN-AML patient and the SAA-CNL patient. The bold genes 
are overlapping (SUZ12 and EZH2 together form the polycomb-repressive complex 2). (B-C) GSEA 
comparing nonleukemic CD34high cells from (B) 3 healthy controls with CD34high cells obtained from 
the SAA-CNL patient, (C) CD34high cells from 3 healthy controls with CD34high cells obtained from the 
SCN patient (SCN-phase before AML became clinically overt), both showing increased IFN-related 
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signalling. (D) Expression levels (in transcript per million, TPM) of various IFN-inducable genes, which 
are significantly increased in both the SAA-CNL and the SCN stage. NES = normalized enrichment score, 
FDR = false discovery rate, TPM = transcript per million, * = p<0.05.
Discussion
The low probability of an unrelated, sequential occurrence of CNL after SAA in the same 
patient prompted the question of a causal link and possible mechanisms underlying 
the leukemic transformation to CNL. Per se, the course of AA can be complicated by the 
development of clonal disorders such as MDS and AML, in particular after IST as it was 
repeatedly given to our reported SAA-CNL patient.22-25 Recent analyses of myeloid precursor 
cells of AA patients demonstrated recurrent somatic mutations in a defined spectrum 
of genes with a low VAF and certain founder mutations with the potential to initiate the 
progression to MDS.26,27 
In comparison with genetic alterations found in MDS or age-related clonal hematopoiesis, 
certain sets of mutations are overrepresented (BCOR, BCORL1, PIGA) in AA, whereas other 
mutations (TET2, JAK2) occur less frequently, suggesting distinct clonal selection mechanisms 
in the aplastic BM environment. Interestingly, CSF3R mutations have not been reported 
in AA so far, but are linked to leukemic transformation in SCN. Sequential myeloid colony 
assays during the development from SCN to secondary AML revealed that CSF3R-truncating 
mutations occur early and are disease driving9 whereas RUNX1 and CSF3R-T618I mutations 
appear shortly before MDS/AML becomes clinically overt.28 The specific CSF3R mutation 
(T618I) in the present case was previously shown to enable myeloid colony formation in 
the absence of CSF3, thereby suggesting a constitutive ligand-independent activation of the 
receptor.5 
A molecular connection between the pathogenesis of SCN-AML and CNL has been suggested 
before because HSPCs in these malignancies acquire truncating and/or autoactivating 
mutations in CSF3R at an increased frequency.5,29 Although the exact time point at which 
CSF3R mutations are acquired during CNL development remains unknown, a possible 
explanation is that CNL is preceded by a CSF3-hyporesponsive preleukemic state, from 
which HSPC clones escape through the acquisition of CSF3R mutations.29 The SAA-CNL 
patient reported here could serve as a unique clinical case to support this hypothesis. 
Comparative gene-expression analysis of the nonleukemic CD34high HSPCs in the SCN and 
the SAA-CNL patient revealed strikingly similar transcriptional profiles, characterized by 
upregulation of type I (IFN-α) and type II (IFN-γ) interferon responses (Figure 4). These 
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results corroborate the important role of inflammatory signaling pathways in preleukemic 
stem cells, particularly in the context of secondary leukemia,30,31 and may suggest that an 
inflammatory BM environment in which the SAA and SCN mutant CD34high HSPCs reside 
contribute to a permissive condition for the development of leukemic cells.32,33
In summary, this patient with CNL evolving from SAA provides unique insights into potentially 
important mechanisms of leukemic transformation of BM failure syndromes. The molecular 
similarities with SCN and the resembling transcriptional profiles corroborate the role of 
inflammatory signaling pathways in preleukemic and leukemic stem cells, particularly in the 
context of secondary leukemia.
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Supplemental Data
Table S1: Diagnostic criteria for CNL
WHO (2016) Diagnostic Criteria for CNL Diagnostic Findings SAA-CNL
1. PB
- WBC ≥25x109/L ü 28.5 x 109/L
- Segmented neutrophils plus band forms ≥80% of WBCs ü 88% of WBCs
- Neutrophil precursors (promyelocytes, myelocytes, 
metamyelocytes) <10% of WBC ü 2.5% of WBC
- Myeloblasts rarely observed ü None observed
- Monocyte count <1x109/L ü 0.64x109/L
- No dysgranulopoiesis ü Not observed
2. Hypercellular BM
- Neutrophil granulocytes increased in percentage and number ü Hypercellular with markedly increased myelopoiesis
- Neutrophil maturation appears normal ü All maturation stages present
- Myeloblasts <5% of nucleated cells ü 1% of nucleated cells
3. Not meeting WHO criteria for BCR-ABL1+ CML, PV, ET, or PMF ü Not meeting criteria
4. No rearrangement of PDGFRA, PDGFRB, FGFR1, or PCM1-JAK2 ü No rearrangement
5. Presence of CSF3R T618I or other activating CSF3R mutation ü Present 
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Table S2: Bone marrow failure panel with a focus on genes indicating a predisposition for myeloid 
leukemia if mutated)
No Gene No Gene No Gene
1 ACD 31 FANCL 62 RPL35A
2 ALAS2 32 FANCM 63 RPL5
3 ANKRD26 33 G6PC3 64 RPS10
4 ATG2B 34 GATA1 65 RPS17
5 ATM 35 GATA2 66 RPS19
6 BLM 36 GFI1 67 RPS24
7 BRCA1 37 GSKIP 68 RPS26
8 BRCA2 38 HAX1 69 RPS7
9 BRIP1 39 IKZF1 70 RTEL1
10 CBL 40 MLH1 71 RUNX1
11 CEBPA 42 MSH2 72 SAMD9
12 CHEK2 43 MSH6 73 SAMD9L
13 CSF3R 44 NAF1 74 SBDS
14 CTC1 45 NBN 75 SBF2
15 CXCR4 46 NF1 76 SLX4
16 DDX41 47 NHP2 77 SRP72
17 DKC1 48 NOP10 78 TERC
18 DNAJC21 49 PALB2 79 TERT
19 ELANE 50 PARN 80 TINF2
20 EPCAM 51 PAX5 81 TP53
21 ERCC4 52 PMS2 82 UBE2T
22 ETV6 53 POT1 83 USB1
23 FANCA 54 PTPN11 84 VPS45
24 FANCB 55 RAD51 85 WAS
25 FANCC 56 RAD51C 86 WRAP53
26 FANCD2 57 RBBP6
27 FANCE 58 RBM8A
28 FANCF 59 RPL11
29 FANCG 60 RPL15
30 FANCI 61 RPL26
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Table S3: IonTorrent Oncomine Myeloid research gene panel
No Gene No Gene No Gene
1 ABL1 14 ETV6 27 PDGFRA
2 ASXL1 15 EZH2 28 PDGFRB
3 BCR 16 FLT3 29 PTPN11
4 BRAF 17 GATA2 30 RUNX1
5 CALR 18 IDH1 31 SETBP1
6 CBL 19 IDH2 32 SF3B1
7 CEBPA 20 JAK2 33 SH2B3
8 CHEK2 21 KIT 34 SRSF2
9 CSF3R 22 KRAS 35 TET2
10 DNMT3A 23 MPL 36 TP53
11 EGLN1 24 NF1 37 U2AF1
12 EPOR 25 NPM1 38 VHL
13 ETNK1 26 NRAS 39 ZRSR2
Table S4: TruSight Myeloid panel
No Gene No Gene No Gene
1 ABL1 19 FLT3 37 NRAS
2 ASXL1 20 GATA1 38 PDGFRA
3 ATRX 21 GATA2 39 PHF6
4 BCOR 22 GNAS 40 PTEN
5 BCORL1 23 HRAS 41 PTPN11
6 BRAF 24 IDH1 42 RAD21
7 CALR 25 IDH2 43 RUNX1
8 CBL 26 IKZF1 44 SETBP1
9 CBLB 27 JAK2 45 SF3B1
10 CBLC 28 JAK3 46 SMC1A
11 CDKN2A 29 KDM6A 47 SMC3
12 CEBPA 30 KIT 48 SRSF2
13 CSF3R 31 KRAS 49 STAG2
14 CUX1 32 MLL 50 TET2
15 DNMT3A 33 MPL 51 TP53
16 ETV6/TEL 34 MYD88 51 U2AF1
17 EZH2 35 NOTCH1 53 WT1
18 FBXW7 36 NPM1 54 ZRSR2
















































































Figure S1. Comparative analysis between the transcriptional profiles of nonleukemic CD34high cells 
from the SAA-CNL and SCN patient 
(A-B) GSEA comparing nonleukemic CD34high cells from (A) 3 healthy controls with CD34high cells obtained 
from the SAA-CNL patient, (B) CD34high cells from 3 healthy controls with CD34high cells obtained from 
the SCN patient (SCN-phase before AML became clinically overt), both showing induction of apoptosis, 
activation of the p53 pathway, mTORC1 signaling, and responses to reactive oxygen species.
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9.1 Summary
Severe congenital neutropenia (SCN) is a bone marrow failure syndrome characterized by a 
neutrophil differentiation block at the promyelocyte stage. SCN patients are effectively treated 
by colony stimulating factor 3 (CSF3/G-CSF) administration, alleviating the neutropenia in 
>90% of patients. A major concern in treating SCN patients with CSF3 is the highly increased 
risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). 
Progression to MDS/AML is associated with the appearance of hematopoietic clones with 
somatic mutations in the gene encoding the CSF3 receptor (CSF3R), resulting in a truncated 
form of CSF3R with defective internalization and aberrant signaling properties.1-3 These 
clones can persist for months or years before MDS/AML, most frequently characterized by 
additional mutations in RUNX1, becomes clinically overt.1,4 The work presented in this thesis 
focusses on the mechanisms involved in the leukemic progression of SCN by modelling the 
various sequential steps in induced pluripotent stem cells (iPSC) or mice.
Chapter 2 comprises a book chapter focusing on modeling SCN in iPSC. Since mouse models 
with patient specific mutations in ELANE and HAX1 do not show signs of neutropenia5,6, 
human models are needed to study the biology of SCN. Before the introduction of iPSC 
technology, attempts to model SCN in human cells have been mainly restricted to retroviral 
introduction of ELANE mutations in the promyelocytic leukemia cell line HL-60. The outcome 
of these experiments was mixed7,8, and leukemic cell lines are now generally considered as 
less suitable for studying the biology of SCN. Since the introduction of iPSC technology9,10, 
various SCN patient-derived iPSC have been generated and described. The development of 
CRISPR-Cas9 mediated genome editing made it feasible to precisely target modifications in 
iPSC, e.g., to repair disease causative gene defects in patient-derived lines or to introduce 
patient-derived mutations in normal controls.11 By generating these so-called isogenic lines, 
it is possible to study phenotypic consequences of mutations without possible confounding 
factors, e.g., differences due to viral introduction/overexpression or differences between 
iPSC lines or clones.
In Chapter 3 three new SCN patient-derived iPSC lines (ELANE-I60F, ELANE-R103L and HAX1-
W44X) and one control iPSC line are described, which are employed to study the effect of 
ELANE/HAX1 mutations on hematopoietic progenitor cells (HPCs). Increased oxidative stress 
levels, leading to activation of NRF2-mediated antioxidant responses, could be observed in 
SCN patient-derived HPCs. Additionally, in ELANE-SCN patients with a mutation that leads to 
misfolding of the neutrophil elastase (NE) protein, HPCs showed strongly increased numbers 
of promyelocytic leukemia protein nuclear bodies (PML-NBs). PML-NBs are a hallmark of 
more acute/excessive oxidative stress, but are also linked to a plethora of other processes 
194 | Chapter 9
like metabolism, DNA damage response, and apoptosis.12-18 In the case of ELANE mutations 
resulting in NE protein misfolding, PML enhanced the metabolic state of the HPCs, while also 
strongly elevating the expression of mutant ELANE, suggestive of a feed-forward mechanism 
of disease development. In addition, PML inhibited CSF3-induced outgrowth of neutrophil 
progenitors from these ELANE-mutant HPCs, implying an important role for PML in CSF3 
therapy response and SCN-pathogenesis. 
In Chapter 4 CRISPR-Cas9 mediated genome editing is employed to introduce the patient-
specific CSF3R-truncating mutation d715 (Q739X) in the previously described iPSC lines. 
RNA sequencing analyses indicate major differences between control and SCN-derived 
HPCs upon introduction of the truncated CSF3R. Where control-d715 HPCs mimic findings 
previously reported in cell lines and mouse models19,20, the CSF3R-d715 in a SCN background 
does not induce proliferation but inflammation, while inducing differentiation instead of 
inhibiting neutrophil maturation. These findings might explain why in SCN patients CSF3R-
mutant clones persist as minor clones for years before leukemia becomes clinically overt.21,22 
In addition, these data provide a possible explanation for the high frequency of CSF3R 
mutations found in the leukemic clone, since induction of pro-inflammatory signaling might 
induce the selection and outgrowth of clones that acquired additional mutations, making 
them more resistant to the inflammatory stimuli. Cells with loss of function mutations in, 
e.g., RUNX1 and TET2, both frequently found mutated in AML, are described to be more 
resistant to an inflammatory environment, possibly explaining why RUNX1 mutations are 
observed in the majority of CSF3R mutant SCN clones.4,23,24
Chapter 5 comprises a (p)review that discusses the role of RUNX1 mutations in SCN, mainly 
focusing on the Csf3r-d715/RUNX1-D171N mouse model described in Chapter 6, which 
shows a selective expansion of immature lineage negative, c-Kit positive, Sca-1 negative (LK) 
myeloblasts, but no absolute neutrophil differentiation arrest, upon CSF3 treatment. In line 
with this, additional experiments in iPSC show a reduction in neutrophil maturation upon 
introduction of the patient specific RUNX1-D171N mutation in CSF3R-d715 cells derived 
from a healthy control.
Chapter 6 describes how the combination of CSF3 therapy, CSF3R, and RUNX1 mutations 
contribute to AML development. CSF3-, but not PBS-, treated Csf3r/RUNX1 mutant 
mice show a selective expansion of lineage negative, c-Kit positive, Sca-1 negative (LK) 
hematopoietic progenitors in the peripheral blood, but no overt AML. Intriguingly, one 
Csf3r/RUNX1 mutant, CSF3-treated, mouse (1/9) acquired an additional mutation in Cxxc4 
which resulted in AML upon serial transplantations. The Cxxc4 alteration, an insertion of 2 
glycine residues in a glycine-repeat, causes increased CXXC4 protein stability resulting in 
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elevated CXXC4 levels and reduced TET2 protein levels. In addition, elevated expression 
of multiple pro-inflammatory pathways is observed in both mouse AML and human SCN-
AML, which could be mimicked in iPSC by inhibiting (TET2’s) HDAC recruitment function, 
suggesting that inflammation driven by down-regulation of TET2 activity is a critical step in 
the malignant transformation of SCN. 
In Chapter 7 we screened 1706 AML patients from various HOVON clinical trials for the 
presence of mutations in the glycine-repeat region of CXXC4, which we found altered in 
de leukemic mice. CXXC4 insertions, deletions and missense mutations were observed in 
46 AML patients. Saliva samples were available from 12 CXXC4 mutant patients, which all 
showed the presence of this mutations in the germline. In addition, analyses of 5 follow-
up samples of CXXC4 mutant patients showed the presence of the CXXC4 mutations upon 
reaching complete morphological remission. Although CXXC4 mutations could be detected 
in the germline, incidences were significantly higher in pre-leukemic conditions in which 
inflammatory signaling plays an important role; high-risk MDS and myeloproliferative 
neoplasm, compared to AML and low-risk MDS (p=0.008). These data suggest that CXXC4 
mutations might contribute to, but are not sole drivers of, leukemic transformation by 
providing an inflammatory environment important for the clonal expansion of hematopoietic 
stem and progenitor cells (HSPCs). Leukemic transformation is then dependent on acquisition 
of additional mutations which are often proceeded by a more “benign” pre-leukemic stage 
like MDS.
In Chapter 8 the first patient with severe aplastic anemia (SAA) evolving to secondary 
chronic neutrophilic leukemia (CNL) is described. Somatic driver mutations in CSF3R, RUNX1 
and a polycomb repressor complex 2 (PRC2) gene (EZH2) in this SAA-CNL patient are shared 
with the previously described SCN patient (mutation in PRC2 gene SUZ12) that transformed 
to AML.1 Comparative transcriptome analysis on non-leukemic CD34high HSPCs of this SAA-
CNL patient, or the SCN patient, with 3 healthy controls showed resembling transcriptional 
profiles indicative of interferon (IFN)-driven pro-inflammatory responses. These findings 
indicate the presence of a pro-inflammatory milieu in SAA and SCN, possibly contributing 
to the pre-leukemic state of these cells, thereby providing further insights in possible 
mechanisms underlying leukemic transformation in bone marrow failure syndromes. 
In conclusion, this thesis reveals new mechanisms of how SCN mutations, and possibly other 
bone marrow failure syndromes like SAA, contribute to leukemic progression. We show that 
PML-NBs play an important role in ELANE-mutant patients with predicted NE-misfolding, 
while inflammatory signaling plays a critical step in the malignant transformation of SCN.  In 
addition, we identified a mutation in Cxxc4, which can also be found in de novo AML, as an 
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additional driver for leukemic progression in a mouse model of SCN.
 Summary and General Discussion | 197
9
9.2 General discussion
Severe congenital neutropenia (SCN) is a family of genetic diseases associated with low 
neutrophil counts and an increased risk of leukemic transformation. To date, more than 
20 distinct genes have been identified to be able to cause SCN.25 In addition to the classical 
SCN, characterized by a promyelocyte differentiation arrest, the SCN family comprises 
various other bone marrow failure syndromes, e.g., glycogen storage disease Ib (mutation in 
SLC37A4), Shwachman-Diamond syndrome (mutation in SBDS), WHIM syndrome (mutation 
in CXCR4), GATA2 syndrome (mutation in GATA2) and Barth disease (mutation in TAZ).26-30 
Mutations in many of these genes result in additional defects in other organs. For example, 
Shwachman-Diamond syndrome patients present with abnormalities in the pancreas and 
bone, GATA2 mutant patients can present with lymphedema and deafness, while Barth 
disease patients present with cardiac abnormalities. The common denominator between 
SCN patients is the increased risk of infections due to the neutropenia, while also showing 
high risk of leukemic transformation. How mutations in these genes cause neutropenia and 
why they show such a highly increased risk of leukemic transformation remains an important 
point of study. 
In this thesis we used SCN, more specifically patients with mutations in ELANE and HAX1, as 
model disease to study the sequential steps of leukemic transformation. 
9.2.1 Increased oxidative stress as possible common denominator of CNs
As mentioned in Chapter 1, mutations in a plethora of genes have been shown to result 
in SCN, all affecting proteins with different cellular locations and functions, where ELANE 
encodes the primary granule protein neutrophil elastase (NE)31,32, HAX1 encodes a 
mitochondrial protein33, WAS a cytoskeletal protein34, G6PC3 a metabolic enzyme35, VPS45 
an endosomal membrane trafficking protein36, GFI1 a myeloid transcription factor37,  JAGN138 
a transmembrane protein and CSF3R a cytokine receptor.39 One of the remaining questions 
is how mutations in these very different genes can result in the same phenotype and can 
cause the same disease. We showed that, although the mutations in the 3 SCN patients 
used to generate iPSC are in different genes or are predicted to have different effects on 
the protein, they all result in increased oxidative stress levels in hematopoietic progenitor 
cells (HPCs). Excessive ROS has been observed in various other diseases like Alzheimer, 
Parkinson disease, and different types of cancer40,41, and are extensively studied for their 
contribution in aging.42 When not efficiently cleared, an excessive and toxic oxidative stress 
burden results in DNA, protein and lipid damage due to oxidation by free oxygen radicals 
present.42 Whether increased oxidative stress levels in SCN patients result in these kind of 
damages needs to be further studied, and might give insights into which patients might have 
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an increased risk of acquiring additional mutations and potential leukemic transformation 
due to inefficient clearing of ROS. In line with this, a mouse model of Shwachman-Diamond 
syndrome showed increased oxidative stress levels in HSPCs which resulted in increased 
DNA damage and genotoxic stress.43 
It remains to be answered whether increased oxidative stress levels are observed in SCN 
patients with mutations in other genes, e.g., WAS, G6PC3 or JAGN1, and if all mutations 
result in similar increases in ROS levels. Our studies on the ELANE-I60F mutation would 
suggest differences between patients and mutations, since these cells, but not the other 
SCN-derived HPCs, showed increased numbers of promyelocytic leukemia nuclear bodies 
(PML-NBs), associated with more acute/excessive oxidative stress.12 We could link the 
increased PML-NBs with ELANE-mutant cases with predicted NE misfolding (ELANE-I60F 
and ELANE-P139L), but more patients need to be screened to verify if this holds true for all 
predicted misfolding cases. 
9.2.2 The promyelocytic leukemia protein PML as important player in SCN
9.2.2.1 PML and promyelocyte arrest
The PML protein has first been described in acute promyelocytic leukemia (APL), where 
it forms a fusion protein with retinoic acid receptor α (RARA), resulting in disorganized 
PML-NBs.44 The PML-RARA fusion protein interferes with the function of wildtype PML 
protein45, resulting in a promyelocyte arrest, similar as observed in SCN. This is especially 
interesting in the light of ELANE-mutant cases with predicted NE misfolding, since PML 
functions might be altered due to the increased need for clearing of excessive ROS and/
or the misfolded protein. One of the possibilities could be that the SUMOylation status of 
important myeloid transcription factors is altered, rendering them less efficient in inducing 
transcription. Another option could be that transcription factors are trapped inside of PML-
NBs preventing them from binding DNA. Suggestive of a role for PML and SUMOylation in 
differentiation is the fact that hematopoietic transcription factors c-MYB, MECOM and IKZF1 
are differentially SUMOylated upon PML loss in the myeloid leukemia cell line K562 (data 
not shown). These observations merit a rich substrate for further studies which are needed 
to unravel the potential role of SUMOylation of these proteins on transcriptional activity 
and myeloid differentiation.
9.2.2.2 Canonical and PML-driven clearing of misfolded proteins
Studies on the effect of ELANE mutations have mainly focused on activation of the classical 
unfolded protein response (UPR). The first paper suggesting a possible involvement of the 
UPR in ELANE-SCN was published in 2006 by Köllner et al.46 They showed that overexpression 
of mutant NE moderately increased expression of the UPR gene BiP (HSPA5) in U937 
cells, although mainly after induction of apoptosis with camptothecin. Shortly thereafter, 
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Grenda et al. showed significant upregulation of BiP and the short isoform of XBP1 after 
overexpression of 4/5 ELANE-mutants in U937, providing more compelling evidence of the 
possible NE-misfolding and activation of the UPR in some of the ELANE mutant cases.47 
However, both studies involved overexpression of the various mutant NE proteins, hence 
studying the effects of ELANE mutations at nonphysiological levels. In addition, not all 
mutations seem to activate the UPR, indicating that various mutations can have different 
effects on the protein. This is not unexpected given that more than 200 different ELANE 
mutations have been described, spanning the whole ELANE gene including 3’ UTR and 
various introns.48-52 In line with this, several other mechanisms have been suggested as 
initiators of neutropenia, e.g., mislocalization of the mutant NE protein and an altered 
enzymatic activity.46,51 However, when using mutation prediction programs, the majority of 
mutations in ELANE are predicted to result in protein misfolding.53
In addition, functional studies of the effect of ELANE mutations in iPSC generated from 
ELANE-SCN patients, studying the mutations at physiological levels, have mainly focused 
on activation of the UPR. Also here, evidence for a role of the canonical UPR is rather weak, 
as only the expression of less than a handful of UPR genes was measured and consistent 
differences could often not be observed when multiple UPR genes were analyzed.54-56 
Another pathway that is described to be able to clear misfolded proteins involves PML.57 
We showed upregulation of PML-NBs in HPCs from ELANE-mutant cases with predicted NE 
misfolding (ELANE-I60F and ELANE-P139L), but no activation of the classical UPR pathway 
genes, not even in more differentiated granulocytic cells. The difficulty to properly and 
accurately define and study the promyelocyte stage might explain the variably outcomes 
reported in the various iPSC studies, where no clearly defined cell population is used to 
study the expression of various UPR genes and apoptosis. It would be interesting to see 
whether predicted misfolding mutations in other genes associated with SCN would cause 
the same upregulation of PML-NBs, or if this is specific for ELANE. In addition, whether 
PML is able to clear misfolded NE remains to be determined57, since ELANE transcript levels 
are significantly reduced upon PML loss in ELANE-I60F iPSC-derived HPCs. One could think 
of performing peptide specific mass spectrometry to investigate the ratio of wildtype and 
mutant protein, but this is a tedious procedure which does not work for the majority of 
peptides due to limited enzymatic cut locations that yield the required peptide length. 
9.2.3 Inflammatory signaling
In this thesis we describe inflammatory signaling as an important player in the leukemic 
progression of SCN (Chapter 6), while non-leukemic HSPCs in SCN and SAA-CNL already 
show upregulation of interferon-related signaling pathways (Chapter 8). In addition to SCN 
and SAA-CNL, an inflammatory bone marrow microenvironment has been described in aging 
and various other hematological malignancies, e.g., AML, MDS, and Shwachman-Diamond 
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syndrome, and it is believed that the presence of this inflammatory environment plays an 
important role in the progression of myeloid leukemias.43,58-62 The majority of cytokines, 
including inflammatory cytokines, signal via downstream NF-κB and JAK-STAT molecules.63 
The dimerization of the different phosphorylated STAT proteins, and subsequent nuclear 
translocation and DNA binding, results in expression of various target genes depending 
on which STATs dimerize. In CSF3R-d715 SCN-HPCs an increase in inflammatory signaling 
pathways is observed compared to their wildtype counterparts, while proliferation-related 
pathways are decreased, which is in contrast to what is observed in control cells (Chapter 
4). It would be interesting to see whether different STATs are activated depending on the 
cell’s background, resulting in expression of different target genes. In addition, these studies 
might then provide new insights into possible new therapies by reducing the activation of 
inflammatory pathways.
The high overlap between the different pathways in downstream signaling makes it difficult 
to accurately verify activation of specific inflammatory pathways, besides looking at 
upregulation of target genes or presence of inflammatory cytokines themselves. However, 
inflammatory cytokines might not easily be detectable since there is increasing evidence 
that these cytokines might be produced by cells of the bone marrow microenvironment 
or more differentiated myeloid cells instead of the HSPCs, increasing the local cytokine 
level.43,62 This local change makes it difficult to detect changes in cytokine levels globally, by, 
e.g., looking for cytokine levels in the peripheral blood.
9.2.4 The effect of CSF3R mutations and CSF3 treatment
Acquired CSF3R truncating mutations almost always appear in the context of an underlying 
SCN mutation and are not observed during leukemic transformation of other CNs.64 
Whether CSF3 treatment, which is prescribed to SCN patients but usually not to other CN 
patients25, might play a role in the acquisition of CSF3R mutations and subsequent leukemic 
transformation remains unanswered. The observation that patients treated with higher 
dosages of CSF3 show an increased risk of leukemic transformation suggests a contributing 
role for CSF3 treatment, but whether these hyporesponsive patients acquire CSF3R mutations 
and whether CSF3 might contribute before and/or after acquisition of the truncated CSF3R 
is not known.65 In line with a role for CSF3-treatment after acquisition of a truncating 
CSF3R mutation is the finding that lineage negative Csf3r-d715 murine bone marrow cells 
show a CSF3-induced hyperproliferative phenotype in vitro, while mice transplanted with 
Csf3r-d715 RUNX1-D171N bone marrow show a CSF3-dependent expansion of lineage- c-Kit+ 
(LK) cells (Chapter 6). Additionally, CSF3R-d715 control HPCs show a significant increase in 
CSF3-induced colony forming potential (Chapter 4).
So far studies on the function of truncated CSF3R have only been performed in cell lines or 
mouse models lacking the underlying SCN mutation. Therefore, our studies in SCN patient 
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derived iPSC give valuable new information on how the truncated receptor functions in 
a disease relevant context. Surprisingly, CSF3-induced myeloid colony formation was not 
increased in SCN CSF3R-d715 cells compared to their wildtype counterparts, where a 1.5 
to 2-fold increase is observed in CSF3R-d715 cells derived from control iPSCs and mouse 
bone marrow (Chapters 4 and 6). This finding was accompanied by RNA sequencing 
experiments which showed no increase, and even a decrease, in proliferative signatures 
in SCN-d715 HPCs, while control-d715 HPCs showed a significant induction of proliferative 
signaling pathways compared to their wildtype counterparts (Chapter 4). In addition, where 
control-d715 HPCs showed increased expression of pathways associated with hematopoietic 
stem/progenitor cells and a reduction in myeloid differentiation pathways, SCN-d715 HPCs 
showed the opposite suggesting induction of myeloid differentiation upon introduction of 
the truncated CSF3R (Chapter 4). These findings might explain why several minor CSF3R 
mutant clones can be present and persist in SCN patients receiving CSF3 therapy without 
becoming a major clone, unless additional mutations are acquired.1 
Additional studies need to be done to investigate the downstream signaling alterations due 
to the truncated CSF3R in a SCN background in more detail, encompassing downstream 
signaling molecules like STAT3 and STAT5. Differences in activation of the STAT proteins 
between control and SCN mutant cells might explain the different effects observed on 
proliferation and differentiation.66
9.2.5 Overlap with chronic neutrophilic leukemia
The genetic hallmark of chronic neutrophilic leukemia (CNL) is an auto-activating mutation 
in the CSF3R (T618I), which is observed in >80% of patients. Some patients also present 
with truncating mutations, but this is often accompanied by the CSF3R-T618I mutation.67 
In addition, some SCN patients acquire the CSF3R-T618I mutation, often in the allele that 
also acquired the CSF3R truncating mutation.1 These cases fuel the concept that CNL might 
be preceded by a premalignant state characterized by CSF3 hyporesponsiveness, just like in 
SCN, which can be overcome by the acquisition of CSF3R mutations.64 In line with a possible 
pre-malignant state preceding CNL, we identified the acquisition of CNL in a severe aplastic 
anemia (SAA) patient (Chapter 8). RNA sequencing of non-leukemic CD34+ hematopoietic 
stem and progenitor cells (HSPCs) indicate upregulation of interferon (IFN)-α and -γ signaling 
pathways in both the SCN patient and the SAA-CNL patient (Chapter 8). These data suggest 
that the SCN and SAA HSPCs reside in an inflammatory bone marrow microenvironment, 
which might contribute to a permissive condition for the development of leukemic cells.68,69
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9.2.6 The effect of RUNX1 mutations
Acquired mutations in the hematopoietic transcription factor RUNX1 are frequently 
found in SCN patients who progress to MDS or AML (64.5%).4 In contrast to truncating 
CSF3R mutations, mutations in RUNX1 are also observed in various other hematological 
malignancies like de novo AML and acute lymphocytic leukemia (ALL).70 Mutations in 
RUNX1 include deletions, missense mutations, splicing alterations, frameshift and nonsense 
mutations and these alterations can result in a truncated protein lacking/perturbing the 
transactivation domain (TAD), and sometimes also the DNA binding runt-homology domain 
(RHD), or a RUNX1 protein that show disrupted DNA binding due to missense mutations 
in the RHD.71-73 In addition, various chromosomal translocations, e.g., t(8;21) and t(12;21), 
involve the RUNX1 gene and generate RUNX1-RUNX1T1 and ETV6-RUNX1 fusion proteins, 
respectively.74-79 Germline mono-allelic RUNX1 mutations are also described and cause 
familial platelet disorder with predisposition to AML (FDP/AML).80
Since RUNX1 mutations are found throughout the protein, different mutations might have 
different effects on myeloid differentiation and leukemic transformation. In line with this, 
the SCN-patient-specific mutation RUNX1-S291fsX9, resulting in a premature termination 
codon and a truncated protein lacking part of the transactivation domain (TAD), results in a 
selective expansion of lineage-negative, c-Kit-positive, Sca-1-positive (LSK, in contrast to LK 
cells in the RUNX1-D171N (RHD) mutant) cells in in vitro Csf3r-d715 mouse bone marrow 
cells (Figure 1). Data from these in vitro experiments, in combination with our observations 
in vivo, indicate that mutations in RUNX1 result in selective expansion of immature cells but 





















63.7% 35.2% 86.4% 13.6% 15.4% 82.7% 
d715-RHD d715-TAD
Figure 1: LK/LSK distribution is differently affected upon introduction of various RUNX1-mutations 
Representative FACS contour plots showing LK/LSK distribution of d715-ev (left panel), d715-RHD 
(middle), and d715-TAD (right panel) in CSF3-supplemented cultures (day 9).
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In addition to an effect on myeloid differentiation, RUNX1 mutations have also been 
described to result in defective DNA repair81,82, possibly by dysregulated expression or 
activity of important DNA repair proteins, as has been described for the RUNX1-RUNX1T1 
(AML1-ETO) fusion protein.83-86 RUNX1 mutations may also promote the survival of HSPCs, 
since Runx1 deficient HSPCs show lower p53 protein levels and a decreased percentage of 
apoptotic cells.87-89 Additionally, wildtype RUNX1 inhibits inflammatory cytokine production 
by neutrophils, suggesting that loss-of-function mutations in RUNX1 increase inflammation.90 
However, various studies showed a decrease in long-term HSCs in Runx1-mutant mice, 
indicating that Runx1 mutations do not give a proliferative- or competitive-advantage and 
might even result in stem cell exhaustion.87,91,92 These data combined suggest that RUNX1 
mutations might provide a favorable environment for the acquisition and survival of mutant 
HSPCs, but additional mutations are needed to provide a competitive advantage.23
9.2.6.1 Modeling RUNX1 mutations in vitro
Lentiviral introduction of mutant RUNX1 results in overexpression at possible non-
physiological levels if not controlled properly. In addition, viral transductions induce an 
inflammatory response in the cells, making it impossible to study changes in inflammatory 
signaling pathways shortly after transduction. Therefore, taking along the proper controls to 
be able to correct for this transduction effect is essential. Transduction with wildtype RUNX1 
would be the best control, but overexpression of wildtype RUNX1 results in apoptosis 
and can therefore not be used (data not shown).93,94 To correct for changes due to viral 
transduction we used an empty vector control.
Another option would be to introduce RUNX1 mutations with genome editing strategies, 
making it possible to study the effect of the mutation under physiological conditions. 
However, CRISPR-Cas9 mediated genome editing of RUNX1 results in the absence/severe 
reduction of HPCs derived from iPSC, making it impossible for downstream applications 
(Figure 2). This finding is in line with published studies on iPSC from familial platelet 
syndrome (FPD) patients who have a germline RUNX1 mutation and also show severely 
reduced numbers of HPCs.95 Another alternative would be to generate an inducible model 
with CRISPR-Cas9 mediated genome editing, inducing the mutation in RUNX1 after the 
generation of hematopoietic progenitor cells. However, besides the challenges of generating 
such a model, the recombination efficiency will be low and a good screening mechanism 
is needed. In addition, overexpression of RUNX1 has been observed in SCN-AML cases, 
while also trisomy 21 (containing the RUNX1 gene) is frequently observed, making the 
overexpression model (if the levels remain physiological) the best available option to date.4



















wt d715 wt d715 wt d715 wt d715
wt wt TAD TAD wt wt TAD TAD
control ELANE-I60F
Figure 2: RUNX1-TAD mutation affects production of HPCs from control and ELANE-I60F mutant iPSCs
Quantification of number of HPCs upon hematopoietic induction of various CRISPR-Cas9 genome 
edited iPSC lines.
9.2.7 Hierarchical acquisition of mutations 
A remaining unanswered question concerns the order of acquired mutations during leukemic 
transformation. Various CSF3R mutant clones can be detected in SCN patients, years before 
a potential leukemia becomes clinically overt, indicating that these types of mutations 
are the “second hit” towards leukemic transformation, when counting the SCN mutation 
as being first. The majority of CSF3R mutant clones acquire a RUNX1 mutation relatively 
shortly before leukemia becomes clinically overt. However, lack of sequential sampling of 
SCN patients progressing to AML makes it impossible to accurately determine when RUNX1 
mutations are acquired.1,4 The question if the combination of these 3 mutations (SCN/CSF3R/
RUNX1) is enough for the leukemic progression remains unanswered. In our mouse model, 
lacking the SCN mutation, the combination of a Csf3r and RUNX1 mutation resulted in a pre-
leukemic condition but not overt AML. However, when an additional mutation in Cxxc4 was 
acquired mice progressed to a CSF3-independent AML, showing a severe reduction in TET2 
levels and upregulation of inflammatory signaling pathways. Whether mutations in CXXC4 
occur in SCN patients is unknown, because the majority of patients nowadays undergo bone 
marrow transplantation before they progress to leukemia, making material very scarce. 
Mutations in other epigenetic genes, e.g., SUZ12, EZH2, ASXL1 or EP300, are described to 
be present in SCN-AML and might provide a similar function as mutant CXXC4.1,4 In line with 
this, EZH2, which together with SUZ12 forms the polycomb repressive complex 2 (PRC2), 
regulates CXXC4 protein level.96 It would be interesting to determine if EZH2, and possibly 
also SUZ12, mutations observed in SCN-AML result in increased CXXC4 protein abundance 
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and a reduction of TET2 levels. Another option would be that all epigenetic regulators are 
able to induce the transcription of genes important for inflammatory signaling, as is seen 
upon iPSC treatment with the HDAC inhibitor MS275, and that this phenomenon is the 
missing “fourth step” in leukemic transformation. However, it might still be possible that 
the combination of CSF3R and RUNX1 mutations is sufficient for leukemic transformation in 
a SCN mutant background. Therefore, the field would benefit greatly if it would be feasible 
to generate long-term hematopoietic stem cells (LT-HSCs) from iPSC, making it possible to 
transplant SCN patient derived cells into mice.
9.2.8 Conclusions and Outlook
In conclusion, this thesis provides various mechanistical insights into SCN and its leukemic 
progression. Further studies into these mechanisms are needed and might provide new/
better treatment options for CSF3-hyporesponsive (ELANE-mutant) SCN patients by, e.g., 
reducing oxidative stress levels, thereby preventing the increased formation of PML-
NBs. Whether PML-NBs play an important role in other types of SCN, and/or all CSF3-
hyporesponsive patients remains to be determined. Additionally, lowering inflammatory 
signaling might decrease the possibility of acquiring additional (RUNX1) mutations, 
thereby preventing the leukemic transformation of SCN. Investigating the downstream 
signaling cascade upon activation of the CSF3R-d715 in SCN-HPCs might provide leads for 
a more targeted therapy approach, e.g., by specifically preventing the phosphorylation or 
dimerization of specific STAT molecules. 
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ALL acute lymphoblastic leukemia
AML acute myeloid leukemia






CNL chronic neutrophilic leukemia
CsA cyclosporine-A
CSF3 colony-stimulating factor 3 (a.k.a. G-CSF)
CSF3R colony-stimulating factor 3 receptor
CSF3R-d715 mutated colony-stimulating factor 3 receptor at amino acid 715 (Q739*)
ER endoplasmic reticulum
FAB French-American-British 
FACS fluorescence-activated cell sorter
FDR false discovery rate
FPD familial platelet syndrome
G-CSF granulocyte-colony-stimulating factor (a.k.a. CSF3)
gnomAD genome aggregation database 




HOVON Dutch–Belgian cooperative trial group for hematology–oncology
HPC hematopoietic progenitor cell
HSCT hematopoietic stem cell transplantation
HSPC hematopoietic stem and progenitor cell
iBMF inherited bone marrow failure syndrome
IFN interferon
iPSC induced pluripotent stem cell
IPSS international prognostic scoring system
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IST immunosuppressive therapy
ITD internal tandem duplication
L liter
LK lineage negative, Sca-1 negative, c-Kit positive cell
LSK lineage negative, Sca-1 positive, c-Kit positive cell






NES normalized enrichment score
NGS next generation sequencing
NMD nonsense-mediated mRNA decay
PB peripheral blood
PML promyelocytic leukemic protein
PML-NBs promyelocytic leukemic protein nuclear bodies
PRC2 polycomb repressor complex 2
RAEB refractory anemia with excess of blasts
RAEB-t refractory anemia with excess of blasts in transformation
RARA retinoic acid receptor α 
redox reduction-oxidation 
RHD runt-homology domain
ROS reactive oxygen species
SAA severe aplastic anemia
SAKK Swiss group for clinical cancer research
SCN severe congenital neutropenia
sMDS secondary myelodysplastic syndrome
SUMO small ubiquitin-like modifier
TAD transactivation domain
TPM transcripts per million
UPR unfolded protein response
VAF variant allele frequency
WES whole exome sequencing
WGS whole genome sequencing
WT wildtype
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Ernstige aangeboren neutropenie (SCN) is een erfelijke beenmerg stoornis veroorzaakt 
door een uitrijpingsdefect van neutrofielen. Mutaties (genetische veranderingen) in 
verschillende genen kunnen SCN veroorzaken. De meeste Europese SCN-patiënten hebben 
een mutatie in de genen ELANE (~50%) of HAX1 (~11%). SCN wordt gekarakteriseerd 
door een differentiatie blok ter hoogte van het promyelocyt stadium en een sterk tekort 
aan uitgerijpte neutrofielen in het bloed (<0.5x109/L). Uitgerijpte neutrofielen zijn een 
belangrijk onderdeel van het primaire afweermechanisme van het lichaam en zorgen ervoor 
dat bacteriën en schimmels worden opgeruimd. Patiënten met SCN vertonen veel, ernstige 
en vaak ook levens-bedreigende bacteriële infecties die onder andere tandvlees-, oor-, long- 
en huidontstekingen veroorzaken. Deze ontstekingen beginnen vaak al vier weken na de 
geboorte. Gelukkig is SCN een zeldzame aandoening (3-8,5 gevallen per miljoen individuen) 
en worden SCN-patiënten tegenwoordig effectief behandeld met de groeifactor CSF3 
(ook bekend als G-CSF). CSF3-therapie resulteert in voldoende uitgerijpte neutrofielen in 
het bloed in meer dan 90% van de SCN-patiënten, waardoor hun kwaliteit van leven sterk 
verbeterd. Verontrustend is wel dat SCN-patiënten die behandeld worden met CSF3 een 
sterk verhoogd risico hebben op het ontwikkelen van myelodysplastisch syndroom (MDS) 
en acute myeloïde leukemie (AML). Tijdens de leukemische progressie van SCN worden 
vaak nieuw verkregen mutaties gevonden in de receptor voor CSF3 (CSF3R). Deze mutaties 
resulteren in een verkorte vorm van de receptor waardoor deze niet meer afgebroken kan 
worden en op een andere manier signaleert. Deze mutante CSF3R klonen zijn vaak al jaren 
voor de ontwikkeling van MDS/AML in het lichaam aanwezig en regelmatig worden er 
zelfs meerdere kleine CSF3R-mutant klonen gevonden. Op het moment dat SCN-patiënten 
gediagnosticeerd worden met MDS of AML hebben ze vaak, bovenop de CSF3R-mutatie, 
ook een mutatie verkregen in het gen RUNX1. RUNX1 is een transcriptiefactor welke erg 
belangrijk is voor de vorming van bloedcellen. Het werk beschreven in dit proefschrift focust 
zich op de mechanismen die betrokken zijn bij de leukemische progressie van SCN door 
deze verschillende stappen in geïnduceerde pluripotente stamcellen (iPSCs) en muizen na 
te bootsen. 
Hoofdstuk 2 is een boekhoofdstuk gefocust op het gebruiken van iPSCs voor het bestuderen 
van SCN. iPSCs zijn cellen die geherprogrammeerd zijn tot een pluripotente stamcel vanuit 
uitgerijpte cellen. Deze cellen kunnen vervolgens onder de juiste condities uitgroeien 
tot alle type lichaamscellen. De ontwikkeling van deze technologie is een revolutie voor 
het bestuderen van zeldzame ziektes doordat nu patiënt-specifieke modellen kunnen 
worden gemaakt. Voor SCN in het bijzonder zijn iPSCs een bijzonder nuttig model, omdat 
muismodellen met SCN-patiënt-specifieke mutaties in ELANE of HAX1 geen tekenen van 
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neutropenie vertonen. Voordat iPSC modellen beschikbaar waren werden humane cellijnen, 
gemaakt van niet SCN-gerelateerde leukemische cellen, gebruikt waar met een retrovirus het 
mutante ELANE-gen in werd ingebracht. De uitkomsten van deze experimenten zijn gemixt 
en cellijnen worden nu beschouwd als minder geschikt voor het bestuderen van de SCN-
biologie. Sinds de introductie van de iPSC technologie zijn er verschillende lijnen beschreven 
die gemaakt zijn van materiaal van SCN-patiënten. Met de introductie van CRISPR-Cas9-
gemedieerde genoommodificatie kwam de mogelijkheid om specifieke veranderingen aan 
te brengen in de iPSCs, waarbij bijvoorbeeld SCN-veroorzakende mutaties kunnen worden 
gecorrigeerd of extra mutaties kunnen worden aangebracht. Doordat deze cellen verder 
identiek zijn aan de niet-gemodificeerde cellen kan goed gekeken worden naar de effecten 
van deze specifieke veranderingen, zonder de aanwezigheid van verstorende factoren door 
bijvoorbeeld virale over-expressie of verschillen in iPSC lijnen of klonen.
In Hoofdstuk 3 worden vier nieuwe iPSC-lijnen beschreven, gegenereerd van drie 
SCN-patiënten (met SCN-veroorzakende mutaties ELANE-I60F, ELANE-R103L en HAX1-
W44X) en een gezonde controle. Deze iPSCs zijn gebruikt om onrijpe bloedcellen, de 
zogenaamde hematopoietische voorlopercellen (HPCs), van te maken waarin de effecten 
van de ELANE/HAX1 mutaties zijn bestudeerd. De HPCs verkregen uit de SCN-patiënten 
iPSCs vertoonde tekenen van verhoogde oxidatieve stress, met als gevolg dat de NRF2-
gemedieerde antioxidant respons werd geactiveerd. In ELANE SCN-patiënten waarin de 
mutatie resulteert in verkeerde vouwing van het NE-eiwit werden verhoogde aantallen 
van PML-lichaampjes (PML-NBs) in de kernen van de cellen gevonden. PML-NBs zijn een 
kenmerk van meer acute oxidatieve stress, maar zijn ook gelinkt aan verschillende andere 
processen zoals metabolisme, het herstellen van DNA-schade en apoptose. In het geval van 
ELANE-mutaties die resulteren in een verkeerd gevouwen NE-eiwit zorgde PML voor een 
verhoogde metabole staat van de HPCs, terwijl ook de expressie van mutant ELANE sterk 
werd verhoogd, suggestief voor een versterkende rol van PML in de ziekteontwikkeling. 
Daarnaast remde PML de CSF3-geinduceerde uitrijping van neutrofiel voorlopercellen van 
deze ELANE-mutant HPCs, duidend op een belangrijke rol van PML in CSF3-therapie respons 
en SCN-pathogenese.
In Hoofdstuk 4 is CRISPR-Cas9-gemedieerde genoommodificatie gebruikt om de patiënt-
specifieke CSF3R mutatie d715 (Q739X), resulterend in een verkorte (getrunceerde) vorm 
van de receptor, in te brengen in de hierboven beschreven iPSCs. RNA sequencing analyses 
lieten grote verschillen zien tussen controle- en SCN-HPCs wanneer de gemuteerde CSF3R 
werd geïntroduceerd. Waar CSF3R-d715 controle HPCs de bevindingen die eerder in 
cellijnen en muismodellen zijn gedaan bevestigde, resulteerde de CSF3R-d715 in SCN-HPCs 
niet in verhoogde proliferatie maar in activatie van inflammatoire signaleringsroutes, terwijl 
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neutrofiel uitrijping werd geïnduceerd in plaats van geremd. Deze data verklaren mogelijk 
waarom CSF3R-mutante klonen jaren in het lichaam aanwezig kunnen zijn als kleine kloon 
voordat leukemie klinisch detecteerbaar wordt. Verder verklaren deze data mogelijk ook 
de hoge frequentie van CSF3R mutaties in de leukemische kloon, aangezien de activering 
van inflammatoire signaleringsroutes mogelijk de selectie en uitgroei bevorderd van klonen 
met extra mutaties die ervoor zorgen dat de cellen hier beter tegen bestand zijn.  Het is 
beschreven dat cellen met mutaties in bijvoorbeeld RUNX1 en TET2, beiden vaak gemuteerd 
in AML, hogere resistentie hebben tegen een inflammatoire omgeving. Deze data geven 
hierdoor mogelijk een verklaring voor de vele RUNX1 mutaties die gevonden worden in 
CSF3R-mutante klonen in SCN-patiënten. 
Hoofdstuk 5 bevat een (p)review dat de rol van RUNX1 mutaties in SCN bespreekt. De focus 
ligt voornamelijk op het Csf3r-d715/RUNX1-D171N muismodel dat beschreven wordt in 
Hoofdstuk 6. In dit muismodel lijdt de combinatie van deze twee mutaties, in combinatie met 
CSF3-behandeling, tot een selectieve expansie van onrijpe lineage- c-Kit+ (LK) myeloblasten. 
Aanvullende experimenten in iPSC laten ook een verminderde neutrofiel-uitrijping zien als 
de RUNX1-D171N mutatie wordt ingebracht in CSF3R-d715 cellen van een gezonde controle.
Hoofdstuk 6 beschrijft hoe de combinatie van CSF3-behandeling, CSF3R en RUNX1 mutaties 
bijdraagt aan de ontwikkeling van AML. CSF3-behandelde, maar niet PBS-behandelde, Csf3r/
RUNX1 mutante muizen laten een selectieve expansie van onrijpe lineage negatieve, c-Kit 
positieve, Sca-1 negatieve (LK) myeloblasten zien, maar dit lijdt niet tot AML. Een van de 
Csf3r/RUNX1 mutante muizen die behandeld werd met CSF3 (1/9) ontwikkelde AML nadat 
de beenmergcellen van deze muis opnieuw getransplanteerd werden. Deze muis had een 
extra mutatie verkregen in het gen Cxxc4, wat resulteerde in een insertie van 2 glycines in 
een glycine-repeat. Deze verandering zorgde voor een stabieler CXXC4 eiwit, resulterend in 
verhoogde CXXC4 levels en verlaagde TET2 eiwit levels. Verder vertoonde de muis AML-cellen 
verhoogde expressie van inflammatoire signaleringsroutes, welke ook hoger tot expressie 
kwamen in menselijke SCN-AML cellen. Deze verhoogde inflammatoire signaleringsroutes 
konden worden nagebootst in iPSC door (TET2’s functie in) de rekrutering van HDACs 
te remmen, duidend op een mogelijke belangrijke rol voor verhoogde inflammatoire 
signaleringsroutes door verlaagde TET2-activiteit in de leukemische transformatie van SCN.
In Hoofdstuk 7 worden 1706 MDS/AML patiënten beschreven die mee hebben gedaan 
aan verschillende HOVON klinische trials. Het DNA van deze patiënten werd gescreend op 
mutaties in de glycine-repeat regio van CXXC4, welke veranderd was in de leukemische 
muizen beschreven in Hoofdstuk 6. Inserties, deleties en missense mutaties in CXXC4 
werden gevonden in 46 MDS/AML patiënten. Speeksel materiaal was beschikbaar van 12 
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CXXC4-mutante patiënten, welke allemaal de aanwezigheid van de mutatie in het kiembaan-
materiaal lieten zien wat betekent dat deze mutatie aangeboren/erfelijk is. Van vijf 
aanvullende patiënten was materiaal beschikbaar van remissiemateriaal, het stadium waarop 
de MDS/AML niet meer detecteerbaar is, en ook deze patiënten lieten de aanwezigheid van 
de mutatie in dit materiaal zien. Ook al werden CXXC4 mutaties in het kiembaanmateriaal 
gevonden, meer CXXC4-mutante patiënten vertoonde een pre-leukemische ziekte waarvan 
beschreven is dat inflammatoire signaleringsroutes een belangrijke rol spelen, zoals hoog 
risico MDS en myeloproliferatieve neoplasmata (MPN) (p=0.008). Deze data suggereren dat 
CXXC4-mutaties mogelijk een rol spelen in, maar niet de enige veroorzakers zijn van, de 
leukemische transformatie door een inflammatoire omgeving te creëren die belangrijk is 
voor de klonale uitgroep van hematopoietische stamcellen. Leukemische transformatie is 
vervolgens afhankelijk van het verwerven van aanvullende mutaties die vaak voorafgegaan 
worden door een pre-leukemisch stadium zoals MDS.
In Hoofdstuk 8 wordt een patiënt beschreven met ernstige aplastische anemie (SAA) die 
een chronische neutrofiele leukemie (CNL) heeft ontwikkeld. De verworven driver-mutaties 
in CSF3R, RUNX1 en een van de polycomb onderdrukkende complex 2 (PRC2) genen 
(EZH2) in deze SAA-CNL patiënt overlappen met de mutaties in een eerder beschreven 
SCN-AML patiënt (mutatie in PRC2 gen SUZ12). Transcriptoom analyses gedaan op niet-
leukemische CD34++ HPCs van de SAA-CNL patiënt of de SCN-patiënt in vergelijking met 3 
gezonde controles liet een sterk overlappend transcriptioneel profiel zien met verhoogde 
interferon (IFN)-gedreven inflammatoire responses. Deze bevindingen wijzen op de 
aanwezigheid van een pro-inflammatoir milieu in SAA en SCN, welke mogelijk bijdragen aan 
de pre-leukemische staat van deze cellen. Verder geven deze resultaten nieuwe inzichten 
in de mogelijke mechanismen die onderliggend zijn aan de leukemische transformatie van 
beenmerg stoornissen.
Concluderend, dit proefschrift onthult nieuwe mechanismen in hoe SCN-mutaties, en 
mogelijk andere beenmerg stoornissen zoals SAA, bijdragen aan de leukemische progressie. 
Een aparte groep SCN-patiënten met mutaties in ELANE die lijden tot een verkeerd 
gevouwen NE-eiwit zijn geïdentificeerd, waarin PML-NBs een belangrijke rol spelen in 
de ziekteontwikkeling en CSF3-therapie respons. Daarnaast laat dit proefschrift zien dat 
inflammatoire signalerings-routes een belangrijke rol spelen in de leukemische transformatie 
van SCN en wordt een Cxxc4-mutatie beschreven, welke ook in mensen voorkomt, als extra 
driver-mutatie in AML-cellen van een SCN-muismodel.
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PhD portfolio
Courses and workshops ECTS Year
Annual Course on Molecular Medicine 0.7 2014
MGC Technology Facilities 1.2 2014
Course and Master Classes on Molecular Aspects of Hematological Disorders 1 2014
Browsing Genes and Genomes with UCSC: Basic and Advanced Workshop 0.8 2015
Course on Molecular Aspects of Hematological Disorders 0.7 2015
Microscopic Image Analysis: From Theory to Practice 0.8 2016
Course on Molecular Aspects of Hematological Disorders 0.7 2016
Introduction in Graph Pad Prism 6 0.3 2016
Galaxy for NGS 1 2017
Course on Molecular Aspects of Hematological Disorders 0.7 2017
Workshop on Photoshop and Illustrator CS6 0.3 2017
Workshop Indesign 0.3 2017
Course on Molecular Aspects of Hematological Disorders 0.7 2018
Gene expression data analysis using R: 
How to make sense out of your RNA-Seq/microarray data 2 2019
Scientific meetings department of Hematology ECTS Year
Work discussions department (weekly) 14 2014-2020
Hematology seminar series (monthly) 3.5 2014-2020
PhD lunch with seminar speakers (monthly) 3.5 2014-2020
AIO/Postdoc presentations (monthly) 1 2014-2015
Journal club (bi-weekly) 10.5 2014-2020
Attendance national/international conferences ECTS Year
Molecular Medicine day, Rotterdam, NL 3 2014-2016
Daniel den Hoed day, Rotterdam, NL 3 2014-2016
Dutch Hematology congress, Arnhem, NL 1 2016
Dutch Society of Stem Cell Research meeting, Utrecht, NL 1 2015
Annual iPSC user meeting, NL 2 2016-2017
24th Congress of the European Hematology Association, Amsterdam, NL 1 2019
Poster presentations at national/international meetings ECTS Year
9th Annual meeting of the Dutch Society for Stem Cell Research, Utrecht, NL 1 2016
23th Congress of the European Hematology Association, Stockholm, Sweden 1 2018
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Oral presentations at national/international meetings ECTS Year
Annual iPSC user meeting, Nijmegen, NL 2 2015
9th Dutch Hematology Congress, Arnhem, NL 2 2015
60th Annual meeting of the American Society of Hematology, San Diego, USA 2 2018
61st Annual meeting of the American Society of Hematology, Orlando, USA 2 2019
Invited presentations ECTS Year
Annual iPSC user meeting, Rotterdam, NL 2 2014
Molecular Aspects of Hematological Disorders, Rotterdam, NL 2 2018
12th Dutch Hematology Congress, Arnhem, NL 2 2018
Meeting of the Young European Hematology Association, Amsterdam, NL 2 2019
13th Dutch Hematology Congress, Arnhem, NL 2 2019
14th Dutch Hematology Congress, Arnhem, NL 2 2020
1st European Network for Innovative Diagnosis and Treatment of Chronic 
Neutropenias (EuNet-INNOCHRON) meeting, online 2 2020
2nd European Network for Innovative Diagnosis and Treatment of Chronic 
Neutropenias (EuNet-INNOCHRON) meeting, online, 2 presentations 3 2021
Total 81.70
Awards Prize Year
European Hematology Association Travel Grant Award €500 2018
American Society of Hematology Abstract Achievement Award $500 2019
Committees and organization activities Year
Lab day committee 2015-2016
Organization and supervision PhD lunch with seminar speakers 2015-2016
Young EuNet-INNOCHRON committee 2020
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Dankwoord
Ja, het is zo ver, mĳn proefschrift is af! Wie had gedacht dat deze dag toch nog zou komen?! 
Uiteraard had ik dit nooit alleen kunnen halen, dus via deze weg wil ik graag de mensen 
bedanken die direct of indirect een bĳdrage hebben geleverd aan dit proefschrift.
Te beginnen met natuurlĳk mĳn promotor. Beste Professor Touw, beste Ivo, bedankt dat je 
mĳ de kans hebt gegeven om mĳn promotieonderzoek in jouw groep te doen. Het zĳn een 
aantal bewogen jaren geweest maar we hebben het tot een mooi einde weten te breien. Ik 
heb veel respect voor je kritische blik, je tomeloze inzet in het verbeteren van projecten en 
het proberen te behouden van wetenschappelĳke kwaliteit. Bedankt voor je enthousiasme 
en de vele discussies die we de afgelopen jaren hebben mogen voeren. Veel succes in de 
toekomst. Ik hoop dat je nog een tĳdje door mag/kan hobbyen!
Beste dr. de Pater, beste Emma, ik weet nog goed dat je op de afdeling kwam en begon 
aan de uitdaging om je eigen groep op te starten. Je kwam terecht op een afdeling met 
voornamelĳk mannen, maar daar heb je je geen moment door uit het veld laten slaan. 
Bedankt voor de vele peptalks en adviezen door de jaren heen en dat je mijn copromotor 
hebt willen zijn. Ik wens je veel succes in je verdere carrière!
Beste Professor Raaĳmakers, dr. von Lindern en dr. van der Reĳden, beste Marc, Marieke 
en Bert, bedankt dat jullie in de beoordelingscommissie willen plaats nemen. Ik heb altĳd 
genoten van onze discussies tĳdens werkbesprekingen en/of congressen en kĳk er dan ook 
naar uit om nogmaals met jullie van gedachten te wisselen over mĳn proefschrift.
Dear dr. Drexler and dr. Schmied, dear Beatrice and Laurent, I remember our first meeting 
like yesterday, where you, Beatrice, approached me after my talk at the ASH meeting in San 
Diego to discuss a SAA-CNL patient with very similar mutations as our SCN-AML patient. 
I’m glad that conversation resulted in a fruitful collaboration and a nice publication. Dear 
Professor Vertegaal, Professor Shimamura, and Professor Newburger, dear Alfred, Akiko, 
and Peter, thank you for the nice collaborations. I hope everything will result in a nice 
publication, even though I’m not there to finish the projects anymore. Beste dr. Erkeland 
en Professor Delwel, beste Stefan en Ruud, bedankt voor de vele adviezen en gezellige 
gesprekken door de jaren heen. Ik kon altijd bij jullie terecht voor uitdagende discussies over 
mijn werk of wetenschap in het algemeen en ik ben dan ook erg blij dat jullie in de grote 
commissie willen plaatsnemen. Beste dr. Bartels, beste Marije, mensen die geïnteresseerd 
zijn in SCN zijn erg schaars in Nederland, maar ik ben blij dat jij altijd erg betrokken bent 
geweest bij het SCN-onderzoek. Bedankt voor de vele patiëntensamples die je hebt 
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opgestuurd door de jaren heen en ik hoop dat je je altijd blijft inzetten voor onderzoek naar 
dit soort zeldzame ziektes. Beste dr. van der Velden, beste Vincent, bedankt voor de vele 
flow cytometry analyses die je voor ons hebt gedaan met het EuroFlow panel. Ik ben blij dat 
dit mooie publicaties heeft opgeleverd en dat alle moeite en energie die jullie erin hebben 
gestoken niet voor niets is geweest.
Beste Paulette en Onno, bedankt voor alle hulp de afgelopen 7 jaar. Zonder jullie had ik nu 
nog steeds iPSCs zitten kweken of achter de confocal gezeten! Ik wens jullie veel succes in 
de toekomst en hoop dat jullie een leuke nieuwe groep vinden. Beste Dennis, wat had ik 
zonder jouw hulp in de laatste jaren van mĳn PhD moeten beginnen?! Bedankt voor de vele 
uren iPSCs kweken, CRISPR lĳnen maken en experimenten doen. Veel succes in de groep 
van Mathĳs en ik hoop dat je je enthousiasme voor de wetenschap behoudt! Beste Hans, 
ook jouw hulp is van ontschatbare waarde geweest voor meerdere hoofdstukken van mĳn 
proefschrift. Bedankt voor je hulp met het maken en screenen van de CRISPR lĳnen en je 
doorzettingsvermogen om CXXC4 gesequenced en gekloneerd te krĳgen! Succes met de 
brouwerĳ, ik kom snel weer biertjes halen! 
In dit rĳtje mag natuurlĳk ook labpapa Eric niet ontbreken! Dr. Bindels, bedankt voor de 
vele keren dat je in het weekend voor onze celletjes wilden zorgen. Vooral Liesbeth is je hier 
heel dankbaar voor (en ik ook wel een beetje hoor :p). Ook wil ik je bedanken voor de vele 
adviezen en peptalks die je me door de jaren heen hebt gegeven. Je bent echt onmisbaar 
voor de afdeling en alle PhD studenten!
Dear Professor Schneider, dear Rebekka, you have been, and are, a huge example for many 
of us. Being a PI hasn’t changed you and you still behave like one of the mere mortal lab 
people. Thanks for the many nice, motivating, and inspiring talks we had over the years. I 
wish you all the best for the rest of your career, and a lot of happy times with your beautiful 
family. I hope our paths cross again in the future!
Dear Dr. Gleitz-Brothers, dear Hélène, we’ve been hitting it of since you joined Rebekka’s lab 
and I’m glad I get to call you my friend! Although you’re way too young to be a postdoc, you 
are more talented and experienced than many others. Thanks for having my back during my 
defense by acting as my paranimf. Beste Inge Snoeren, ook jĳ mag natuurlĳk niet in het rĳtje 
ontbreken! Toen je als analist begon in Rebekka’s groep was ik meteen onder de indruk van 
je skills om naast experimenten uit te voeren deze ook zelf te bedenken en te analyseren. 
Waarom je nooit een PhD bent gaan doen is me nog steeds een raadsel. Ook wĳ hadden 
meteen een klik en ik ben blĳ dat we in contact zĳn gebleven! Hopelĳk kunnen we snel weer 
barbecuen bĳ ons in de tuin :).
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Dear office 1330b, what would I have done without you guys? All of you made this 
experience more fun and I miss all our work and non-work discussions every day. Dear Julia, 
dear Germy, thanks for being there for me when I started my PhD. We’ve had many nice 
moments together and I recall our sarcastic jokes fondly. I’m glad we stayed in touch and 
picked up our monthly Skype talks again! Beste Davine, succes met het afronden van je PhD 
en het oppakken van het werk in de kliniek. Hopelĳk vind je snel een baan die bĳ je past! 
Dear dr. Avelino, dear Roberto, I admire your (scientific) knowledge and insights and I’ve 
always been impressed by the amount of papers you seem to know by heart! Thanks for all 
the peptalks and the faith you’ve always had in me. I wish you the best of luck in Israel. Beste 
dr. Smeenk, beste Leonie, you’ve had some big shoes to fill nadat je Julia’s plek op kantoor 
had overgenomen, maar je hebt je er knap door heen weten te slaan. Ook al verpestte 
je het Hufflepuf karakter van 1330b, we hebben een hoop mooie en gezellige momenten 
gedeeld samen. Ik wens je veel succes met het uitvogelen van je vervolgstap maar heb er 
alle vertrouwen in dat het goed gaat komen! Beste Maurice, beste Swinki, je verhuizing 
naar de 13e was een schot in de roos. Niet alleen kwam je terecht in het leukste kantoor, het 
kwam ook je project en je liefdesleven ten goede. Ik wens je veel succes met het afronden 
van je PhD en het vinden van een passende nieuwe baan. Hopelĳk is het niet al te ver van 
Rotterdam ;-). Beste Dorien en Emma B, de nieuwste aanwinsten van 1330b, bedankt voor 
alle gezellige momenten en succes met jullie PhD. Hopelĳk kunnen we snel ons geplande 
spelletjes avond houden!
Waar zou de afdeling zijn zonder jullie? Gedurende de afgelopen 7 jaar heb ik heel veel 
gehad aan jullie lab expertises en ik ben erg dankbaar voor jullie hulp Lianne, Eline, Pia, 
Anke, de rest van de BMT, de dames van de moleculaire diagnostiek, François, Michael, 
Elwin, Claudia, Marije en Claire. Uiteraard was dit proefschrift er ook nooit gekomen zonder 
de hulp van de bioinformatici Remco, Mathijs, Roger en Elodie. Dankjulliewel voor de vele 
analyses die jullie voor mij hebben gedaan! Ook de secretaresses Tessa, Leenke, Ans en 
Annelies zijn onmisbaar. Bedankt voor het vele papierwerk wat jullie telkens in orde hebben 
gemaakt!
To all the current PhD students, Cansu, Emanuele, Paola, Eline, Martijn, Jacqueline, Tim, 
Sophie, Madelon, Jess and Bella, I wish you lots of luck finishing your PhDs, and during the 
rest of your careers. Furthermore, I would like to thank Iris, Petra, Stanley, Stijn, Isabel, 
Andrea, Joyce and the rest of the current and former Hematology department members for 
the fun times in- and outside of the lab. I also wish to thank the other PIs of the department 
including dr. Ruben Bierings, dr. Tom Cupedo, dr. Peter Valk, Prof. Jan Cornelissen, Dr. Mojca 
Jongen-Lavrencic, Prof. Bob Löwenberg, and Prof. Frank Leebeek for discussions and advice 
in the lab and during the floor meetings.
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Niet alleen de mensen die direct hebben bijgedragen aan de verschillende hoofdstukken 
zijn belangrijk geweest voor de totstandkoming van dit proefschrift, de mensen die indirect 
een bijdrage hebben geleverd zijn minstens net zo belangrijk! Lieve Martijn, Silke, Mariska, 
Inge Loonen en Jennifer, bedankt dat jullie mij van tijd tot tijd uit het lab hebben getrokken. 
Ik kon altijd bij jullie terecht om mijn gedachten te verzetten en te ontspannen en ik ben 
blij dat ik jullie tot mijn beste vrienden mag rekenen! Lieve familie, lieve Bob, Ad, Martha, 
Wouter, opa, oma, Ada, Richard, Steven, Marieke, Tineke, Peter, Bianca, Rob, Edwin en 
Claudia, bedankt voor alle gezelligheid. Ook al begrijpen jullie niet veel van mijn onderzoek 
jullie hebben altijd interesse getoond en jullie best gedaan om er iets van te snappen. Ik kijk 
uit naar de nieuwe familiebijeenkomsten zodra deze weer plaats kunnen vinden!
Lieve papa en mama, bedankt voor jullie vertrouwen in mij. Zonder jullie had ik het nooit 
aangedurfd om naar de Universiteit te gaan, laat staan aan een promotieonderzoek te 
beginnen. Ook al zien we elkaar nu minder vaak, ik koester alle momenten dat we samen 
zijn en kijk er naar uit om dit succes met jullie te vieren. Lieve Natascha, mijn niet meer zo 
kleine zusje, bedankt dat je mijn paranimf wilt zijn! Ook jij bent essentieel geweest voor het 
succes van mijn PhD door altijd een luisterend oor te bieden en voor afleiding te zorgen. 
Bedankt dat ik altijd bij je terecht kan als er iets is!
Last but not least: mijn wifey. Lieve Liesbeth, toen jij in mijn leven kwam werd alles een stuk 
mooier. Bedankt dat je er altijd voor me bent, of ik nou een luisterend oor of een knuffel 
nodig heb. Thuiskomen bij jou is elke dag een feestje en ik kan niet wachten om met jou een 
gezinnetje te starten. 
